

INFORMAZIONI PERSONALI



SANTORO MARIA

 Via Isonzo 71, Latina 04100

 +39 3496302532

 santormaria@gmail.com; maria.santoro@uniroma2.it

Sesso F | Data di nascita 24/05/1973 | Nazionalità Italiana

POSIZIONE RICOPERTA

**Ricercatore a tempo determinato di tipo B** presso la Cattedra di Virologia, Dipartimento di Medicina Sperimentale, Università di Roma “ Tor Vergata”, Via Montpellier 1, 00133 Roma

ESPERIENZA PROFESSIONALE

(13/07/2017 - 13/07/2023)

**Abilitata come professore di II Fascia II per il Settore Concorsuale 06/A3**

(19/11/2018 - 19/11/2024)

**Abilitata come professore di II Fascia II per il Settore Concorsuale 06/A3**

(29/11/2019 – in corso)

**Ricercatore a tempo determinato di tipo B**

Università degli Studi di ROMA "Tor Vergata" – Dipartimento di Medicina Sperimentale - ROMA

L'attività attualmente consiste nel management e analisi di dati relativi al test di resistenza genotipica effettuato su pazienti con infezione croniche determinate da HIV e virus epatitici sia per routine clinica che per attività di ricerca. Inoltre svolgo attività di guida e supervisione delle attività di ricerca di laureandi in Biotecnologie Mediche e in Scienze Biologiche, di dottorandi di Microbiologia Medica e Immunologia, e specializzandi in Malattie Infettive e in Microbiologia e Virologia. Infine, svolgo attività didattica presso le Facoltà di Farmacia e di Medicina e Chirurgia dell'Univeristà degli Studi di ROMA “Tor Vergata”.

Attività o settore Virologia

(01/12/2015 - 28/11/2019)

**Funzionario tecnico (categoria D1)**

Università degli Studi di ROMA "Tor Vergata" – Dipartimento di Medicina Sperimentale - ROMA  
ROMA

Attività o settore Virologia

(01/10/2013 - 30/11/2015)

**Ricercatore a tempo determinato di tipo A**

Università degli Studi di ROMA "Tor Vergata" - -ROMA

Attività o settore Virologia

(20/06/2010 – 20/08/2010)

**Partecipazione ad un Visiting Research Scholar Program**

▪ Department of Pathology, College of Medicine, University of Florida, Florida.

Studi di epidemiologia molecolare di HIV-1 nel bacino del Mediterraneo.

Attività o settore Virologia

(01/02/2008 - 30/09/13)

**Assegnista di ricerca**

Università degli Studi di ROMA "Tor Vergata" – Dipartimento di Medicina Sperimentale - ROMA  
ROMA

- Analisi sperimentale, controllo e gestione di dati genotipici di HIV e virus epatitici.

Attività o settore Virologia

(2007) **Contratto (per tre mesi) di collaborazione occasionale**

Istituto Nazionale per le Malattie Infettive "Lazzaro Spallanzani, Unità di Monitoraggio Terapie Antivirali e Antineoplastiche – ROMA

- Attività di ricerca sulle "Le resistenze ai farmaci anti-HIV: metodologie diagnostiche innovative e impatto clinico - azione concertata".

Attività o settore Virologia

(2006-2007) **Contratto di collaborazione**

Università degli Studi di ROMA "Tor Vergata" – Cattedra Virologia, Dipartimento di Medicina Sperimentale e Scienze Biochimiche - ROMA

- Analisi e produzione dati al fine di definire il profilo di mutazioni genotipiche associate ai farmaci antiretrovirali come tenofovir per conto della Gilead Sciences Srl.

Attività o settore Virologia

(2005) **Contratto di collaborazione occasionale**

Università degli Studi di ROMA "Tor Vergata" - Cattedra Virologia, Dipartimento di Medicina Sperimentale e Scienze Biochimiche – ROMA

- Analisi e produzione dati al fine di definire il profilo di mutazioni genotipiche associate ai farmaci antiretrovirali come tenofovir per conto della Gilead Sciences Srl.

Attività o settore Virologia

(2004) **Contratto di collaborazione occasionale**

Università degli Studi di ROMA "Tor Vergata" - Cattedra Virologia, Dipartimento di Medicina Sperimentale e Scienze Biochimiche –ROMA

- Analisi e produzione dati genotipici di HIV.

Attività o settore Virologia

(01/10/2002-30/09/2004) **Borsista**

Università degli Studi di ROMA "Tor Vergata" – Cattedra Virologia, Dipartimento di Medicina Sperimentale e Scienze Biochimiche - ROMA

- Analisi biomolecolare dei meccanismi associati alla Fitness virale.

Attività o settore Virologia

(01/06/2002-30/09/2002) **Contratto di collaborazione**

Istituto Nazionale per le Malattie Infettive "Lazzaro Spallanzani, Unità di Monitoraggio Terapie Antivirali e Antineoplastiche – ROMA

- Compilazione e studio di un database di pazienti affetti da HIV.

Attività o settore Virologia

## ISTRUZIONE E FORMAZIONE

- (05/07/2006) **Conseguimento del titolo di dottore di ricerca in "Immunomicrobiologia Medica" presso la II Università di Roma "Tor Vergata", Dipartimento di Medicina Sperimentale e Scienze Biochimiche.**

- (28/01/2004) **Abilitazione professionale di Biologo presso l'Università di Viterbo**
- (05/07/2001) **Laurea con votazione 108/110 in Scienze Biologiche, presso la II Università di Roma "Tor Vergata".**

## COMPETENZE PERSONALI

Lingua madre Italiano

Altre lingue	COMPRESIONE		PARLATO		PRODUZIONE SCRITTA
	Ascolto	Lettura	Interazione	Produzione orale	
Inglese	B	B	B	B	B
Francese	B	B	A	A	A

Livelli: A1/2 Livello base - B1/2 Livello intermedio - C1/2 Livello avanzato

**Competenze comunicative** Discussione e presentazione di dati scientifici in congressi e workshop nazionali e internazionali. Frequente collaborazione con istituzioni quali ospedali e centri di ricerca nello scambio, discussione e analisi di dati scientifici.

**Competenze organizzative e gestionali** Esperienza nella gestione di studi clinici multicentrici e nel coordinamento del flusso di dati dai diversi centri. Collabora con diversi gruppi/enti di ricerca nazionali e internazionali grazie a fondi di ricerca dell'Istituto Superiore di Sanità, del Ministero della Salute, dell'Università e della Ricerca Scientifica, della Comunità Europea e del CNR.

**Competenze professionali** Oltre alle basilari procedure di laboratorio, la sottoscritta ha acquisito negli anni una padronanza di varie metodiche in diversi settori utili per la microbiologia.

**Altre competenze** ▪ Dal 1992 al 2013 ho svolto anche altri tipi di attività lavorative quali: cameriera presso pub (2001 - ad al 2013), animatrice per feste, promoter; segretaria presso studio dentistico; commessa.

**Attività sportiva** ▪ Nuoto, yoga, bicicletta.

**Patente di guida** ▪ B

## ULTERIORI INFORMAZIONI

## Attività didattica

(01/07/2010 - 17/01/2011) Tutor, Docente e Collaboratrice nella segreteria scientifica per il Corso di Perfezionamento in Gestione Clinica delle Resistenze ai Farmaci Antivirali (Direttore del Corso Prof. Carlo Federico Perno), tenutosi presso la Facoltà di Medicina dell'Università degli Studi di Roma Tor Vergata (A.A. 2009-2010) (CFU: 20).

(01/11/2014 – 31/10/2015) Docente di lezioni integrative e componente delle commissioni d'esame di profitto per il Corso di Microbiologia Ambientale, nell'ambito del Corso di Laurea in Biologia Evoluzionistica ed Ecologia (Macroarea di Scienze MM.FF.NN) dell'Università degli Studi di Roma "Tor Vergata", Roma.

(01/11/2014 – 31/10/2018) Docente (CFU: 1) di Virologia speciale e componente delle commissioni d'esame di profitto per il Corso Integrato di Microbiologia e Microbiologia Clinica I 2anno, nell'ambito del Corso di Laurea in Tecniche di Laboratorio Biomedico (Dipartimento di Medicina E Chirurgia) dell'Università degli Studi di Roma "Tor Vergata", Roma.

(01/11/2014 - oggi) Docente di Virologia (CFU: 1) per il Corso di Medicina pratica 3 afferente al Corso di Laurea Magistrale in Medicina e Chirurgia (Macroarea di Medicina e Chirurgia) dell'Università degli Studi di Roma "Tor Vergata", Roma.

(01/11/2015 - oggi) Docente di lezioni integrative e componente delle commissioni d'esame di profitto per il Corso Integrato di Microbiologia, nell'ambito del Corso di Laurea Magistrale a ciclo unico in Medicina e Chirurgia (Dipartimento di Medicina E Chirurgia) dell'Università degli Studi di Roma "Tor Vergata", Roma.

- (01/11/2015 - oggi) Docente di Virology (CFU: 1) e componente delle commissioni d'esame di profitto per il Corso Integrato di Microbiology (in lingua inglese), nell'ambito della International Medical School (Medicine and Surgery degree).
- (01/11/2015 - 31/10/2019) Cultore della materia e componente delle commissioni d'esame di profitto per il Corso Microbiology and Immunology (in inglese) nell'ambito del Corso di Laurea Magistrale in Farmacia (Area di Scienze MM.FF.NN. e Medicina e Chirurgia) dell'Università degli Studi di Roma "Tor Vergata", Roma.
- (22/03/2017 – 13/05/2017) Docente per il Corso di Perfezionamento in Terapia Antiretrovirale - Antiretroviral therapy (Direttore del Corso Prof. Paolo Rossi), presso la Facoltà di Medicina dell'Università degli Studi di Roma "Tor Vergata" nell'ambito della Scuola di Alta Formazione in Pediatria in convenzione con l'IRCCS Bambino Gesù (A.A. 2015-2016) (CFU: 9).
- (01/11/2018 - 31/10/2019) Cultore della materia in Virologia Generale e Speciale e componente delle commissioni d'esame di profitto per il Corso Integrato di Microbiologia e Microbiologia Clinica I 2anno, nell'ambito del Corso di Laurea in Tecniche di Laboratorio Biomedico (Macroarea di Medicina e Chirurgia).
- (01/11/2019 - in corso) Docente di Virologia speciale (CFU: 1) e componente delle commissioni d'esame di profitto per il Corso Integrato di Microbiologia e Microbiologia Clinica I 2anno, nell'ambito del Corso di Laurea in Tecniche di Laboratorio Biomedico (Macroarea di Medicina e Chirurgia).
- (01/11/2019-31/10/2020) Docente di Microbiology (CFU: 1) e componente delle commissioni d'esame di profitto per il Corso Microbiology and Immunology (in inglese) nell'ambito del Corso di Laurea Magistrale in Farmacia (Area di Scienze MM.FF.NN. e Medicina e Chirurgia).
- (01/11/2020-in corso) Docente di Microbiology (CFU: 2) e componente delle commissioni d'esame di profitto per il Corso Microbiology and Immunology (in inglese) nell'ambito del Corso di Laurea Magistrale in Farmacia (Area di Scienze MM.FF.NN. e Medicina e Chirurgia).

**Incarichi speciali**

- (28/05/2015 - oggi ) Membro dello Steering Committee dell'Italian Cohort of antiretroviral-naive patients (ICONA) Study group.
- (21/05/2012 - 2017) Membro del panel delle "Linee Guida Italiane sull'utilizzo dei farmaci antiretrovirali e sulla gestione diagnostico-clinica delle persone con infezione da HIV-1"
- (05/12/2016 - oggi ) Membro del Board Scientifico del Database ARCA (Antiviral Response Cohort Analysis).
- (14/12/2017 - oggi ) Membro dello Steering Committee del Registro Italiano dei Pazienti con Infezione da HIV-1 con RESistenza agli Inibitori della Trascrittasi inversa, dell'InteGrasl e della PrOteasi virale (PRESTIGIO).
- (04/12/2019 – oggi) Membro del Collegio del Dottorato in Microbiologia, Immunologia, Malattie Infettive, Trapianti d'Organo e Patologie Connesse – Direttore Prof.ssa Francesca Ceccherini Silberstein - Università degli Studi di Roma "Tor Vergata".
- (2018- oggi) Membro della Scuola di Specializzazione in Microbiologia e Virologia – Direttore Prof. Sandro Grelli - Università degli Studi di Roma "Tor Vergata".

**Attività di revisore**

Dal 2008 ad oggi revisore di articoli scientifici dalle seguenti riviste "peer reviewed": AIDS patient CARE and STDs; AIDS Research and Human Reotroviruses; BMC Infectious Diseases; Current HIV Research; Clinical Microbiology and Infection; Clinical Epidemiology; EBiomedicine; EFuture Virology; HIV/AIDS - Research and Palliative Care; HIV Medicine; Journal of Antimicrobial Chemotherapy; Journal of Antivirals & Antiretrovirals; Journal of Public Health and Epidemiology; Journal of the International AIDS Society; International Journal of Virology and AIDS; Journal of Global Antimicrobial Resistance; Journal of Medical Virology; Liver International; PlosOne; Sexually Transmitted Infections; The Lancet Microbe; Scientific reports

**Premi e Riconoscimenti**

Ha ricevuto 14 premi a riconoscimento della propria attività scientifica.

**Attività scientifica personale**

Autrice di >400 articoli scientifici e presentazioni a congressi, di cui 130 in extenso su riviste internazionali citate su PubMed con IF. Totale Citazioni (fonte: Scopus, 10/03/2022): 1602  
 Indice H (fonte: Scopus, 10/03/2022): 1602  
 Impact Factor medio articoli pubblicati: 3,995  
 Le pubblicazioni della sottoscritta sono relative ai seguenti filoni di ricerca: infezione da HIV e la sua epidemiologia; farmaci antivirali; farmacoresistenza di HIV/HBV/HCV; patogenesi virale; tropismo virale; evoluzione e dinamica virale; diagnostica molecolare; analisi strutturale e funzionale delle proteine virali.

**Partecipazione a congressi**

Ha partecipato a numerosi congressi scientifici nazionali e internazionali presentandovi comunicazioni orali e poster. Ha tenuto letture a invito a Congressi Nazionali e/o Internazionali.

## PUBBLICAZIONI

Lavori in exentso su riviste con  
impact factor

1. Fokam J, Ngoufack Jagni Semengue E, Armenia D, Takou D, Dambaya B, Teto G, Chenwi CA, Nka AD, Beloumou GA, Ndjeyep SCD, Tchouaket MCT, Fainguem N, Sosso SM, Colizzi V, Perno CF, Ndjolo A, Ceccherini-Silberstein F, and **Santoro Maria Mercedes**. High performance of integrase genotyping on diverse HIV-1 clades circulating in Cameroon: toward a successful transition to dolutegravir-based regimens in low and middle-income countries. *Diagn Microbiol Infect Dis*. 2022 Feb;102(2):115574. doi: 10.1016/j.diagmicrobio.2021.115574. Epub 2021 Oct 22. PMID: 34864527. **IF 2.803**
2. Teto G, Nka AD, Fokam J, Bouba Y, Takou D, Fabeni L, Carioti L, Armenia D, Semengue ENJ, Dambaya B, Sosso SM, Colizzi V, Perno CF, Ceccherini-Silberstein F, **Santoro Maria Mercedes**, and Ndjolo A. Detection of Gag C-terminal mutations among HIV-1 non-B subtypes in a subset of Cameroonian patients. *Sci Rep*. 2022 Jan 26;12(1):1374. doi: 10.1038/s41598-022-05375-9. PMID: 35082353; PMCID: PMC8791941. **IF 4.379**
3. Rusconi S, Saladini F, Bellocchi MC, Galli L, Gagliardini R, Gazzola L, Francisci D, Vichi F, Focà E, Zazzi M, **Santoro Maria Mercedes**, Gabrieli A, Castagna A; PRESTIGIO Registry study group; Leronlimab (PRO 140) activity against 4-class drug resistant HIV-1 from heavily treatment experienced subjects. *Pharmacol Res*. 2022 Jan 6:106064. doi: 10.1016/j.phrs.2022.106064. Epub ahead of print. PMID: 34999223. **IF 7.658**
4. Armenia D\*, **Santoro Maria Mercedes\***, Bellocchi MC, Carioti L, Galli L, Galli A, Scutari R, Salsi E, Mussini C, Sterrantino G, Calza L, Rossetti B, Zazzi M, and Antonella Castagna. Viral resistance burden and APOBEC editing correlate with virological response in heavily treatment-experienced people living with multi-drug resistant HIV. *Int J Antimicrob Agents*. 2021 Dec 3:106492. doi: 10.1016/j.ijantimicag.2021.106492. Epub ahead of print. PMID: 34871747. **Eguale contributo. Autore corrispondente. IF 5.283**
5. Fokam J, Mpouel Bala ML, **Santoro Maria Mercedes**, Takou D, Tala V, Beloumou G, Ngoufack ES, Chenwi C, Pabo Willy Leroi T, Njume D, Teto G, Dambaya B, Djupsa S, Sosso S, Ateba F, Kamta C, Bala L, Njom Nlend AE, Koki Ndombo P, Colizzi V, Perno CF, Ndjolo A. Archiving of mutations in HIV-1 cellular reservoirs among vertically infected adolescents is contingent with clinical stages and plasma viral load: Evidence from the EDCTP-READY study. *HIV Med*. 2021 Dec 23. doi: 10.1111/hiv.13220. Epub ahead of print. PMID: 34951111. **IF 3.18**
6. Bouba Y, Armenia D, Forbici F, Bertoli A, Borghi V, Gagliardini R, Vergori A, Cicalini S, Mazzotta V, Malagnino V, Lichtner M, Latini A, Mussini C, Andreoni M, Antinori A, Perno CF, Ceccherini-Silberstein F, and **Santoro Maria Mercedes**. Genotypic HIV-1 tropism determination might help to identify people with exhausted treatment options and advanced disease. *J Antimicrob Chemother*. 2021 Sep 16:dkab322. doi: 10.1093/jac/dkab322. Epub ahead of print. PMID: 34529797. **IF 5.439**
7. Fokam J, Takou D, Njume D, Pabo W, **Santoro Maria Mercedes**, Njom Nlend AE, Beloumou G, Sosso S, Moudourou S, Teto G, Dambaya B, Djupsa S, Tetang Ndiang S, Ateba FN, Billong SC, Kamta C, Bala L, Lambo V, Tala V, Chenwi Ambe C, Mpouel ML, Cappelli G, Cham F, Ndip R, Mbuagbaw L, Koki Ndombo P, Ceccherini-Silberstein F, Colizzi V, Perno CF, Ndjolo A. Alarming rates of virological failure and HIV-1 drug resistance amongst adolescents living with perinatal HIV in both urban and rural settings: evidence from the EDCTP READY-study in Cameroon. *HIV Med*. 2021 Aug;22(7):567-580. doi: 10.1111/hiv.13095. Epub 2021 Mar 31. PMID: 33792134. **IF 3.18. Cites 1**
8. Scutari R, Costabile V, Galli L, Bellocchi MC, Carioti L, Barbaliscia S, Poli A, Galli A, Perno CF, **Santoro Maria Mercedes**, Castagna A, Ceccherini-Silberstein F, Alteri C, and Spagnuolo V. Impact of Analytical Treatment Interruption on Burden and Diversification of HIV Peripheral Reservoir: A Pilot Study. *Viruses*. 2021 Jul 19;13(7):1403. doi: 10.3390/v13071403. PMID: 34372609; PMCID: PMC8310290. **IF 5.048**
9. Nka AD, Teto G, **Santoro Maria Mercedes**, Ngum Ndze V, Takou D, Dambaya B, Ngoufack Jagni Semengue E, Fabeni L, Perno CF, Colizzi V, Ceccherini-Silberstein F, Fokam J. HIV-1 Gag gene mutations, treatment response and drug resistance to protease inhibitors: A systematic review and meta-analysis protocol. *PLoS One*. 2021 Jul 1;16(7):e0253587. doi: 10.1371/journal.pone.0253587. PMID: 34197501; PMCID: PMC8248685. **IF 3.24. Cites 1**

10. Sinopoli A, Isonne C, **Santoro Maria Mercedes**, Baccolini V. The effects of orally administered lactoferrin in the prevention and management of viral infections: A systematic review. *Rev Med Virol*. 2021 May 28:e2261. doi: 10.1002/rmv.2261. Epub ahead of print. PMID: 34133812. **IF 6.989. Cites 2**
11. Alkhatib M, Di Maio VC, De Murtas V, Polilli E, Milana M, Teti E, Fiorentino G, Calvaruso V, Barbaliscia S, Bertoli A, Scutari R, Carioti L, Cento V, **Santoro Maria Mercedes**, Orro A, Maida I, Lenci I, Sarmati L, Craxì A, Pasquazzi C, Parruti G, Babudieri S, Milanese L, Andreoni M, Angelico M, Perno CF, Ceccherini-Silberstein F, Svicher V, Salpini R, On Behalf Of Hirma Hepatocarcinoma Innovative Research MARKers And Fondazione Vironet C Hcv Virology Italian Resistance. Genetic Determinants in a Critical Domain of NS5A Correlate with Hepatocellular Carcinoma in Cirrhotic Patients Infected with HCV Genotype 1b. *Viruses*. 2021 Apr 23;13(5):743. doi: 10.3390/v13050743. PMID: 33922732; PMCID: PMC8146897. **IF 5.048**
12. E Semengue, D Armenia, Daniele, S Inzaule, **Maria Mercedes Santoro**, B Dambaya, D Takou, G Teto, AD Nka, Y Bouba, L Fabeni, C Collins, G Beloumou, SC Djupsa, V Colizzi, CF Perno, F Ceccherini-Silberstein, Francesca, and J Fokam. Baseline Integrase Drug Resistance Mutations and Conserved Regions across HIV-1 Clades in Cameroon: Implications for Transition to Dolutegravir in Resource-Limited Settings. *Journal of Antimicrobial Chemotherapy*. 2021 Jan 27:dkab004. doi: 10.1093/jac/dkab004. Epub ahead of print. PMID: 33501504. **IF 5.439. Cites 1**
13. D Armenia, Y Bouba, R Gagliardini, L Fabeni, V Borghi, G Bero, A Vergori, S Cicalini, C Mussini, A Antinori, F Ceccherini-Silberstein, CF Perno, and **Maria Mercedes Santoro**. Virological response and resistance profile in highly treatment-experienced HIV-1 infected patients switching to dolutegravir plus boosted-darunavir in clinical practice. *HIV Medicine*. 2021 Jan 21. doi: 10.1111/hiv.13062. Epub ahead of print. PMID: 33480094. **Autore corrispondente. IF 3.18. Cites 1**
14. F Lombardi, A Giacomelli, D Armenia, A Lai, A Dusina, A Bezench, L Timelli, F Saladini, F Vichi, P Corsi, G Colao, B Bruzzone, R Gagliardini, A Callegaro, A Castagna, and **Maria Mercedes Santoro**, for the ARCA Study Group. Prevalence and factors associated with HIV-1 multidrug resistance over the past two decades in the Italian Arca database. *Int J Antimicrob Agents*. 2020 Nov 28:106252. doi: 10.1016/j.ijantimicag.2020.106252. Epub ahead of print. PMID: 33259914. **Autore corrispondente. IF 5.283 Cites 1**
15. L Galli, MR Parisi, A Poli, M Menozzi, M Fisco, E Garlassi, D Francisci, A Di Biagio, G Sterrantino, C Fomabaio, A Degli Antoni, G Angarano, FM Fusco, A D'Arminio Monforte, GM Corbelli, **Maria Mercedes Santoro**, M Zazzi, and A Castagna. Burden of disease in PLWH harboring a multidrug resistant virus: data from PRESTIGIO Registry. *Open Forum Infect Dis*. 2020 Sep 26;7(11):ofaa456. doi: 10.1093/ofid/ofaa456. PMID: 33241063; PMCID: PMC7673611. **IF 3.835. Cites 3**
16. Lai A, Franzetti M, Bergna A, Saladini F, Bruzzone B, Di Giambenedetto S, Di Biagio A, Lo Caputo S, **Santoro Maria Mercedes**, Maggiolo F, Parisi SG, Rusconi S, Gianotti N, and Balotta C. Marked decrease in acquired resistance to antiretrovirals in latest years in Italy. *Clin Microbiol Infect*. 2020 Sep 23:S1198-743X(20)30580-2. doi: 10.1016/j.cmi.2020.09.028. Epub ahead of print. PMID: 32979570. **IF 8.067**
17. Armenia D, Bouba Y, Gagliardini R, Gori C, Bertoli A, Borghi V, Gennari W, Micheli V, Callegaro AP, Gazzola L, Bruzzone B, Giannetti A, Mazzotta M, ergori A, Mastrocrosa I, Colafigli M, Lichtner L, di Biagio A, Maggiolo F, Rizzardini G, D'Arminio Monforte A, Andreoni M, Mussini C, Antinori A, Ceccherini-Silberstein F, Perno CF, and **Maria Mercedes Santoro**, for the Italian INI-Surveillance Group. Evaluation of virological response and resistance profile in HIV-1 infected patients starting a first-line integrase inhibitor-based regimen in clinical settings. *J Clin Virol*. 2020 Sep;130:104534. doi: 10.1016/j.jcv.2020.104534. Epub 2020 Jul 11. PMID: 32769022. **Autore corrispondente. IF 3.168. Cites 1**
18. F Saladini, A Giannini, F Giammarino, F Maggiolo, F Vichi, GM Corbelli, A Galli, A Bigoloni, A Poli, **Maria Mercedes Santoro**, M Zazzi, and A Castagna. In vitro susceptibility to fostemsavir is not affected by long-term exposure to antiviral therapy in multidrug resistant HIV-1 infected patients. *J Antimicrob Chemother*. 2020 Sep 1;dkaa178. doi:10.1093/jac/dkaa178. **IF 5.439 Cites 6**
19. A Artese, V Svicher, G Costa, R Salpini, V Chiara Di Maio, M Alkhatib, FA Ambrosio, **Maria Mercedes Santoro**, YG Assaraf, S Alcaro, and F Ceccherini-Silberstein. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses. *Drug Resist Updat*.

2020 Aug 26;53:100721. doi: 10.1016/j.drug.2020.100721. Epub ahead of print. PMID: 33132205; PMCID: PMC7448791. **IF 18.5. Cites 34**

20. Fokam J, Takou D, Semengue ENJ, Teto G, Beloumou G, Dambaya B, **Santoro Maria Mercedes**, Mossiang L, Billong SC, Cham F, Sosso SM, Temgoua ES, Nanfack AJ, Moudourou S, Kamgaing N, Kamgaing R, Ngako Pamen JN, Etame MMN, Bissek AZ, Elat JN, Moussi EE, Colizzi V, Perno CF, and Ndjolo A; VIROFORUM. First case of Dolutegravir and Darunavir/r multi drug-resistant HIV-1 in Cameroon following exposure to Raltegravir: lessons and implications in the era of transition to Dolutegravir-based regimens. *Antimicrob Resist Infect Control*. 2020 Aug 26;9(1):143. doi: 10.1186/s13756-020-00799-2. PMID: 32843050; PMCID: PMC7449072. **IF 3.594. Cites 1**

21. L Fabeni\*, **Maria Mercedes Santoro\***, P Lorenzini, S Rusconi, N Gianotti, A Costantini, L Sarmati, A Antinori, F Ceccherini-Silberstein, A d'Arminio Monforte, A Saracino, and E Girardi, on behalf of the Icona Foundation Study Cohort. Evaluation of HIV Transmission Clusters among Natives and Foreigners Living in Italy. *Viruses* 2020;12(8):E791. Published 2020 Jul 23. doi:10.3390/v12080791 **\*Egual contributo; Autore corrispondente. IF 5.048. Cites 4**

22. Bouba Y, Berno G, Fabeni L, Carioti L, Salpini R, Aquaro S, Svicher V, Perno CF, Ceccherini-Silberstein F, and **Santoro Maria Mercedes**. Identification of gp120 polymorphisms in HIV-1 B subtype potentially associated with resistance to fostemsavir. *J Antimicrob Chemother*. 2020 Jul 1;75(7):1778-1786. doi: 10.1093/jac/dkaa073. PMID: 32160290. **IF 5.439. Cites 5**

23. **Santoro Maria Mercedes**, Fornabaio C, Malena M, Galli L, Poli A, Menozzi M, Zazzi M, White KL, Castagna A; PRESTIGIO Study Group. Susceptibility to HIV-1 integrase strand transfer inhibitors (INSTIs) in highly treatment-experienced patients who failed an INSTI-based regimen. *Int J Antimicrob Agents*. 2020 Jul;56(1):106027. doi: 10.1016/j.ijantimicag.2020.106027. Epub 2020 May 23. PMID: 32450199. **IF 5.283. Cites 3**

24. J Fokam, D Takou, G Teto, OP Kome, SE Nforbih, **Maria Mercedes Santoro**, ES Ngoufack, M Eyongetah, D Palmer, ET Fokunang, CN Fokunang, V Colizzi, CF Perno, and A Ndjolo. Pre-treatment Drug Resistance and HIV-1 Genetic Diversity in the Rural and Urban Settings of Northwest-Cameroon. *PLoS One*. 2020 Jul;15(7):e0235958. Published 2020 Jul 21. doi:10.1371/journal.pone.0235958. **IF 3.24. Cites 2**

25. Canetti D, Galli L, Gianotti N, Celotti A, Calza L, Gagliardini R, Rusconi S, Modica S, Cenderello G, Ferrara M, **Santoro Maria Mercedes**, Zazzi, M, and Castagna A, on behalf of PRESTIGIO Study Group. Simplification to High Genetic Barrier 2-Drug Regimens in People Living With HIV Harboring 4-Class Resistance Enrolled in the PRESTIGIO Registry. *Journal of acquired immune deficiency syndromes*. 2020 Aug 1;84(4),e24–e28. <https://doi.org/10.1097/QAI.0000000000002378>. **IF 3.731**

26. Fokam J, Nangmo A, Wandum C, Takou D, **Santoro Maria Mercedes**, Nlend AN, Ateba FN, Ndombo PK, Kamgaing N, Kamta C, Essiane A, Lambo V, Fokunang C, Mbanya D, Colizzi V, Perno CF, and Ndjolo A. Programme quality indicators of HIV drug resistance among adolescents in urban versus rural settings of the centre region of Cameroon. *AIDS Res Ther*. 2020 May 12;17(1):14. doi: 10.1186/s12981-020-00270-7. PubMed PMID: 32398107. Free su PUBMED. **IF 2.092. Cites 2**

27. D Armenia, D Di Carlo, P Flandre, Y Bouba, V Borghi, F Forbici, A Bertoli, C Gori, L Fabeni, W Gennari, C Pinnetti, A Mondì, S Cicalini, R Gagliardini, A Vergori, R Bellagamba, V Malagnino, F Montella, M Colafigli, A Latini, R Marocco, M Lichtner, M Andreoni, C Mussini, F Ceccherini-Silberstein, A Antinori, CF Perno, and **Maria Mercedes Santoro**. HIV multi-drug resistance is still a relevant issue despite its dramatic drop over the years. *J Antimicrob Chemother*. 2020 May 1;75(5):1301-1310. doi:10.1093/jac/dkz554. **Autore corrispondente. IF 5.439. Cites 4**

28. Semengue ENJ, **Santoro Maria Mercedes**, Ndze VN, Dambaya B, Takou D, Teto G, Nka AD, Fabeni L, Wiyeh A, Ceccherini-Silberstein F, Colizzi V, Perno CF, and Fokam J. HIV-1 integrase resistance associated mutations and the use of dolutegravir in Sub-Saharan Africa: a systematic review and meta-analysis protocol. *Syst Rev*. 2020 Apr 25;9(1):93. doi: 10.1186/s13643-020-01356-z. PubMed PMID: 32334643. **IF 1.76**

29. C Soulie, **Maria Mercedes Santoro**, A Storto, B Abdi, C Charpentier, D Armenia, A Jary, F Forbici, A Bertoli, W Gennari, M Andreoni, C Mussini, A Antinori, CF Perno, V Calvez, F Ceccherini-Silberstein, D Descamps, and AG Marcelin. Prevalence of Doravirine associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy. *J Antimicrob Chemother*. 2020 Apr 1;75(4):1026-1030. doi:10.1093/jac/dkz553. **IF 5.439. Cites 10**

30. R Scutari, C Alteri, I Vicenti, D Di Carlo, V Zuccaro, F Incardona, V Borghi, A Bezenchekf, M Andreoni, A Antinori, CF Perno, A Cascio, A De Luca, M Zazzi, and **Maria Mercedes Santoro**, on behalf of the ARCA (Antiviral Response Cohort Analysis) study Group. Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors. *J Glob Antimicrob Resist*. 2020;20:163-169. doi:10.1016/j.jgar.2019.07.015. Epub 2019 Jul 19. **Autore corrispondente. IF 2.70. Cites 5**
31. J Fokam, SM Sosso, B Yagai, SC Billong, Re Djubgang Mbadie, R Kamgaing Simo, SV Edimo, A Durand Nka, A Tiga Ayissi, Jf Yimga, D Takou, S Moudourou, M Ngo Nemb, JBE Nfetam, **Maria Mercedes Santoro**, CF Perno, V Colizzi, and Alexis Ndjolo. Viral Suppression in Adults, Adolescents and Children receiving Antiretroviral Therapy in Cameroon: Adolescents at High Risk of Virological Failure in the Era of "Test and Treat". *AIDS Research and Therapy* 2019 Nov 19;16(1):36. **IF 2.092. Cites 7**
32. J Fokam, **Maria Mercedes Santoro**, D Takou, AE Njom Nlend, P Koki Ndombo, N Kamgaing, C Kamta, A Essiane, SM Sosso, A Ndjolo, V Colizzi, and CF Perno. Evaluation of Treatment Response, Drug Resistance and HIV-1 Variability among Adolescents on First- and Second-Line Antiretroviral Therapy: An observational and prospective study in the Centre Region of Cameroon (EDCTP READY-Study). *BMC Pediatr*. 2019;19(1):226. Published 2019 Jul 5. doi:10.1186/s12887-019-1599-z. **IF (2018) 2.042. Cites 2**
33. C Alteri, R Scutari, C Stingone, G Maffongelli, M Brugnati, F Falasca, S Martini, A Bertoli, O Turriziani, L Sarmati, N Coppola, M Andreoni, **Maria Mercedes Santoro**, CF Perno, F Ceccherini-Silberstein, and V Svicher. Quantification of HIV-DNA and residual viremia in patients starting ART by droplet digital PCR: their dynamic decay and correlations with immunological parameters and virological success". *J Clin Virol*. 2019 Aug;117:61-67. **IF 2.777. Cites 13**
34. S Rusconi\*, **Maria Mercedes Santoro\***, A Antinori, S Bonora, A Cingolani, N Gianotti, F Ceccherini Silberstein, A Tavelli, A d'Arminio Monforte, and A Cozzi-Lepri for the Icona Foundation Study Group. Is the rate of virological failure to cART continuing to decline in recent calendar years? **\*Egual contributo alla stesura del lavoro**. *J Clin Virol*. 2019 Jul;116:23-28. doi: 10.1016/j.jcv.2019.04.009. Epub 2019 May 3. **IF 2.777. Cites 1**
35. L Fabeni, C Alteri, G Berno, R Scutari, N Orchi, G De Carli, A Bertoli, L Carioti, C Gori, F Forbici, R Salpini, A Vergori, R Gagliardini, S Cicalini, A Mondì, C Pinnetti, L Mazzuti, O Turriziani, M Colafigli, V Borghi, F Montella, A Pennica, M Lichtner, E Girardi, M Andreoni, C Mussini, A Antinori, F Ceccherini-Silberstein, CF Perno, and **Maria Mercedes Santoro**, the SENDIH Study group. Characterization of HIV-1 molecular transmission clusters among newly diagnosed individuals infected with non-B subtypes in Italy. *Sex Transm Infect*. 2019 May 10. pii: sextrans-2019-054017. doi: 10.1136/sextans-2019-054017. **IF 3.396. Cites 8**
36. Armenia D, Di Carlo D, Cozzi-Lepri A, Calcagno A, Borghi V, Gori C, Bertoli A, Gennari W, Bellagamba R, Castagna A, Latini A, Pinnetti C, Cicalini S, Saracino A, Lapadula G, Rusconi S, Castelli F, Di Giambenedetto S, Andreoni M, Di Perri G, Antinori A, Mussini C, Ceccherini-Silberstein F, Monforte AD, Perno CF, and **Santoro Maria Mercedes**; ICONA Foundation Study Group. Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen. *Antivir Ther*. 2019 Apr 12. doi: 10.3851/IMP3309. [Epub ahead of print] PubMed PMID: 30977466. **Autore corrispondente. IF 2.043. Cites 3**
37. Takou D, Fokam J, Teto G, **Maria Mercedes Santoro**, Ceccherini-Silberstein F, Nanfack AJ, Sosso SM, Dambaya B, Salpini R, Billong SC, Gori C, Fokunang CN, Cappelli G, Colizzi V, Perno CF, and Ndjolo A. HIV-1 Drug Resistance Testing is Essential for Heavily-Treated Patients Switching from First- to Second-Line Regimens in Resource-Limited Settings: Evidence from Routine Clinical Practice in Cameroon. *BMC Infect Dis*. 2019 Mar 12;19(1):246. doi: 10.1186/s12879-019-3871-0. PubMed. PMID: 30871487; PubMed Central PMCID: PMC6419466. **Free article. IF 2.62; Cites 6**
38. C Soulié, **Maria Mercedes Santoro**, C Charpentier, A Storto, D Paraskevis, D Di Carlo, W Gennari, G Sterrantino, M Zazzi, CF Perno, V Calvez, D Descamps, F Ceccherini-Silberstein, and AG Marcelin. Rare occurrence of doravirine resistance associated mutations in HIV-1-infected treatment-naïve patients. *J Antimicrob Chemother*. 2019 Mar 1;74(3):614-617. doi: 10.1093/jac/dky464. PMID:30476106 **IF 5.439. Cites 12**
39. C Alteri, R Scutari, A Bertoli, D Armenia, C Gori, G Fabbri, CM Mastroianni, C Cerva, A Cristaudo, I Vicenti, B Bruzzone, M Zazzi, M Andreoni, A Antinori, V Svicher, F Ceccherini-Silberstein, CF Perno, and **Maria Mercedes Santoro**. Integrase strand transfer inhibitor-based regimen is related with a limited



HIV-1 V3 loop evolution in clinical practice. *Virus Genes*. 2019 Feb 22. doi: 10.1007/s11262-019-01649-z. **IF 1.542**

**40.** Antinori A, Santoro Maria Mercedes, Gagliardini R, Marchetti G, Mondì A, Cento V, Perno CF, Andreoni M; Two-Drug Antiretroviral Regimens expert panel. Italian expert panel consensus statements on two-drug antiretroviral regimens to treat naïve and virologically suppressed HIV-1 infected patients. *New Microbiol*. 2019 Feb 20;42(1). [Epub ahead of print] PubMed PMID: 30785209. **Free article. Review. IF 1.953. Cites 1**

**41.** Pougá L, Santoro Maria Mercedes, Charpentier C, Di Carlo D, Romeo I, Artese A, Alcaro S, Antinori A, Wiriden M, Perno CF, Ambrosio FA, Calvez V, Descamps D, Marcelin AG, Ceccherini-Silberstein F, Lambert-Niclot S. New Resistance Mutations to Nucleoside Reverse Transcriptase Inhibitors at Codon 184 of HIV-1 Reverse Transcriptase (M184L and M184T). *Chem Biol Drug Des*. 2019 Jan;93(1):50-59. doi: 10.1111/cbdd.13378. Epub 2018 Nov 27. PMID: 30103267 **IF 2.328. Cites 1**

**42.** C Alteri, L Fabeni, R Scutari, G Berno, D Di Carlo, C Gori, A Bertoli, A Vergori, I Mastroianni, R Bellagamba, C Mussini, M Colafigli, F Montella, A Pennica, CM Mastroianni, E Girardi, M Andreoni, A Antinori, V Svicher, F Ceccherini-Silberstein, CF Perno, and Maria Mercedes Santoro. Genetic divergence of HIV-1 B subtype in Italy over the years 2003-2016 and impact on CTL escape prevalence. *Sci Rep*. 2018 Oct 24;8(1):15739. doi: 10.1038/s41598-018-34058-7. PubMed PMID: 30356083; PubMed Central PMCID: PMC6200748. **Free PMC Article. IF 4.122**

**43.** Spertilli Raffaelli C, Rossetti B, Paglicci L, Colafigli M, Punzi G, Borghi V, Pecorari M, Santoro Maria Mercedes, Penco G, Antinori A, Zazzi M, De Luca A, Zanelli G. Impact of transmitted HIV-1 drug resistance on the efficacy of first-line antiretroviral therapy with two nucleos(t)ide reverse transcriptase inhibitors plus an integrase inhibitor or a protease inhibitor. *J. Antimicrob. Chemother*. 2018 Jun 25. doi: 10.1093/jac/dky211. **IF 5.217. Cites 11**

**44.** Armenia D, Zaccarelli M, Borghi V, Gennari W, Di Carlo D, Giannetti A, Forbici F, Bertoli A, Gori C, Fabeni L, Pinnetti C, Marocco R, Latini A, Ceccherini-Silberstein F, Mastroianni CM, Mussini C, Antinori A, Perno CF, and Santoro Maria Mercedes. Resistance detected in PBMCs predicts virological rebound in HIV-1 suppressed patients switching treatment. *J Clin Virol*. 2018 Jul; 104:61-64. doi: 10.1016/j.jcv.2018.04.001. Epub 2018 Apr 3. PMID: 29738896. **IF 3.051. Cites 9**

**45.** Fokam J, Bellocchi MC, Armenia D, Nanfack AJ, Carioti L, Continenza F, Takou D, Temgoua ES, Tangimpundu C, Torimiro JN, Koki PN, Fokunang CN, Cappelli G, Ndjolo A, Colizzi V, Ceccherini-Silberstein F, Perno CF, and Santoro Maria Mercedes. Next-generation sequencing provides an added value in determining drug resistance and viral tropism in Cameroonian HIV-1 vertically infected children. *Medicine (Baltimore)*. 2018 Mar;97(13):e0176. doi: 10.1097/MD.00000000000010176. PubMed PMID: 29595649. **Free PMC Article. IF 1.803. Cites 9**

**46.** Santoro Maria Mercedes, Di Carlo D, Armenia D, Zaccarelli M, Pinnetti C, Colafigli M, Prati F, Boschi A, Antoni AMD, Lagi F, Sighinolfi L, Gervasoni C, Andreoni M, Antinori A, Mussini C, Perno CF, Borghi V, Sterrantino G. Viro-immunological response of drug-naïve HIV-1-infected patients starting a first-line regimen with viraemia >500,000 copies/ml in clinical practice. *Antivir Ther*. 2018;23(3):249-257. doi: 10.3851/IMP3197. PMID: 28935850 **Autore corrispondente. IF 2.146. Cites 5**

**47.** Libonati A, Di Taranto V, D'Agostini C, Santoro Maria Mercedes, Di Carlo D, Ombres D, Gallusi G, Favalli C, Marzo G, Campanella V. Comparison of coronal leakage of different root canal filling techniques: an ex vivo study. *J Biol Regul Homeost Agents*. 2018 Mar-Apr;32(2):397-405. PubMed PMID: 29685025. **IF 1.558. Cites 32**

**48.** Fabeni L, Alteri C, Di Carlo D, Orchi N, Carioti L, Bertoli A, Gori C, Forbici F, Continenza F, Maffongelli G, Pinnetti C, Vergori A, Mondì A, Ammassari A, Borghi V, Giuliani M, De Carli G, Pittalis S, Grisetti S, Pennica A, Mastroianni CM, Montella F, Cristaudo A, Mussini C, Girardi E, Andreoni M, Antinori A, Ceccherini-Silberstein F, Perno CF, and Santoro Maria Mercedes; SENDIH Study Group; SENDIH (Studio Epidemiologico Nuove Diagnosi Infezione da HIV) Study Group. Dynamics and phylogenetic relationships of HIV-1 transmitted drug resistance according to subtype in Italy over the

years 2000-14. J Antimicrob Chemother. 2017 Oct 1;72(10):2837-2845. doi: 10.1093/jac/dkx231. PubMed PMID: 29091206. **IF. 5.071. Cites 12**

49. Fabeni L, Berno G, Fokam J, Bertoli A, Alteri C, Gori C, Forbici F, Takou D, Vergori A, Zaccarelli M, Maffongelli G, Borghi V, Latini A, Pennica A, Mastroianni CM, Montella F, Mussini C, Andreoni M, Antinori A, Perno CF, and **Santoro Maria Mercedes**, on behalf of the Resistance Study group. Comparative evaluation of subtyping tools for the surveillance of newly emerging HIV-1 strains. J Clin Microbiol. 2017 Sep;55(9):2827-2837. doi: 10.1128/JCM.00656-17. Epub 2017 Jul 12. **Free PMC Article. IF. 3.712; Cites 9**

50. Soo-Yon Rhee, Vici Varghese, Susan P. Holmes, ....., **Maria Mercedes Santoro**, ....., Sergio Carmona, Ravindra K. Gupta, and Robert W. Shafer. Mutational correlates of virological failure in individuals receiving a WHO-recommended tenofovir-containing first-line regimen. EBioMedicine. 2017 Apr;18:225-235. doi: 10.1016/j.ebiom.2017.03.024. Epub 2017 Mar 19. **Free PMC Article. IF. 6.183; Cites 22**

51. Armenia D, Di Carlo D, Calcagno A, Vendemiati G, Forbici F, Bertoli A, Berno G, Carta S, Continenza F, Fedele V, Bellagamba R, Cicalini S, Ammassari A, Libertone R, Zaccarelli M, Ghisetti V, Andreoni M, Ceccherini-Silberstein F, Bonora S, Di Perri G, Antinori A, Perno CF, and **Santoro Maria Mercedes**. Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen. J Antimicrob Chemother. 2017 Mar 1;72(3):855-865. doi: 10.1093/jac/dkw512. **Autore corrispondente. IF 4.919; Cites 9**

52. AJ Nanfack, D Takou, J Fokam, R Salpini, **Maria Mercedes Santoro**, G Cappelli, M Baane, SM Tetang, J Eberle, L Gürtler, F Ceccherini-Silberstein, JN Torimiro, V Colizzi, CF Perno and A Ndjolo. HIV-1 Drug Susceptibility to Potential Second- and Third-Line Antiretroviral Regimens among Cameroonian Patients: Evidence from a Cross-sectional Design. Curr HIV Res. 2016 Dec 29. [Epub ahead of print] **IF. 1.612; Cites 7**

53. Zaccarelli M\*, **Santoro Maria Mercedes\***, Armenia D, Borghi V, Gennari W, Gori C, Forbici F, Bertoli A, Fabeni L, Giannetti A, Cicalini S, Bellagamba R, Andreoni M, Mastroianni CM, Mussini C, Ceccherini-Silberstein F, Perno CF, and Antinori A. Genotypic resistance test in proviral DNA can identify resistance mutations never detected in historical genotypic test in patients with low level or undetectable HIV-RNA. Journal of Clinical Virology 2016, vol. 82, p. 94-100, ISSN: 1386-6532, doi: 10.1016/j.jcv.2016.07.007 **\*Eguale contributo alla stesura del lavoro. Autore corrispondente. IF 3.051; Cites 23**

54. D Armenia, D Di Carlo, G Maffongelli, V Borghi, C Alteri, F Forbici, A Bertoli, C. Gori, M Giuliani, E Nicastrì, M Zaccarelli, C Pinnetti, S Cicalini, G D'Offizi, F Ceccherini-Silberstein, C Mussini, A Antinori, M Andreoni, CF Perno, and **Maria Mercedes Santoro**. Virological response and resistance profile in HIV-1 infected patients starting darunavir containing regimens. HIV Med. 2017 Jan;18(1):21-32. doi: 10.1111/hiv.12388. Epub 2016 Jun 28. **Autore corrispondente. IF 3.257; Cites 7**

55. **Santoro Maria Mercedes**, and Perno CF. Clinical relevance of genotypic resistance testing today. NEW MICROBIOLOGICA 2016, vol. 39, p. 91-92, ISSN: 1121-7138. **IF. 1.568; Cites 4**

56. Gregson J, Tang M; Ndembu N,..... **Maria Mercedes Santoro**, .....; Kantor K, Robert W Shafer RW, Gupta RK, on behalf of the TenoRes Study Group. Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicenter retrospective cohort study. Lancet Infect Dis. 2016 May;16(5):565-575. doi: 10.1016/S1473-3099(15)00536-8. Epub 2016 Jan 29. **Free PMC Article. IF. 21.372; Cites 168**

57. J Fokam, D Takou, **Maria Mercedes Santoro**, HZ Akonie, C Kouanfack, F Ceccherini-Silberstein, V Colizzi, CF Perno, and A Ndjolo. Population-Based Surveillance of HIV-1 Drug Resistance in Cameroonian Adults Initiating Antiretroviral Therapy According to the World Health Organization Guidelines. AIDS Res Hum Retroviruses. 2016 Apr;32(4):329-33. doi: 10.1089/AID.2015.0065. Epub 2016 Jan 20. **Autore corrispondente. IF. 1.603; Cites 4**

58. Maffongelli G, Alteri C, Gentilotti E, Bertoli A, Ricciardi A, Malagnino V, Svicher V, **Santoro Maria Mercedes**, Dori L, Perno CF, Andreoni M, Sarmati L. Impact of HIV-1 Tropism on the Emergence of

- non-AIDS Events in HIV-Infected Patients Receiving Fully Suppressive Antiretroviral Therapy. *AIDS*. 2016 Mar 13;30(5):731-41. doi: 10.1097/QAD.0000000000000977. **IF. 5.003; Cites 7**
- 59.** A De Luca, P Flandre, D Dunn, M Zazzi, A Wensing, **Maria Mercedes Santoro**, HF Günthard, L Wittkop, T Kordossis, F Garcia, A Castagna, CF Perno, A Cozzi-Lepri, D Churchill, S De Wit, Wolfgang Fuchs, A Imaz, C Mussini, N Obel, B Roca, E Schülter, C Torti, A van Sighem, R Zangerle, and D Descamps on behalf of CHAIN and COHERE in Eurocood working group. Improved Darunavir Genotypic Mutation Score Predicting Treatment Response for HIV- subtype B and non-B Infected Patients Receiving a Salvage Regimen. *J Antimicrob Chemother*. 2016 May;71(5):1352-60. doi: 10.1093/jac/dkv465. Epub 2016 Jan 28. PMID:**26825119**. **IF. 5.071; Cites 3**
- 60.** R Salpini, J Fokam, L Ceccarelli, **Maria Mercedes Santoro**, A Nanfack, SM Sosso, M Kowo, V Cento, J Torimiro, L Sarmati, M Andreoni, V Colizzi, CF Perno, and O Njoya. High Burden of HBV-Infection and Atypical HBV Strains among HIV-infected Cameroonians. *Curr HIV Res*. 2016;14(2):165-71. **IF 1.612; Cites 18**
- 61.** Andreoni M, Marcotullio S, Puro V, De Carli G, Tambussi G, Nozza S, Gori A, Rusconi S, **Santoro Maria Mercedes**, Clementi M, Perno CF, d'Arminio Monforte A, Maggiolo F, Castagna A, De Luca A, Galli M, Giacomelli A, Borderi M, Guaraldi G, Calcagno A, Di Perri G, Bonora S, Mussini C, Di Biagio A, Puoti M, Bruno R, Zuccaro V, Antinori A, Cinque P, Croce D, Restelli U, Rizzardini G, Lazzarin A. An update on integrase inhibitors: new opportunities for a personalized therapy? The NEXtAim Project. *New Microbiol*. 2015 Nov;38(4):443-90. **IF. 1.603; Cites 12**
- 62.** L Fabeni, C Alteri, N Orchi, C Gori, A Bertoli, F Forbici, F Montella, A Pennica, G De Carli, M Giuliani, F Continenza, C Pinnetti, E Nicastrì, F Ceccherini-Silberstein, CM Mastroianni, E Girardi, M Andreoni, A Antinori, **Maria Mercedes Santoro**, and CF Perno. Recent Transmission Clustering of HIV-1 C and CRF17<sub>BF</sub> Strains characterized by NNRTI-related mutations among Newly Diagnosed Men in Central Italy. *PLoS One*. 2015 Aug 13;10(8):e0135325. doi: 10.1371/journal.pone.0135325. eCollection 2015. **IF 3.54; Cites 14**
- 63.** Fabeni L, Berno G, Svicher V, Ceccherini-Silberstein F, Gori C, Bertoli A, Mussini C, Lichtner M, Zaccarelli M, Ammassari A, Pinnetti C, Cicalini S, Mastroianni CM, Andreoni M, Antinori A, Perno CF, and **Santoro Maria Mercedes**. Genotypic Tropism Testing in HIV-1 Proviral DNA Can Provide Useful Information at Low-Level Viremia. *J Clin Microbiol*. 2015 Jul 1. pii: JCM.00893-15. [Epub ahead of print] PMID:26135872 **Autore corrispondente**. **IF 3.631; Cites 2**
- 64.** D Armenia, L Fabeni, C Alteri, D Di Pinto, D Di Carlo, A Bertoli, C Gori, S Carta, V Fedele, F Forbici, R D'Arrigo, V Svicher, G Berno, D Pizzi, E Nicastrì, L Sarmati, C Pinnetti, A Ammassari, G D'Offizi, A Latini, M Andreoni, A Antinori, F Ceccherini-Silberstein, CF Perno and **Maria Mercedes Santoro**. HIV-1 integrase genotyping is reliable and reproducible for routine clinical detection of integrase resistance mutations also in patients with low-level viremia. *Journal of Antimicrobial Chemotherapy* 2015 Jun;70(6):1865-73. doi: 10.1093/jac/dkv029. Epub 2015 Feb 23. **Autore corrispondente**. **IF 4.919; Cites 22**
- 65.** J Vingerhoets, V Calvez, P Flandre, A-G Marcelin, F Ceccherini-Silberstein, C-F Perno, **Maria Mercedes Santoro**, R Bateson, M Nelson, A Cozzi-Lepri, J Grarup, and J Lundgren. Efficacy of etravirine combined with darunavir or other ritonavir-boosted protease inhibitors in HIV-1-infected patients: an observational study using pooled European cohort data. *HIV Med*. 2015 Jan 14. doi: 10.1111/hiv.12218. **IF 3.341; Cites 8**
- 66.** Mirabelli C, Surdo M, Van Hemert F, Lian Z, Salpini R, Cento V, Cortese MF, Aragri M, Pollicita M, Alteri C, Bertoli A, Berkhout B, Micheli V, Gubertini G, **Maria Mercedes Santoro**, Romano S, Visca M, Bernassola M, Longo R, De Sanctis GM, Trimoulet P, Fleury H, Marino N, Mazzotta F, Cappiello G, Spanò A, Sarrecchia C, Zhang JM, Andreoni M, Angelico M, Verheyen J, Perno CF, Svicher V. Specific mutations in the C-terminus domain of HBV surface antigen significantly correlate with low level of serum HBV-DNA in patients with chronic HBV infection. *J Infect*. 2015 Mar;70(3):288-98. doi: 10.1016/j.jinf.2014.10.015. Epub 2014 Nov 6. **IF 3.39; Cites 11**
- 67.** J.L. Blanco, J. Montaner, V.C. Marconi, **Maria Mercedes Santoro**, A.E. Campos-Loza, R.W. Shafer, M.D. Miller, R. Paredes, R. Harrigan, M.L. Nguyen, C.F. Perno, L.A. Gonzalez-Hernandez and J.M. Gatella. Lower prevalence of drug resistance mutations at first-line virological failure to first-line therapy with atipla vs. tenofovir+emtricitabine/lamivudine+efavirenz administered on a multiple tablet therapy. *AIDS*. 2014 Nov 13;28(17):2531-9. **IF 6.557; Cites 23**
- 68.** Armenia D, Soulie C, Di Carlo D, Fabeni L, Gori C, Forbici F, Svicher V, Bertoli A, Sarmati L, Giuliani M, Latini A, Boumis E, Zaccarelli M, Bellagamba R, Andreoni M, Marcelin AG, Calvez V, Antinori A, Ceccherini-Silberstein F, Perno CF, and **Maria Mercedes Santoro**. A very low geno2pheno false

positive rate is associated with poor viro-immunological response in drug-naïve patients starting a first-line HAART. *PLoS One*. 2014 Aug 25;9(8):e105853. doi: 10.1371/journal.pone.0105853. **Autore corrispondente**. IF 3.234. Cites 9

69. V Svicher, C Alteri, **Maria Mercedes Santoro**, F Ceccherini-Silberstein, AG Marcelin, V Calvez, CF Perno. The multifactorial pathways towards resistance to the cytosine analogues emtricitabine and lamivudine: Evidences from literature. *J Infect*. 2014 May 15. pii: S0163-4453(14)00127-3. doi: 10.1016/j.jinf.2014.05.001. IF. 4.017; Cites 2

70. **Maria Mercedes Santoro**, L Fabeni, D Armenia, C Alteri, D Di Pinto, F Forbici, A Bertoli, D Di Carlo, C Gori, S Carta, V Fedele, R D'Arrigo, G Bero, A Ammassari, C Pinnetti, E Nicastrì, A Latini, C Tommasi, E Boumis, N Petrosillo, G D'Offizi, M Andreoni, F Ceccherini-Silberstein, A Antinori, and CF Perno. Reliability and Clinical Relevance of the HIV-1 Drug-Resistance Test in Patients with Low Viremia Levels. *Clin Infect Dis*. 2014 Apr;58(8):1156-64. doi: 10.1093/cid/ciu020. Epub 2014 Jan 14. IF. 8.886; Cites 60

71. M Giuliani\*, **Maria Mercedes Santoro**\*, A Lo Presti, E Cella, P Scognamiglio, A Lai, A Latini, L Fabeni, C Gori, C Pinnetti, E Girardi, CF Perno, G Zehender, and M Ciccozzi. Circulation of HIV-1 CRF02\_AG among MSM Population in Central Italy: A Molecular Epidemiology-Based Study. *BioMed Research International*, Volume 2013 (2013), Article ID 810617. <http://dx.doi.org/10.1155/2013/810617>. **\*Egual contributo nella redazione del manoscritto**. IF 2.880; Cites 7

72. Alteri C, Artese A, Beheydt G, **Maria Mercedes Santoro**, Costa G, Parrotta L, Bertoli A, Gori C, Orchi N, Girardi E, Antinori A, Alcaro S, d'Arminio Monforte A, Theys K, Vandamme AM, Ceccherini-Silberstein F, Svicher V, Perno CF. Structural modifications induced by specific HIV-1 protease-compensatory mutations have an impact on the virological response to a first-line lopinavir/ritonavir-containing regimen. *J Antimicrob Chemother*. 2013 May 29. IF. 5.338; Cites 10

73. **Santoro Maria Mercedes**, C Sabin, F Forbici, L Bansi, D Dunn, E Fearnhill, E Boumis, E Nicastrì, A Antinori, G Palamara, A Callegaro, D Francisci, A Zoncada, F Maggiolo, M Zazzi, CF Perno, F Ceccherini-Silberstein, and C Mussini. Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues. *HIV Medicine*. 2013 Oct;14(9):571-7. doi: 10.1111/hiv.12044. Epub 2013 May 13. IF. 3.155; Cites 6

74. **Santoro Maria Mercedes**, D Armenia, C Alteri, P Flandre, A Calcagno, M Santoro, C Gori, L Fabeni, R Bellagamba, V Borghi, F Forbici, A Latini, G Palamara, R Libertone, V Tozzi, E Boumis, C Tommasi, C Pinnetti, A Ammassari, E Nicastrì, A Buonomini, V Svicher, M Andreoni, P Narciso, C Mussini, A Antinori, F Ceccherini-Silberstein, G Di Perri and CF Perno. Impact of pre-therapy viral load on virological response to modern first-line HAART. *Antivir Ther*. 2013;18(7):867-76. doi: 10.3851/IMP2531. Epub 2013 Jan 23. IF. 3.073; Cites 37

75. V Svicher, V Cento, G Rozera, I Abbate, **Maria Mercedes Santoro**, D Armenia, L Fabeni, A Bruselles, G Palamara, V Micheli, G Rizzardini, C Gori, F Forbici, G Ippolito, M Andreoni, A Antinori, F Ceccherini-Silberstein, MR Capobianchi, and CF Perno. The Genotypic False Positive Rate Determined by V3 Population Sequencing can Predict the Burden of X4 Quasispecies Detected by Pyrosequencing. *PLoS One*. 2013;8(1):e53603. doi: 10.1371/journal.pone.0053603. Epub 2013 Jan 14. **Free PMC Article**. IF. 3.73; Cites 15

76. Ciccozzi M, **Santoro Maria Mercedes**, Giovanetti M, Andriani L, Bertoli A, Ciotti M. HIV-1 Non-B subtypes in Italy: a growing trend. *New Microbiol*. 2012 Oct;35(4):377-86. Epub 2012 Oct 1. **Review**. **Free PMC Article**. IF. 1; Cites 20

77. **Santoro Maria Mercedes**, Armenia D, Fabeni L, Santoro M, Gori C, Forbici F, Svicher V, Bertoli A, Dori L, Surdo M, Balestra E, Palamara G, Girardi E, Angarano G, Andreoni M, Narciso P, Antinori A, Ceccherini-Silberstein F, Perno CF. The lowest X4 Geno2Pheno false-positive rate is associated with greater CD4 depletion in HIV-1 infected patients. *Clin Microbiol Infect*. 2012 Aug;18(8):E289-98. doi: 10.1111/j.1469-0691.2012.03905.x. Epub 2012 Jun 8. **Free PMC Article**. IF. 4.54; Cites 15

78. Ceccarelli L, Salpini R, Moudourou S, Cento V, **Santoro Maria Mercedes**, Fokam J, Takou D, Nanfack A, Dori L, Torimiro J, Sarmati L, Andreoni M, Perno CF, Colizzi V, Cappelli G. Characterization of drug resistance mutations in naïve and ART-treated patients infected with HIV-1 in Yaounde, Cameroon. *J Med Virol*. 2012 May;84(5):721-7. doi: 10.1002/jmv.23244. IF. 2.82; Cites 31

- 79. Santoro Maria Mercedes**, Alteri C, Ronga L, Flandre P, Fabeni L, Mercurio F, D'Arrigo R, Gori C, Palamara G, Bertoli A, Forbici F, Salpini R, Boumris E, Tozzi V, Visco-Comandini U, Zaccarelli M, Van Houtte M, Pattery T, Narciso P, Antinori A, Ceccherini-Silberstein F, Perno CF. Comparative Analysis of Drug Resistance Among B and the Most Prevalent Non-B HIV Type 1 Subtypes (C, F, and CRF02\_AG) in Italy. *AIDS Res Hum Retroviruses*. 2012 Oct;28(10):1285-93. Epub 2012 Apr 18. **Free PMC Article. Autore corrispondente. IF. 2.246; Cites 17**
- 80.** Alcaro S, Alteri C, Artese A, Ceccherini-Silberstein F, Costa G, Ortuso F, Bertoli A, Forbici F, **Santoro Maria Mercedes**, Parrotta L, Flandre P, Masquelier B, Descamps D, Calvez V, Marcelin AG, Perno CF, Sing T, Svicher V. Docking Analysis and Resistance Evaluation of Clinically Relevant Mutations Associated with the HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors Nevirapine, Efavirenz and Etravirine. *Chem Med Chem*. 2011 Dec 9;6(12):2203-13. doi: 10.1002/cmcd.201100362. Epub 2011 Sep 27. **IF. 3.151; Cites 15**
- 81.** C Alteri, **Santoro Maria Mercedes**, I Abbate, G Rozera, A Bruselles, B Bartolini, C Gori, F Forbici, N Orchi, V Tozzi, G Palamara, A Antinori, P Narciso, E Girardi, V Svicher, F Ceccherini-Silberstein, MR Capobianchi, and CF Perno. "Sentinel" mutations in standard population sequencing can predict the presence of HIV-1 Reverse Transcriptase major mutations detectable only by ultra-deep pyrosequencing. *Journal of Antimicrobial Chemotherapy*. 2011 Nov;66(11):2615-23. Epub 2011 Sep 2. **Free PMC Article; IF. 5.068; Cites 16**
- 82.** J Fokam, R Salpini, **Santoro Maria Mercedes**, V Cento, CF Perno, V Colizzi, PM Ndumbe, C Fokunang Ntungen, SM Ndiang Tetang, AJ Nanfack, DA Takou Komego, and G Cappelli. Drug Resistance Among Drug-naïve and First-line Antiretroviral Treatment-failing Children in Cameroon. *Pediatric Infectious Disease Journal*. 2011 Dec;30(12):1062-8. **IF. 3.577; Cites 34**
- 83.** A De Luca, S Di Giambenedetto, R Maserati, N Gianotti, P Narciso, A Antinori, G Di Perri, M Prosperi, F Baldanti, V Micheli, M Zazzi, CF Perno and **Maria Mercedes Santoro for the TMC114-C226 and the ARCA study groups**. Interpretation of genotypic HIV-1 resistance to darunavir and virological response: validation of available systems and of a new score. *Antiviral Therapy*. 2011;16(4):489-97. **IF. 3.161; Cites 8**
- 84.** J Fokam, R Salpini, **Santoro Maria Mercedes**, V Cento, R D'Arrigo, C Gori, CF Perno, V Colizzi, A Nanfack, LC Gwom, G Cappelli, and D. Takou. Performance evaluation of an in-house human immunodeficiency virus type-1 protease-reverse transcriptase genotyping assay in Cameroon. *Archive of Virology*. 2011 Jul;156(7):1235-43. **IF. 2.111; Cites 28**
- 85.** N Mendonca Collaço Vêras\*, **Santoro Maria Mercedes\***, RR Gray, AJ Tatem, A Lo Presti, F Olearo, G Cappelli, V Colizzi, D Takou, J Torimiro, G Russo, AP Callegaro, R Salpini, R D'Arrigo, CF Perno, MM Goodenow, M Ciccozzi, and M Salemi. Molecular epidemiology of HIV type 1 CRF02\_AG in Cameroon and African patients living in Italy. *AIDS Res Hum Retroviruses*. 2011 Nov;27(11):1173-82. doi: 10.1089/AID.2010.0333. Epub 2011 May 6. **\*Egual contributo nella redazione del manoscritto. Free PMC Article; IF. 2.246; Cites 18**
- 86.** Ciccozzi M, Vujošević D, Lo Presti A, Mugoša B, Vratnica Z, Lai A, Laušević D, Drašković N, Marjanovic A, Cella E, **Santoro Maria Mercedes**, Alteri C, Fabeni L, Ciotti M, Zehender G. Genetic Diversity of HIV-1 in Montenegro. *AIDS Res Hum Retroviruses*. 2011 Aug;27(8):921-4. Epub 2010 Dec 31. **IF. 2.082; Cites 19**
- 87.** JM Schapiro, J Scherer, CA Boucher, JD Baxter, H Gellerman, CF Perno, F Maggiolo, **Santoro Maria Mercedes**, and DB Hall. Improving the prediction of virological response to tipranavir: the development and validation of a tipranavir-weighted mutation score. *Antiviral Therapy*. 2010;15(7):1011-9. **IF. 3.774; Cites 18**
- 88.** V Svicher, C Alteri, A Artese, F Forbici, **Santoro Maria Mercedes**, D Schols, K Van Laethem, S Alcaro, G Costa, C Tommasi, M Zaccarelli, P Narciso, A Antinori, F Ceccherini-Silberstein, J Balzarini, and CF Perno. Different Evolution of Genotypic Resistance Profiles to Emtricitabine versus Lamivudine

in Tenofovir Containing Regimens. Journal of Acquired Immune Deficiency Syndrome. 2010 Nov 1;55(3):336-44. **IF 4.262; Cites 29**

89. G Zehender, E Ebranati, A Lai, **Santoro Maria Mercedes**, C Alteri, M Giuliani, G Palamara, CF Perno, M Galli, A Lo Presti, M Ciccozzi. Population dynamics of HIV-1 subtype B in a cohort of men having sex with men in Rome, Italy. J Acquir Immune Defic Syndr. 2010 Oct 1;55(2):156-60. **IF 4.262; Cites 42**

90. C Tommasi, F Ceccherini-Silberstein, R D'Arrigo, R Bellagamba, M Tempestilli, C Dessi, **Santoro Maria Mercedes**, F Forbici, L Pucillo, CF Perno, and P Narciso. Use of novel antiretroviral agents in rescue regimens: a case of early virological failure to raltegravir. Scand Journal Infectious Disease, 2010, Jan; 0(0):1-3. **IF. 1.209; Cites 1**

91. M Zaccarelli, A Antinori, A Cozzi-Lepri, C Mussini, G Palamara, **Santoro Maria Mercedes**, A d'Arminio Monforte, CF Perno, and F Ceccherini-Silberstein. Is there any potential for first line Etravirine use? Analysis from a large dataset of ART-naïve HIV infected patients undergoing resistance test. Journal of Acquired Immune Deficiency Syndrome, 2010 Jan 1;53(1):150-1. **IF 4.262**

92. M Trignetti, T Sing, V Svicher, **Maria Mercedes Santoro**, F Forbici, R D'Arrigo, MC Bellocchi, M Santoro; P Marconi, M Zaccarelli, MP Trotta, R Bellagamba, P Narciso, A Antinori, T Lengauer, and CF Perno. Dynamics of NRTI Resistance Mutations During Therapy Interruption. AIDS Research and Human Retroviruses, 2009 Jan;25(1):57-64. **IF. 2.178; Cites 11**

93. **Santoro Maria Mercedes**, A Bertoli, P Lorenzini, F Ceccherini-Silberstein, N Gianotti, C Mussini, C Torti, G Di Perri, G Barbarini, T Bini, S Melzi, P Caramello, R Maserati, P Narciso, V Micheli, A Antinori, CF Perno, and the CARE Study Group. Two different patterns of mutations involved in the genotypic resistance score for atazanavir boosted versus atazanavir unboosted by ritonavir in multiply failing patients. Infection. 2009 Jun;37(3):233-43. Epub 2009 Jan 23. **IF. 2.051; Cites 5**

94. Giuliani M, S Montieri, G Palamara, A Latini, C Alteri, CF Perno, **Santoro Maria Mercedes**, G Rezza, and M Ciccozzi. Non-B HIV-1 subtypes among Men Who Have Sex With Men in Rome, Italy. AIDS Research and Human Retroviruses. 2009 Jan; 25(2):157-64. **IF. 2.178; Cites 22**

95. **Santoro Maria Mercedes**, M Ciccozzi, C Alteri, S Montieri, I Alexiev, I Dimova, F Ceccherini-Silberstein, D Beshkov, G Rezza, and CF Perno. Characterization of Drug-Resistance Mutations in HIV-1 Isolates from Drug-Naive and ARV Treated Patients in Bulgaria. AIDS Research and Human Retroviruses, 2008 Sep;24(9):1133-1138. **Autore corrispondente. Free PMC Article. IF. 2.024; Cites 19**

96. M Salemi, MM Goodenow, S Montieri, Tulio de Oliveira, **Santoro Maria**, D Beshkov, I Alexiev, I Elenkov, I Elenkov, T Yakimova, T Varleva, G Rezza, and M Ciccozzi. The HIV-1 epidemic in Bulgaria involves multiple subtypes and is sustained by continuous viral inflow from West and East European countries. AIDS Research and Human Retroviruses, 2008 Jun; 24(6):771-779. **Free PMC Article. IF. 2.024; Cites 38**

97. V Svicher, S Aquaro, R D'Arrigo, A Artese, S Dimonte, S Alcaro, **Santoro Maria Mercedes**, G Di Perri, S Lo Caputo, R Bellagamba, M Zaccarelli, U Visco-Comandini, A Antinori, P Narciso, F Ceccherini-Silberstein, and CF Perno. Specific enfuvirtide associated mutational pathways in HIV-1 gp41 are significantly correlated with a gain of CD4 cell count despite virological failure. The Journal of Infectious Diseases, 2008 May 15;197(10):1408-1418. **Free PMC Article. IF. 5.682; Cites 36. Vincitore del Premio Scientifico ReAd files 2008.**

98. **Santoro Maria Mercedes**, A Bertoli, P Lorenzini, A Lazzarin, R Esposito, G Carosi, G Di Perri, G Filice, M Moroni, G Rizzardini, P Caramello, R Maserati, P Narciso, A Cargnel, A Antinori, CF Perno, and the CARE Study Group. Viro-immunologic response to ritonavir-boosted or unboosted atazanavir in a large cohort of multiply treated patients: the CARE Study. AIDS patient care and STDs, 2008 January;22(1):7-16. **Autore corrispondente. IF. 2.392; Cites 11**

99. F Ceccherini-Silberstein, V Svicher, T Sing, A Artese, **Santoro Maria Mercedes**, C Gori, A Bertoli, S Alcaro, G Palamara, A d'Arminio Monforte, A Antinori, T Lengauer, and CF Perno, ICoNA Study Group, INMI-Collaborative Group for Clinical Use of HIV Genotype Resistance Test. Characterization and Structural Analysis of Novel Mutations in HIV-1 Reverse Transcriptase Involved in the Regulation of Resistance to Non-Nucleoside Inhibitors. Journal of Virology 2007 Aug 8. **Free PMC Article; IF. 5.332; Cites 62. Vincitore del Premio Scierntifico G.B. Rossi 2008**

100. V Svicher, T Sing, **Santoro Maria Mercedes**, F Forbici, F Rodriguez-Barrios, A Bertoli, N Beerenwinkel, Maria Concetta Bellocchi, F Gago, A d'Arminio Monforte, A Antinori, T Lengauer, F Ceccherini-Silberstein, and Carlo Federico Perno. Involvement of novel HIV-1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors. Journal of Virology, July 2006; 80 (14): 7186-7198. **Free PMC Article; IF. 5.341; Cites 69**

101. **Santoro Maria Mercedes**, V Svicher, C Gori, M Zaccarelli, V Tozzi, F Forbici, R d'Arrigo, MP Trotta, MC Bellocchi, U Visco-Comandini, A Cenci, A Bertoli, P Narciso, A Antinori, CF Perno, and F Ceccherini-Silberstein. Temporal characterization of drug resistance associated mutations in HIV-1 protease and reverse transcriptase in patients failing antiretroviral therapy. The New Microbiologica, April 2006; 29 (2):89-100. **IF. 0.806; Cites 3**

102. F Ceccherini-Silberstein, F Gago, **Santoro Maria**, C Gori, V Svicher, F Rodríguez-Barrios, M Ciccozzi, R D'Arrigo, A Bertoli, S Boros, A d'Arminio Monforte, J Balzarini, A Antinori, and CF Perno. High Sequence Conservation of HIV-1 reverse transcriptase under drug pressure despite a continuous appearance of mutations. Journal of Virology. August 2005; 79(16):10718-29. **Free PMC Article; IF. 5.178; Cites 48**

103. V Svicher, F Ceccherini-Silberstein, F Erba, **Santoro Maria Mercedes**, C Gori, MC Bellocchi, S Giannella, MP Trotta, A d'Arminio Monforte, A Antinori, and CF Perno. Novel human immunodeficiency virus type 1 protease mutations potentially involved in resistance to protease inhibitors. Antimicrobial Agents and Chemotherapy. May 2005; 49(5):2015-25. **Free PMC Article; IF. 4.379; Cites 59**

104. **Santoro Maria**, F Ceccherini-Silberstein, C Gori, V Svicher, F Forbici, MC Bellocchi, R d'Arrigo, A Bertoli, S Giannella, MP Trotta, S Bonfigli, A Antinori, and CF Perno. Temporal change in the use of genotypic resistance testing over the years 1999-2003. The New Microbiologica. 2004; 27(Suppl 1):141-4. **IF. 1 (anno 2012); Cites 2**

105. A Buschini, A Martino, B Gustavino, M Monfrinotti, P Poli, C Rossi, **Santoro Maria**, AJM Dörr, and M Rizzoni. Comet Assay and micronucleus test in circulating erythrocytes of Cyprinus carpio specimen exposed in situ to lake waters treated with disinfectants for potabilization. Mutation Research. 2004 Feb 14;557(2):119-29. **IF. 2.020; Cites 143 (Google Scholar)**

#### Lavori in Collaborative Groups

106. Bandera A, Lorenzini P, Taramasso L, Cozzi-Lepri A, Lapadula G, Mussini C, Saracino A, Ceccherini-Silberstein F, Puoti M, Quiros-Roldan E, Montagnani F, Antinori A, d'Arminio Monforte A, Gori A; Icona Foundation Cohort (Andreoni M, Castagna A, ... **Santoro Maria Mercedes**, .... Stamini G, Ialungo A). The impact of DAA-mediated HCV eradication on CD4<sup>+</sup> and CD8<sup>+</sup> T lymphocyte trajectories in HIV/HCV coinfecting patients: Data from the ICONA Foundation Cohort. J Viral Hepat. 2021 May;28(5):779-786. doi: 10.1111/jvh.13488. Epub 2021 Mar 11. PMID: 33600068. **IF 3.728. Cites 3**

107. Malagnino V, Cerva C, Cingolani A, Ceccherini-Silberstein F, Vergori A, Cuomo G, Perno CF, Puoti M, d'Arminio Monforte A, Cozzi-Lepri A, Andreoni M, Sarmati L; ICONA Foundation Study Group (d'Arminio Monforte A, Antinori A, ... **Santoro Maria Mercedes**, .... Stamini G, Ialungo A). HBcAb Positivity Increases the Risk of Severe Hepatic Fibrosis Development in HIV/HCV-Positive Subjects From the ICONA Italian Cohort of HIV-Infected Patients. Open Forum Infect Dis. 2020 Nov 18;8(1):ofaa566. doi: 10.1093/ofid/ofaa566. PMID: 33447635; PMCID: PMC7781466. **IF 6.883**

108. d'Arminio Monforte A, Tavelli A, Cozzi-Lepri A, Castagna A, Passerini S, Francisci D, Saracino A, Maggiolo F, Lapadula G, Girardi E, Perno CF, Antinori A; Icona Foundation Study Group (d'Arminio Monforte A, Antinori A, ... **Santoro Maria Mercedes**, .... Stamini G, Ialungo A). Virological response

and retention in care according to time of starting ART in Italy: data from the Icona Foundation Study cohort. *J Antimicrob Chemother.* 2020 Mar 1;75(3):681-689. doi: 10.1093/jac/dkz512. PMID: 31865395.

**IF 5.439. Cites 3**

**109.** Taramasso L, Lorenzini P, Di Biagio A, Lichtner M, Marchetti G, Rossotti R, Lapadula G, Cozzi-Lepri A, Vichi F, Antinori A, Bonora S, d'Arminio Monforte A; ICONA Foundation Study Group (d'Arminio Monforte A, Antinori A, ... Santoro Maria Mercedes, .... Stamini G, Ialungo A). Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort. *J Antimicrob Chemother.* 2019 Nov 1;74(11):3295-3304. doi: 10.1093/jac/dkz353. PMID: 31504633. **IF 5.439**

**110.** Shanyinde M, Girardi E, Puoti M, De Luca A, Sighinolfi L, Caterina UF, Caramello P, Lampe FC, D'Arminio Monforte A, Cozzi-Lepri A; ICONA Foundation Study Group (d'Arminio Monforte A, Andreoni M, ... Santoro Maria Mercedes, .... Pellizzer G, Manfrin V). Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection? *BMC Public Health.* 2019 Oct 15;19(1):1291. doi: 10.1186/s12889-019-7608-1. PMID: 31615542; PMCID: PMC6794785. **IF 2.521. Cites 2**

**111.** Gianotti N, Lorenzini P, Cozzi-Lepri A, De Luca A, Madeddu G, Sighinolfi L, Pinnetti C, Santoro C, Meraviglia P, Mussini C, Antinori A, d'Arminio Monforte A; ICONA Foundation Study Group (d'Arminio Monforte A, Andreoni M, ... Santoro Maria Mercedes, .... Pellizzer G, Manfrin V). Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm<sup>3</sup> and HIV-RNA >5 log<sub>10</sub> copies/mL. *J Antimicrob Chemother.* 2019 Sep 1;74(9):2732-2741. doi: 10.1093/jac/dkz237. PMID: 31173639. **IF 5.439**

**112.** d'Arminio Monforte A, Diaz-Cuervo H, De Luca A, Maggiolo F, Cingolani A, Bonora S, Castagna A, Girardi E, Antinori A, Lo Caputo S, Guaraldi G, Cozzi-Lepri A; ICONA Foundation Study Group (Castelli F, Cauda R, ... Santoro Maria Mercedes, ... Stamini G, Ialungo A). Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004-2014. *HIV Med.* 2019 Feb;20(2):99-109. doi: 10.1111/hiv.12683. Epub 2018 Nov 21. PMID: 30461158. **IF 3.556. Cites 14**

**113.** d'Arminio Monforte A, Cozzi-Lepri A, Di Biagio A, Marchetti G, Lo Caputo S, Rusconi S, Gianotti N, Mazzotta V, Mazzarello G, Costantini A, Castagna A, Antinori A; ICONA Foundation Study Group (d'Arminio Monforte A, Antinori A, ... Santoro Maria Mercedes, .... Stamini G, Ialungo A). Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting. *J Antimicrob Chemother.* 2019 Jan 29. doi: 10.1093/jac/dky566. [Epub ahead of print] PubMed PMID: 30698801. **IF 5.439; Cites 1**

**114.** Mondì A, Cozzi-Lepri A, Tavelli A, Rusconi S, Vichi F, Ceccherini-Silberstein F, Calcagno A, De Luca A, Maggiolo F, Marchetti G, Antinori A, d'Arminio Monforte A; Icona Foundation Study Group (d'Arminio Monforte A, Antinori A, ... Santoro Maria Mercedes, .... Stamini G, Ialungo A). Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort. *J Int AIDS Soc.* 2019 Jan;22(1):e25227. doi: 10.1002/jia2.25227. PubMed PMID:30663278; PubMed Central PMCID: PMC6340053. **IF 5.553; Cites 21**

**115.** Ceccherini-Silberstein F, Cozzi Lepri A, Alteri C, Merlini E, Surdo M, Marchetti G, Capobianchi MR, De Luca A, Gianotti N, Viale P, Andreoni M, Antinori A, Perno CF, d'Arminio Monforte A; ICONA Foundation Study Group (d'Arminio Monforte A, Antinori A, ... Santoro Maria Mercedes, .... Stamini G, Ialungo A). Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline viro-immunological status and outcome in patients under first-line ART. *J Antimicrob Chemother.* 2018 Sep 20. doi: 10.1093/jac/dky350. [Epub ahead of print] PubMed PMID: 30247724. **IF 5.217; Cites 10**

**116.** Taramasso L, Di Biagio A, Maggiolo F, Tavelli A, Lo Caputo S, Bonora S, Zaccarelli M, Caramello P, Costantini A, Viscoli C, d'Arminio Monforte A, Cozzi-Lepri A; Italian Cohort Naive Antiretrovirals (ICONA) Foundation Study Group (Andreoni M, Angarano G, ... Santoro Maria Mercedes, .... Pellizzer G, Manfrin V). First-line antiretroviral therapy with efavirenz plus tenofovir disoproxil



fumarate/emtricitabine or rilpivirine plus tenofovir disoproxil fumarate/emtricitabine: a durability comparison. *HIV Med.* 2018 May 30. doi: 10.1111/hiv.12628. [Epub ahead of print] PubMed PMID: 29846042. **IF 2.932; Cites 8**

117. Mussini C, Lorenzini P, Cozzi-Lepri A, Marchetti G, Rusconi S, Gori A, Nozza S, Lichtner M, Antinori A, Cossarizza A, d'Arminio Monforte A; Icona Foundation Study Group (d'Arminio Monforte A, Antinori A, ... **Santoro Maria Mercedes**, .... Stamini G, Ialungo A). Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: an observational cohort study. *BMC Med.* 2018 May 29;16(1):79. doi: 10.1186/s12916-018-1046-2. PubMed PMID: 29807541; PubMed Central PMCID: PMC5972434. **IF 9.088; Cites 15**

118. Madeddu G, Rusconi S, Cozzi-Lepri A, Di Giambenedetto S, Bonora S, Carbone A, De Luca A, Gianotti N, Di Biagio A, Antinori A; Icona Foundation Study Group (d'Arminio Monforte A, Andreoni M, Angarano G, ... **Santoro Maria Mercedes**, ... Pellizzer G, Manfrin V). Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA  $\leq 50$  cp/mL. *Infection.* 2017 Aug;45(4):521-528. doi: 10.1007/s15010-017-1018-z. Epub 2017 May 5. PubMed PMID: 28477212. **IF 2.773; Cites 8**

119. Hatleberg CI, Ryom L, El-Sadr W, Mocroft A, Reiss P, De Wit S, Dabis F, Pradier C, d'Arminio Monforte A, Kovari H, Law M, Lundgren JD, Sabin CA; Data Collection of Adverse Events of Anti-HIV drugs (D:A:D) Study group (Calvo G, Bonnet F, ... **Santoro Maria Mercedes**, ... Wandeler G, Yerly S.). Gender differences in the use of cardiovascular interventions in HIV-positive persons; the D:A:D Study. *J Int AIDS Soc.* 2018 Mar;21(3). doi: 10.1002/jia2.25083. PubMed PMID: 29509305; PubMed Central PMCID: PMC5839235. **IF 5.131; Cites 1**

120. Svicher V, Marchetti G, Ammassari A, Ceccherini-Silberstein F, Sarmati L; Impact Study Group [Ammassari A, Andreoni M, ... **Santoro Maria**, ... , Zaccarelli M, Zazzi M]. Novelty in Evaluation and Monitoring of Human Immunodeficiency Virus-1 Infection: Is Standard Virological Suppression Enough for Measuring Antiretroviral Treatment Success? *AIDS Rev.* 2017 Sep 19;19(3). [Epub ahead of print] **IF 2.775; Cites 3**

121. Puoti M, Lorenzini P, Cozzi-Lepri A, Gori A, Mastroianni C, Rizzardini G, Mazzarello G, Antinori A, d'Arminio Monforte A, Girardi E; Icona Foundation Study Group [d'Arminio Monforte A, Andreoni M, ... **Santoro Maria Mercedes**, ... Londero A, Pellizzer G, Manfrin V]. Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus. *Clin Microbiol Infect.* 2016 Dec 9. pii: S1198-743X (16) 30608-5. doi: 10.1016/j.cmi.2016.12.003. [Epub ahead of print] **IF 5.292; Cites 5**

122. Antinori A, Marcotullio S, Andreoni M, Chirriani A, d'Arminio Monforte A, Di Biagio A, Galli M, Mazzotta F, Mussini C, Puoti M, Lazzarin; Italian HIV Guidelines Working Group [Adriana A, Gioacchino A, Orlando A, ... **Santoro Maria**, ... Vullo V, Zaccarelli M, Zuccotti VG]. Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2015. *New Microbiol.* 2016 Apr;39(2):93-109. **IF 1.568; Cites 8 (Google Scholar)**

123. Di Maio VC, Cento V, Di Paolo D, ...; HCV Italian Resistance Network Study Group (Mariani R, ... **Santoro Maria Mercedes**, ... Tarquini P). HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels. *J Antimicrob Chemother.* 2016 Mar;71(3):739-50. doi: 10.1093/jac/dkv403. Epub 2015 Dec 17. **IF 4.919; Cites 13**

124. Mussini C, Lorenzini P, Puoti M, Lichtner M, Lapadula G, Di Giambenedetto S, Antinori A, Madeddu G, Cozzi-Lepri A, d'Arminio Monforte A, De Luca A; ICONA Foundation Study Group [Moroni M, Angarano G, Antinori A, ... **Santoro Maria**, ... Londero A, Pellizzer G, Manfrin V]. Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus. *PLoS One.* 2015 Dec 7;10(12):e0140877. doi: 10.1371/journal.pone.0140877. eCollection 2015. **IF 3.057; Cites 6**

125. Antinori A, Marcotullio S, Andreoni M, Ammassari A, d'Arminio Monforte A, Galli M, Girardi E, Mazzotta F, Mussini C, Puoti M, Lazzarin A; Italian HIV Guidelines Working Group [Ammassari A, Angarano G, Armignacco O, ....., **Santoro Maria**, ....., Zaccarelli M, Zuccotti GV]. Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update December 2014. *New Microbiol.* 2015 Jul;38(3):299-328. **IF. 1.603; Cites 8 (Google Scholar)**

126. Antinori A, Andreoni M, Perno CF, Lazzarin A; HEFFICON Study Group [Ammassari A, Bonfanti P, Bonora S, Borderi M, Capobianchi MR, Castagna A, Clementi M, Cinque P, d'Arminio Monforte A, Di Perri G, Galli M, Gori A, Maggi P, Mastroianni C, Mussini C, Nicastrì E, Puoti M, Rusconi S, **Santoro Maria**, Tambussi G]. HEFFICON: HIV Effectiveness Italian Conference. *New Microbiol.* 2015 May;38(2):149-84. **IF. 1.603. Cites 1**

127. Scientific Coordination Committee, Marcotullio S, Andreoni M, Antinori A, d'Arminio Monforte A, Di Perri G, Galli M, Ippolito G, Perno CF, Rizzardini G, Lazzarin A; Rapporteur Committee, Cinque P, Fares G, Foglia E, Gervasoni C, Murri R, Nozza S, Rusconi S. Multidisciplinary Italian Expert Panel on LDR [..Other Members: ... Sangiovanni V, **Santoro Maria**, Scaggiante R,..]. The Less Drugs Regimens (LDRs) therapy approach in HIV-1: an Italian expert panel perspective for the long-term management of HIV-1 infection. *New Microbiol.* 2012 Jul;35(3):259-77. **Free PMC Article; IF. 1; Cites 8 (Google Scholar)**

128. R Granich, S Gupta, AB Suthar, C Smyth, D Hoos, M Vitoria, M Bavicchi Simao, C Hankins, B Schwartlander, R Ridzon, B Bazin, B Williams, YR Lo, C McClure, J Montaner, G Hirschall; on behalf of the ART in Prevention of HIV and TB Research Writing Group [=....., LI Gardner, **Santoro Maria Mercedes**, MLNewell,..]. Antiretrovirals therapy in Prevention of HIV and TB: Update on Current Research Efforts. *Curr HIV Res.* 2011 Sep;9(6):446-69. **IF. 1.923; Cites 101 (Google Scholar)**

129. A Antinori, MP Trotta, P Lorenzini, C Torti, N Gianotti, F Maggiolo, F Ceccherini-Silberstein, C Torti, P Nasta, A Castagna, A De Luca, C Mussini, M Andreoni, and CF Perno for the **GNOMO Study Group** [=Roma: ....., P Lorenzini, **Santoro Maria Mercedes**, A Conte, ....., list available in the supplementary information of the journal]. Virological response to salvage therapy in HIV-infected persons carrying the reverse transcriptase K65R mutation. *Antivir Ther.* 12(8):1175-83 (2007). **IF 4.547; Cites 32 (Google Scholar)**

#### Lavori senza Impact factor

130. J Fokam, **Maria Mercedes Santoro**, I Chimbi, J Chindiura, R Deula, A Rombe, R Massari, A Lungu, and CF Perno. Programmatic Challenges in Implementing PMTCT Option B+ and Pediatric HIV Care: Baseline Assessment from "Save the Families for Africa" in Malawi. *Health Sciences and diseases.* Vol 20, No 3 (2019). ISSN: **2309-6535. Free PMC Article.**

131. C Alteri, M Surdo, VC Di Maio, ....., **Maria Mercedes Santoro**, ....., A Artese, CF Perno, and V Svicher. The HIV-1 reverse transcriptase polymorphism A98S improves the response to tenofovir disoproxil fumarate+ emtricitabine-containing HAART both in vivo and in vitro. *J Glob Antimicrob Resist.* 2016 Jul 25;7:1-7. doi: 10.1016/j.jgar.2016.06.005. [Epub ahead of print] **Cites 2**

132. **Santoro Maria Mercedes**, Perno CF. HIV-1 Genetic Variability and Clinical Implications. *ISRN Microbiol.* 2013 Jun 17;2013:481314. doi: 10.1155/2013/481314. Print 2013. **Review. Free PMC Article. Cites 147 (Google Scholar)**

#### Lavori sottomessi

133. **Santoro Maria Mercedes** Armenia D, Teyssou E, Santos JR, Charpentier C, Lambert-Niclot S, Antinori A, Katlama C, Descamps D, Perno CF, Calvez V, Paredes R, Ceccherini-Silberstein F, and Marcelin A. Virological efficacy of switch to DTG/3TC in a real life cohort of suppressed HIV-1 patients with or without past M184V – The LAMRES Study. *Sottomesso a Journal of Infectious Diseases. Autore corrispondente.*

134. Stella G, Volpicelli L, Di Carlo D, Vicenti I, Celani L, Maggiolo F, Callegaro AP, Gennari G, Francisci D, Lombardi F, Piermatteo L, Bezenchek A, Micheli V, Rossetti B, and **Santoro Maria Mercedes**, for the ARCA Study Group. Impact of pre-existent drug resistance on virological efficacy of single tablet regimens in people living with HIV. *Sottomesso a International Journal Antimicrobial Agents. Autore corrispondente.*

135. B Dambaya, J Fokam, ES Ngoufack, D Takou, **Maria Mercedes Santoro**, G Teto, GA Beloumou, LCM Mouafo, N Kamgaing, SM Sosso, SC Billong, AE Njom Nlend, MS Sobze, C Nkenfou, PN Koki, F Njiokou, V Colizzi, CF Perno, and A Ndjolo. HIV-1 Drug Resistance and Genetic Diversity among Vertically Infected Cameroonian Children. Sottomesso a The Pediatric Infectious Disease Journal.

136. Rusconi S, **Santoro Maria Mercedes**, Capetti AF, Gianotti N, and Zazzi M. The future of long-acting cabotegravir plus rilpivirine therapy: deeds and misconceptions. Sottomesso a International Journal of Antimicrobial Agents.

#### Monografie

137. Carlo F. Perno, **Maria Mercedes Santoro**. Antiretroviral therapy in 2011. Treatment-experienced patients: salvage interventions and switch strategies. Hot topics in HIV and other retroviruses: Issue 2, 2011. Editore: Vincent Soriano.

#### Capitoli libri

138. **Santoro Maria Mercedes**, R Salpini, C Alteri, and CF Perno. Capitolo 11; titolo: Analysis in the Field of HIV Variability and Drug Resistance. Titolo libro: Genomics II - Bacteria, Viruses and Metabolic Pathways. Edited by iConcept Press Ltd. 1st Edition. Publisher iConcept Press Ltd. r2013. ISBN: 978-1-922227-041. Retrieved from <https://www.iconceptpress.com/books/genomics-ii-bacteria-viruses-and-metabolic-pathways/10023002/> (965 downloads all 11/08/2015)

Abstract in proceedings pubblicati con impact factor (l'asterisco indica lo speaker nelle comunicazioni orali)

139. Sinopoli A, Isonne C, Baccolini V, and **Maria Mercedes Santoro**. Revisione sistematica di studi clinici sul ruolo della lattoferrina nelle infezioni virali: una possibile terapia di supporto contro COVID-19? Atti delle giornate della ricerca scientifica e delle esperienze professionali dei giovani SItI 2020. Journal of Preventive Medicine and Hygiene, Volume 62, Issue 1 Supplement 2, March 2021. **IF 2.02**

140. A de Salazar, A Fuentes, E Serrano, C Charpentier, A Beloukas, S Lambert-Niclot, A De Monte, I Diogo, L Fabeni, A Hatzakis, K Stefic, S Fernandes, CF Perno, D Descamps, D Chatzidimitriou, W Gennari, V Sypsa, P Gomes, D Paraskevis, **Maria Mercedes Santoro**, F Ceccherini-Silberstein, AG Marcelin, and F Garcia\*. Integrase-based first-line HIV antiretroviral treatment in the Mediterranean Resistance (MeditRes) HIV collaboration. Virtual meeting on HIV Drug Therapy - Glasgow 2020, 4-7 October 2020 (abstract O322). Journal of the International AIDS Society. Volume 23, Supplement 7, October 2020. **IF 5.553**

141. Gagliardini R\*, Cozzi-Lepri A, Zazzi M, Tavelli A, **Santoro Maria Mercedes**, Armenia D, Castagna A, Gennari, Rusconi S, Mussini C, Laghetti, Perno CF, D'Arminio A, and Antinori A. Impact of multi-drug resistance on mortality: a multi-cohort Italian study. Virtual meeting on HIV Drug Therapy - Glasgow 2020, 4-7 October 2020 (abstract O323). Journal of the International AIDS Society. Volume 23, Supplement 7, October 2020. **IF 5.553**

142. B Rossetti, D Di Carlo, M Fabbiani, G Stella, I Vicenti, F Maggiolo, W Gennari, D Francisci, **Maria Mercedes Santoro**, and M Zazzi. Impact of resistance to antiretroviral drugs on predicted HIV-1 susceptibility to current single-tablet-regimens (STR). Virtual meeting on HIV Drug Therapy - Glasgow 2020, 4-7 October 2020 (abstract P121). Journal of the International AIDS Society. Volume 23, Supplement 7, October 2020. **IF 5.553**

143. E Bruzzesi, R Scutari, MC Bellocchi, V Spagnuolo, L Galli, L Carioti, **Maria Mercedes Santoro**, C Alteri, F Ceccherini-Silberstein, and A Castagna. Analytical treatment interruption and rearrangement of HIV-1 drug resistance mutations in peripheral reservoir. Miami December 2019. Journal of Virus Eradication. 2019; 5 (Supplement 3): 1-58. **IF 2.824**

144. Ralpini R\*, Alkhatib M, Di Maio VC, De Murtas V, Aragri M, Scutari R, Sacco A, Polilli E, Masetti C, Teti E, Barbaliscia S, Bertoli A, Cento V, Calvaruso V, Morisco F, Pace Palitti V, Pasquazzi C, Cacciatore P, Francioso S, Sozio F, Pieri A, Babudieri S, Mussini C, Parruti G, Borghi V, Lenci I, Craxi A, Andreoni M, Angelico M, Maida I, **Santoro Maria Mercedes**, Svicher V, Perno CF, Ceccherini-Silberstein F. On behalf of HIRMA (Hepatocarcinoma Innovative Research MARKers) and Fondazione Vironet C (HCV Virology Italian Resistance Network). Genetic determinants in critical domains of NS5A are associated with genotype 1b HCV-induced hepatocellular carcinoma. International Liver Congress / 54th Annual

Meeting of the European-Association-for-the-Study-of-the-Liver (EASL). Vienna 10-14 April 2019. JOURNAL OF HEPATOLOGY. Volume: 70. Pages: E699-E700. Supplement: 1. Meeting Abstract: SAT-159. DOI: 10.1016/S0618-8278(19)31394-5. **IF 20.582**

145. V Calvez; D Armenia; C Charpentier; **Maria Santoro**; C Soulie; M Wirden; C Perno; D Descamps; F Ceccherini-Silberstein and A Marcelin. Clinical consequences of failing PI- and DTG-based two drug combinations versus PI- and INI-based triple therapies in HIV patients without previous virological failures. HIV Glasgow 2018. 28-31 October 2018. Glasgow, United Kingdom. Journal of the International AIDS Society. Volume 21, Supplement 8, October 2018. Abstract P295. **IF 5.131. Cites 1**

146. D Armenia; C Gori; F Forbici; V Borghi; W Gennari; A Bertoli; A Giannetti; S Cicalini; A Mondì; M Colafigli; M Lichtner; M Andreoni; C Mussini; A Antinori; F Ceccherini Silberstein; C Perno and **Maria Santoro**. Factors associated with virological response and resistance profile in virologically suppressed HIV-1 infected patients switching to a dual therapy containing integrase inhibitors in clinical practice. HIV Glasgow 2018. 28-31 October 2018. Glasgow, United Kingdom. Journal of the International AIDS Society. Volume 21, Supplement 8, October 2018. Abstract P297. **IF 5.131**

147. VC Di Maio, D Armenia, MC Bellocchi, D Di Paolo, V Cento, M Tontodonati, V Micheli, L Carioti, F De Leonardis, M Aragri, E Polilli, A Manunta, C Magni, FP Antonucci, F De Luca, C Sarrecchia, A Bertoli, I Lenci, S Francioso, **Maria Mercedes Santoro**, J Vecchiet, A De Maria, Antonino Picciotto, Lorenzo Nosotti, Filomena Morisco, Savino Bruno, Massimo Puoti, Sergio Babudieri, Maria Stella Mura, Gloria Taliani, Massimo Andreoni, Giuliano Rizzardini, Giustino Parruti, Mario Angelico, Carlo Federico Perno, Francesca Ceccherini-Silberstein. CLINICAL RELEVANCE OF BASELINE/EARLY DETECTION AND PERSISTENCE OF RESISTANT ASSOCIATED VARIANTS IN HCV-1 PATIENTS TREATED WITH PROTEASE-INHIBITORS ASSESSED BY ULTRA-DEEP SEQUENCING. EASL 2015. Journal of Hepatology. Abstract P0915. **IF 10.59. Cites 1**

148. D. Armenia, L. Carioti, V.C. Di Maio, M.C. Bellocchi, D. Di Paolo, F. Guerrieri, L. Calvo, V. Cento, M. Tontodonati, V. Micheli, F. De Leonardis, M. Aragri, E. Polilli, A. Manunta, C. Magni, F.P. Antonucci, F. De Luca, C. Sarrecchia, A. Bertoli, I. Lenci, S. Francioso, **Maria Mercedes Santoro**, J. Vecchiet, S. Marengo, A. Picciotto, L. Nosotti, F. Morisco, S. Bruno, M. Puoti, S. Babudieri, M.S. Mura, M. Andreoni, G. Rizzardini, G. Parruti, M. Levrero, M. Angelico, C.F. Perno, and F. Ceccherini-Silberstein. Clinical relevance of next generation sequencing on baseline detection of minority resistance associated variants in HCV-1 patients treated with protease inhibitors. Digestive and Liver Disease. February 15, 2015. Volume 47, Supplement 1, Page e48. **IF 3.162**

149. **Maria Mercedes Santoro**, D Armenia, C Alteri, L Fabeni, D Di Pinto, D Di Carlo, A Bertoli, C Gori, S Carta, V Fedele, F Forbici, V Svicher, G Berno, E Nicastrì, C Pinnetti, A Ammassari, G D'Offizi, A Latini, M Andreoni, A Antinori, F Ceccherini-Silberstein, and CF Perno. Reliability and Clinical Relevance of HIV-1 Integrase Genotyping in Patients with Low Viremia Levels. International Workshop on Antiviral Drug Resistance Meeting the Global Challenge. 4-6 June 2014 Berlin, German. Poster 97. Antiviral Therapy 2014; 19 Suppl 1:A140. **IF 3.073. Cites 1**

150. A De Luca, P Flandre, A Castagna, F Ceccherini-Silberstein, A Cozzi-Lepri, D Churchill, S De Wit, D Dunn, W Fuchs, F Garcia, H Günthard, A Imaz, T Kordossis, C Mussini, N Obel, B Roca, **Maria Mercedes Santoro**, E Schuelter, C Torti, A van Sighem, AM Wensing, L Wittkop, R Zangerle, M Zazzi and D Descamps on behalf of CHAIN and COHERE in Eurocoord working group. Improved Weighted Darunavir Genotypic Mutation Score Predicting Treatment Response for HIV-1 subtype B and non-B Infected Patients Receiving Darunavir in a Salvage Regimen. International Workshop on Antiviral Drug Resistance Meeting the Global Challenge. 4-6 June 2014 Berlin, German. Poster 99. Antiviral Therapy 2014; 19 Suppl 1:A142. **IF 3.073**

151. V Svicher, M Neumann-Fraune, C Mirabelli, R Salpini, V Cento, VC Di Maio, M Pollicita, A Bertoli, C Alteri, M Aragri, C Gori, **Maria Mercedes Santoro**, A Salso, G Rizzardini, G Gubertini, V Micheli, F Niero, C. Magni, P Trimoulet, H Fleury, J Vecchiet, N Iapadre, A Barlattani, T Mari, C Pasquazzi, G Missale, C Sarrecchia, F Ceccherini-Silberstein, M Andreoni, M Angelico, J Verhejen, CF Perno, on behalf of the HIRMA study group. Key Genetic Markers in the Full-Length HBsAg Gene Correlate with HBV-driven Carcinogenesis by Affecting HBsAg Secretion and Release. 47th Annual Meeting of the

Italian Association for the Study of the Liver (AISF) 2014, Roma 25-27 Febbraio 2014, Digestive and Liver Diseases 2014. **IF 3.162**

**152. Maria Mercedes Santoro**, C Alteri, D Armenia, D Di Pinto, L Fabeni, L Carioti, F Forbici, A Bertoli, C Gori, S Carta, V Fedele, A Ammassari, C Pinnetti, E Nicastrì, C Tommasi, N Petrosillo, E Boumis, G D'Offizi, A Latini, M Andreoni, A Antinori, F Ceccherini-Silberstein, and CF Perno. Reliability of HIV-1 Drug-Resistance Test in Patients with Low Viremia Levels. International Workshop on HIV & Hepatitis Virus Drug Resistance and Curative Strategies. June 4-8, 2013, Toronto, Canada. Antivir Ther, Volume 19, Supplement 1. Abstract 97. **IF 3.073**

**153. Maria Mercedes Santoro**, C Alteri, A Bertoli, C Gori, V Borghi, L Fabeni, I Fantì, N Orchi, C Pinnetti, C Tommasi, N Cesta, E Girardi, G D'Offizi, M Giuliani, A D'Arminio Monforte, M Andreoni, C Mussini, A Antinori, CF Perno, and F Ceccherini-Silberstein. Low Prevalence of Primary Rilpivirine Mutations in NNRTI-Naïve Patients is Found in B and Most Frequent Non-B HIV-1 Subtypes in Italy. V ICAR 2013 - Italian Conference on AIDS and retrovirus HIV-1 Drug-Resistance. Turin, Italy, 12-14 May 2013. New Microbiologica. **IF 1.603**

**154.** L Fabeni, D Di Pinto, D Armenia, C Alteri, L Carioti, F Forbici, A Bertoli, C Gori, S Carta, V Fedele, G Berno, A Ammassari, C Pinnetti, E Nicastrì, C Tommasi, N Petrosillo, E Boumis, G D'Offizi, A Latini, M Andreoni, A Antinori, F Ceccherini-Silberstein, CF Perno, and **Maria Mercedes Santoro**. Test in Patients with Low Viremia Levels is Reliable, Reproducible and Provides Resistance Information. ICAR 2013 - Italian Conference on AIDS and retrovirus. V ICAR 2013 - Italian Conference on AIDS and retrovirus HIV-1 Drug-Resistance. Turin, Italy, 12-14 May 2013. . New Microbiologica. **IF 1.603**

**155.** D. Armenia, **Maria Mercedes Santoro**, A. Cozzi Lepri, A. Calcagno, F. Forbici, R. Bellagamba, A. Castagna, A. Latini, N. Petrosillo, A. Ammassari, F. Castelli, S. Di Giambenedetto, M. Andreoni, A. Antinori, G. Di Perri, C. Mussini, F. Ceccherini-Silberstein, A. D'Arminio Monforte, and C.F. Perno. Patients with very high pre-HAART viremia are at highest risk of experiencing virological rebound. ICAR 2013 - Italian Conference on AIDS and retrovirus. V ICAR 2013 - Italian Conference on AIDS and retrovirus HIV-1 Drug-Resistance. Turin, Italy, 12-14 May 2013. New Microbiologica. **IF 1.603**

**156.** C Alteri, VC Di Maio, A Artese, G Costa, **Santoro Maria Mercedes**, S Alcaro, M Andreoni, A Antinori, F Ceccherini-Silberstein, CF Perno, V Svicher. Structural Modifications in HIV-1 RT induced by Specific RT Polymorphisms Tightly Modulate the First Phase of Viremia Decay to First Line FTC+TDF containing HAART. IXX International HIV Drug Resistance Workshop: Basic Principles and Clinical Implications, Sitges, Spain, June 6-9 2012. Antiviral Therapy 2012; 17 Suppl 1:A18. **IF 3.161**

**157.** JL Blanco, J Montaner, Branstetter D, **Santoro Maria Mercedes**, AE Campos-Loza, J Fessel, MD Miller, Marconi V, R Paredes, M Nguyen, Lima V, CF Perno, LA Gonzalez-Hernandez, SY Rhee, Harrigan R, Shafer RW, Gatell JM (ATRES Study Group). Drug Resistance Prevalence after Failing Antiretroviral Therapy (ART) with Tenofovir (TDF) + Emtricitabine/Lamivudine (3TC/FTC) + Efavirenz (EFV) vs the Single Tablet Regimen (STR) Atripla: The ATRES study. International Workshop on HIV & Hepatitis Virus Drug Resistance and Curative Strategies. Poster. Antiviral Therapy 2012; 17 Suppl 1:A115. **IF 3.161**

**158.** Ceccherini-Silberstein F, Surdo M, Alteri C, Puertas MC, Saccomandi P, Artese, A, Balestra E Chapman D, Lewis M, Valdez H, Clotet B, Alcaro S, **Santoro Maria Mercedes**, Svicher V, Martinez-Picado J, Perno CF. HIV-1 R5(+)/X4-tropic viruses can be inhibited in vitro as well as in vivo by maraviroc: a refined analysis of patients enrolled in the Phase IIb study A4001029. International Workshop on HIV and Hepatitis Virus Drug Resistance and Curative Strategies Location: Los Cabos, MEXICO Date: JUN 07-11, 2011. **Poster presentation.** Antiviral Therapy 2011, Volume: 16 Issue: 4 Pages: A47-A47. **IF 3.161**

**159. Santoro Maria Mercedes\***, D Armenia, L Fabeni, M Santoro, C Gori, F Forbici, V Cento, V Svicher, A Bertoli, L Dori, M Andreoni, P Narciso, A Antinori, F Ceccherini-Silberstein, and CF Perno. The Lowest X4 Geno2Pheno-False Positive Rate Is Associated with Greater CD4-Depletion. 3th ICAR – Italian Conference on AIDS and Retroviruses Firenze, 27-29 marzo 2011. Infection 2011; 39 (Suppl. I): S11, Abstract CO 01. **Vincitore del premio SIVIM. IF 2.659**

160. V Cento\*, V Svicher, G Rozera, I Abbate, **Santoro Maria Mercedes**, D Armenia, L Fabeni, G Palamara, A Latini, G Rizzardini, V Micheli, AR Buonomini, A Antinori, M Andreoni, CF Perno, MR Capobianchi, and F Ceccherini-Silberstein. The Genotypic False Positive Rate Determined by Population V3-Sequencing can Predict the Burden of X4 Quasispecies Detected by Pyrosequencing. 3th ICAR – Italian Conference on AIDS and Retroviruses Firenze, 27-29 marzo 2011. *Infection* 2011; 39 (Suppl. I): S38, Abstract SC 15. **IF 2.659**

161. **Santoro Maria Mercedes**, I Abbate, C Alteri, V Svicher, A Bruselles, B Bartolini, F Forbici, G Rozera, MR Capobianchi, CF Perno, and F Ceccherini Silberstein. Sentinel Mutations in Standard Population Sequencing Can Predict the Hidden Presence of RT Major Mutations Detected only by Ultra deep pyrosequencing. 2th ICAR – Italian Conference on AIDS and Retroviruses Brescia, 20-22 giugno 2010. *Infection* 2010; 38 (Suppl. I): 58, PO 34. **IF 2.244**

162. **Santoro Maria Mercedes\***, C Alteri, I Abbate, V Svicher, A Bruselles, B Bartolini, C Gori, G Rozera, MR Capobianchi, CF Perno, and F Ceccherini Silberstein. Sentinel mutations in standard population sequencing predict a high prevalence of RTI-resistance minor variants in both RNA plasma and DNA cellular samples from hiv-1 drug naïve patients. 4° Congresso Nazionale Società Italiana Virologia Medica, Milano, Italia, 5-7 maggio 2010. *New Microbiologica* 2010, Abstract C18. **IF 0.95**

163. D Armenia\*, L Fabeni, I Malet, R D'Arrigo, S Reigadas, V Micheli, V Cento, MP Trotta, S Lo Caputo, **Santoro Maria Mercedes**, V Svicher, P Flandre, B Bruzzone, G Di Perri, A Capetti, P Narciso, B Masquelier, G Rizzardini, V Calvez, H Gomes da Silva, A Antinori, AG Marcelin, CF Perno, AND F Ceccherini-Silberstein. Impact of baseline HIV-1 integrase polymorphisms with virological response in patients starting a Raltegravir-containing regimen. 4° Congresso Nazionale Società Italiana Virologia Medica, Milano, Italia, 5-7 maggio 2010. *New Microbiologica* 2010, Abstract C09. **IF 0.95**

164. F Ceccherini Silberstein, **Santoro Maria Mercedes**, F Forbici, M Zaccarelli, E Boumis, G Palamara, A Callegaro, D Francisci, G Carnevale, F Maggiolo, P Narciso, A Antinori, M Zazzi, C Mussini, and CF Perno. Different drug-resistance development in HIV-1 infected patients failing a first-line antiretroviral therapy containing NNRTIs with or without thymidine analogues. 12<sup>th</sup> European AIDS Conference/EACS. Cologne, Germany, 11-14 November 2009. *HIV Medicine* 2009, 10 Suppl 2:PE3.4/10. **IF 2.878**

165. V Svicher\*, C Alteri, F Forbici, **Santoro Maria Mercedes**, D Schols, K Van Laethem, E Boumis, De Longis P, P Narciso, A Antinori, F Ceccherini-Silberstein, J Balzarini, CF Perno. Different Evolution and Patterns of Genotypic Resistance Profiles in Emtricitabine plus Tenofovir and Lamivudine plus Tenofovir Containing Regimen. XVIII International HIV Drug Resistance Workshop: Basic Principles and Clinical Implications, Fort Myers, Florida, USA, June 9-13 2009. *Antiviral Therapy* 14:S1A25 (2009). **IF 4.322**

166. **Santoro Maria Mercedes\***, F Silberstein, F Forbici, M Zaccarelli, E Boumis, G Palamara, A Callegaro, D Francisci, G Carnevale, F Maggiolo, P Narciso, A Antinori, M Zazzi, and C Mussini. Evaluation of drug resistance emergence in HIV-1 infected patients failing a first-line highly active antiretroviral therapy containing NNRTIs with or without thymidine analogues. ICAR, Italian Conference on AIDS and Retroviruses. Milano. 24-26 Maggio 2009. *Infection* 37, SII:22 (2009). **IF 2.051**

167. V Svicher\*, D Armenia, **Santoro Maria Mercedes**, F Forbici, B Bruzzone, M Setti, P Corsi, R Maserati, C Mussini, M Zazzi, A De Luca, M Andreoni, P Narciso, A Antinori, CF Perno, F Ceccherini-Silberstein. Impact of mutations at position 135 of HIV-1 reverse transcriptase on virologic response to a first line NNRTI-containing HAART. ICAR, Italian Conference on AIDS and Retroviruses. Milano. 24-26 Maggio 2009. *Infection* 37, SII:33 (2009). **IF 2.051**

168. C Tommasi, F Ceccherini-Silberstein, R D'Arrigo, R Bellagamba, M Tempestilli, C Dessi, **Santoro Maria Mercedes**, F Forbici, L Pucillo, CF Perno, and P Narciso. Successful rescue therapy with maraviroc and etravirine (TMC125) in patient with early virological failure to raltegravir. ICAR, Italian Conference on AIDS and Retroviruses. Milano. 24-26 Maggio 2009. *Infection* 37, SII:33 (2009). **IF 2.051**

169. A De Luca, S Di Giambenedetto, F Marando, R Maserati, N Gianotti, P Narciso, A Antinori, G Di Perri, F Baldanti, M Zazzi, CF Perno, and **Santoro Maria Mercedes** for the TMC114-C226 and the ARCA study groups. Improved interpretation and clinical validation of substitutions in HIV-1 protease predicting the virological response to darunavir/ritonavir. XVII International HIV Drug Resistance Workshop, Sitges, Spain, 10 – 14 Junes, 2008. Antiviral Therapy 2008, 13 Suppl 3:A104. **IF 4.105.**

**Cites 2**

170. F Ceccherini-Silberstein, V Svicher, **Santoro Maria Mercedes**, M Prosperi, F Forbici, A Bertoli, C Mussini, A De Luca, G Palamara, P Narciso, A Antinori, C Balotta, A d'Arminio Monforte, CF Perno, IcoNA Study Group and INMI-Collaborative Group for Clinical Use of HIV Genotype Resistance Test. Impact of HIV-1 Reverse Transcriptase Polymorphism R83K on Virological Response in Drug-Naïve Patients starting Thymidine Analogue Containing HAART. XVI International HIV Drug Resistance Workshop, Barbados, USA, 12 - 16 Junes, 2007. Antiviral Therapy 2007, 12:S77. **IF 4.547**

171. V Svicher, T Sing, **Santoro Maria Mercedes**, A Bertoli, C Gori, A Artese, S Alcaro, A d'Arminio Monforte, A Antinori, T Lengauer, CF Perno and F Ceccherini-Silberstein. Involvement of novel HIV-1 RT mutations in the regulation of NNRTI resistance. Abstract 149. XV International HIV Drug Resistance Workshop, Sitges, Spain 13 - 16 Junes, 2006. Antiviral Therapy 2006, 11:S165. **IF 4.982**

172. A Bertoli, **Santoro Maria Mercedes**, P Lorenzini, F Ceccherini-Silberstein, A Lazzarin, G Di Perri, R Esposito, P Caramello, A Cargnel, P Narciso, G Rizzardini, G Filice, L Minoli, G Carosi, A Antinori, and CF Perno (2006). Different Patterns of mutations involved in the genotypic resistance score for atazanavir boosted versus atazanavir unboosted in multiply failing Patients. XV International HIV Drug Resistance Workshop, Sitges, Spain 13 - 16 June, 2006. Antiviral Therapy 2006, 11:S99. **IF 4.982**

173. F Ceccherini-Silberstein, **Santoro Maria**, C Gori, V Svicher, M Santoro, F Forbici, N Esposito, R Bellagamba, R D'Arrigo, M Zaccarelli, A Cenci, U Visco-Comandini, A Antinori, and CF Perno. The presence of selected mutations influences the disappearance of major protease resistance mutations during treatment interruption. XIV International HIV Drug Resistance Workshop: Basic Principles and Clinical Implications, Québec City, Québec, Canada, 7 – 11 June, 2005. Antiviral Therapy 2005, 10: S171. **IF 5.826**

174. F Ceccherini-Silberstein, V Svicher, T Sing, **Santoro Maria**, N Beerenwinkel, F Gago, A Bertoli, F Forbici, MC Bellocchi, P Narciso, A d'Arminio Monforte, A Antinori, and CF Perno. Involvement of novel HIV-1 reverse transcriptase mutations in the highly ordered regulation of NRTI resistance. XIV International HIV Drug Resistance Workshop: Basic Principles and Clinical Implications, Québec City, Québec, Canada, 7-11 June, 2005, Antiviral Therapy 2005, 10:S106. **The poster awarded the prize for the best poster of the meeting.** **IF 5.826**

175. F Ceccherini-Silberstein, **Santoro Maria**, V Svicher, C Gori, M Zaccarelli, F Forbici, R d'Arrigo, MP Trotta, MC Bellocchi, U Visco-Comandini, S Giannella, A Bertoli, A Antinori, and CF Perno. Temporal characterization of frequency of drug-resistance associated mutations in the HIV-1 protease and reverse transcriptase. XIII International HIV Drug Resistance Workshop: Basic Principles and Clinical Implications, Tenerife, Canary Islands, Spain, 8-12 June, 2004. Antiviral Therapy 2004, 9:S116. **IF 6.036**

176. F. Ceccherini-Silberstein, **Santoro Maria**, V. Svicher, C. Gori, F. Gago, T. Hermsen, M. Ciccozzi, M. Ruiz Alvarez, R. D'Arrigo, A. Bertoli, S. Giannella, A. Cenci, M.P. Trotta, C. Balotta, A. D'Arminio Monforte, A. Antinori and C.F. Perno. High conservation of the HIV-1 reverse transcriptase under drug pressure is maintained despite a continuous appearance of mutations. 2nd European HIV Drug Resistance Workshop: From Basic Science to Clinical Implications. Rome, Italy, 11-13 March, 2004. HIV Medicine 5: Abstract 39, pag 23-24 (2004).

177. V Svicher, **Santoro Maria**, F Forbici, C Gori, A Cenci, R D'Arrigo, MC Bellocchi, S Giannella, A Bertoli, A Antinori, CF Perno and F Ceccherini-Silberstein. Novel mutations in HIV-1 protease potentially involved in drug resistance to protease inhibitors. Second European HIV Drug Resistance Workshop: From basic science to clinical implications, Rome, Italy, 11-13 March, 2004. HIV Medicine 5: Abstract 98, pag. 57 (2004).

Presentazioni orali (l'asterisco indica lo speaker)

178. F Ceccherini-Silberstein, **Santoro Maria**, V Svicher, F Forbici, C Gori, R Esnouf, M Ciccozzi, M Ruiz Alvarez, R D'Arrigo, MC Bellocchi, C Balotta, A Bertoli, S Giannella, A Cenci, MP Trotta, J Balzarini, A d'Arminio Monforte, A Antinori, and CF Perno. Identification of the Minimal Conserved Structure of the HIV-Reverse Transcriptase under the Presence and Absence of Drug Pressure. XII International HIV Drug Resistance Workshop: Basic Principles and Clinical Implications, Los Cabos, Mexico, 10 - 14 June, 2003. *Antiviral Therapy* 2003, 8: S45. **IF 5.932**

179. D Armenia\*, F Forbici, A Bertoli, G Berno, V Malagnino, R Gagliardini, V Borghi, W Gennari, S Cicalini, A Buonomini, E Teti, S Lanini, A Latini, L Sarmati, C Mussini, M Andreoni, A Antinori, CF Perno, F Ceccherini-Silberstein, and **Maria Mercedes Santoro**. Virological response and resistance profile in virologically suppressed HIV-1 infected individuals switching to a bictegravir based treatment in clinical practice. 18<sup>th</sup> European AIDS Conference (EACS) October 27-30, 2021, London (oral poster; abstract #BPD1/2).

180. D Armenia\*, F Forbici, A Bertoli, G Berno, V Malagnino, R Gagliardini, V Borghi, W Gennari, S Cicalini, A Buonomini, E Teti, S Lanini, A Latini, L Sarmati, C Mussini, M Andreoni, A Antinori, CF Perno, **Maria Mercedes Santoro**, and F Ceccherini-Silberstein. Evaluation of virological response and resistance profile in virologically suppressed HIV-1 infected individuals switching to a bictegravir based regimen in a real-life setting. 13° Congresso Nazionale ICAR Italian Conference on AIDS and Antiviral Research. Riccione, 21-23 ottobre 2021 (abstract # OC22).

181. **Santoro Maria Mercedes\***, Gianotti N, Galli L, Scutari R, Alteri C, Poli A, Piermatteo L, Bigoloni A, Perno CF, Lazzarin A, Ceccherini-Silberstein F, and Castagna A. Evaluation of total HIV-DNA and residual viremia in HIV-1 infected individuals enrolled on the Be-OnE study who continue a two-drug regimen with dolutegravir plus one reverse transcriptase inhibitor or switch to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide: results over 96 weeks. 13° Congresso Nazionale ICAR Italian Conference on AIDS and Antiviral Research. Riccione, 21-23 ottobre 2021 (abstract # OC23).

182. F Lombardi\*, Y Bouba, D Di Carlo, V Costabile, E Bruzzesi, M Ranzenigo, F Maggiolo, AP Callegaro, AZoncada, S Paolucci, V Micheli, S Renica, A Bezencheck, B Rossetti, and **Maria Mercedes Santoro**. Evaluation of factors potentially associated with Low-level viremia in PLWH from the Italian ARCA cohort: a matched Case-Control Study. 13° Congresso Nazionale ICAR Italian Conference on AIDS and Antiviral Research. Riccione, 21-23 ottobre 2021 (abstract # OC60).

183. D Armenia\*, V Cento, C Alteri, V Borghi, R Gagliardini, A Vergori, F Forbici, A Bertoli, W Gennari, V Malagnino, M Andreoni, C Mussini, A Antinori, CF Perno, F Ceccherini-Silberstein, and **Maria Mercedes Santoro**. Temporal trend of drug-resistance and APOBEC editing in PBMC genotypic resistance tests on isolates with contextual undetectable HIV-1 plasma viral load performed for clinical routine. 13° Congresso Nazionale ICAR Italian Conference on AIDS and Antiviral Research. Riccione, 21-23 ottobre 2021 (abstract # OC64).

184. M Ranzenigo\*, E Bruzzesi, D Di Carlo, V Costabile, F Lombardi, Y Bouba, F Maggiolo, AP Callegaro, AZoncada, S Paolucci, V Micheli, S Renica, A Bezencheck, B Rossetti, and **Maria Mercedes Santoro**. Characterization of PLWH with low-level viremia: results from the Italian ARCA cohort. 13° Congresso ICAR - Riccione, 21-23 ottobre 2021 (oral poster; abstract #OP 72).

185. A Cozzi-Lepri, B Rossetti, F Incardona, G Di Teodoro, D Di Carlo, M Proserpi, A Shallvari, M Böhm, C Seguin-Devaux, M Zazzi, and **Maria Mercedes Santoro\***, on behalf of EuResist Network. Role of genotypic testing results for predicting virological failure in persons living with HIV with HIV-RNA  $\leq 50$  cps/mL who require an ART switch. 13° Congresso ICAR - Riccione, 21-23 ottobre 2021 (abstract #OC 21).

186. **Maria Mercedes Santoro\***, D Armenia, E Teyssou, J Ramon Santos, C Charpentier, S Lambert-Niclot, A Antinori, C Katlama, D Descamps, CF Perno, V Calvez, R Paredes, F Ceccherini-Silberstein, and AG Marcelin on behalf of the LAMRES Study Group. Virological efficacy of switch to 3TC/DTG in a real life cohort of suppressed HIV-1 patients with or without past M184V – The LAMRES Study. Virtual European Meeting on HIV & Hepatitis 2021. 25-28 May 2021 (abstract #13).

187. Cozzi-Lepri A\*, Gagliardini R, Zazzi M, Tavelli A, **Santoro Maria Mercedes**, Armenia D, Castagna A, Gennari, Rusconi S, Mussini C, Laghetti, Perno CF, D'Arminio A and Antinori A. Exploration of the possible mechanisms leading to greater mortality in people with limited drug options (LDO). Virtual European Meeting on HIV & Hepatitis 2021. 25-28 May 2021 (abstract #16).



188. Armenia D\*, Scutari R, Bellocchi MC, Carioti L, Bouba Y, Barbaliscia S, Gennari W, Borghi V, Malagnino V, Alteri C, Mussini C, Sarmati L, Andreoni M, **Santoro Maria Mercedes**, and Francesca Ceccherini-Silberstein. Usefulness of next-generation sequencing on PBMC samples and HIV-1 DNA quantification in management of treatment optimization in virological suppressed infected individuals. Virtual European Meeting on HIV & Hepatitis 2021. 25-28 May 2021 (abstract #17). **Vincitore del premio per la migliore presentazione orale.**
189. Alteri C, Scutari R\*, Costabile V, Carta S, Colagrossi L, Gori C, Bertoli A, Orchi N, De Carli C, Pittalis S, Chianura LG, Rossotti R, Malagnino V, Cicalini S, Gagliardini R, Latini A, Nava A, Fanti D, Lichtner M, Moioli MC, Ceccherini-Silberstein F, Girardi E, **Santoro Maria Mercedes**, Andreoni M, Puoti M, Antinori A, and Perno CF. Dynamics of HIV-1 transmission clusters in North and Central Italy over the years 2012-2019. Virtual International Workshop of HIV Transmission, 10-11 December 2020. Reviews in Antiviral Therapy & Infectious Diseases 12, 2020 (abstract #3)
190. C Guerrero-Beltrán, E Kostaki, L Carioti, M Álvarez, J Olalla, M Masiá, M Montero, S García-Bujalance, JR Blanco, M Rivero, LJ García-Fraile, Carmen Rodríguez, **Maria Mercedes Santoro**, Dimitrios Paraskevis, and F García\* on behalf of CoRIS. HIV TRACE vs phylogenetic analysis: unraveling transmission clusters in Spain. Virtual European Meeting on HIV & Hepatitis Treatment Strategies & Antiviral Drug Resistance, 28-30 October 2020 (abstract # 2).
191. R Gagliardini\*, P Lorenzini, D Armenia, G Passavanti, S Cicalini, A Vergori, F Forbici, A Bertoli, V Borghi, Cr Mussini, V Malagnino, F Ceccherini-Silberstein, M Andreoni, CF Perno, A Antinori, and **Maria Mercedes Santoro**. High efficacy after switching to integrase strand transfer inhibitors (INSTI) in PLWH with undetectable viremia and past virological failure and/or resistance. Virtual European Meeting on HIV & Hepatitis Treatment Strategies & Antiviral Drug Resistance, 28-30 October 2020 (abstract #6).
192. **Santoro Maria Mercedes**, Armenia D\*, Bellocchi MC, Carioti L, Galli L, Galli A, Scutari R, Salsi E, Mussini C, Sterrantino G, Calza L, Rossetti B, Zazzi M, and Castagna A, on behalf of the PRESTIGIO Registry Study Group. Evaluation of HIV-1 RNA and DNA mutational load in HIV-1 infected heavily treatment-experienced patients harbouring multi-drug resistant strains. Virtual European Meeting on HIV & Hepatitis Treatment Strategies & Antiviral Drug Resistance, 28-30 October 2020 (abstract #8).
193. Alteri C, Scutari R\*, Costabile V, Carta S, Colagrossi L, Gori C, Bertoli A, Orchi N, De Carli C, Pittalis S, Chianura LG, Rossotti R, Malagnino V, Cicalini S, Gagliardini R, Latini A, Nava A, Fanti D, Lichtner M, Moioli MC, Ceccherini-Silberstein F, Girardi E, **Santoro Maria Mercedes**, Andreoni M, Puoti M, Antinori A, and Perno CF. Dynamics of HIV-1 transmission clusters in North and Central Italy over the years 2012-2019. Virtual European Meeting on HIV & Hepatitis Treatment Strategies & Antiviral Drug Resistance, 28-30 October 2020 (abstract #17).
194. A de Salazar, A Fuentes, E Serrano, C Charpentier, A Beloukas, S Lambert-Niclot, A De Monte, I Diogo, L Fabeni, A Hatzakis, K Stefic, S Fernandes, CF Perno, D Descamps, D Chatzidimitriou, W Gennari, V Sypsa, P Gomes, D Paraskevis, **Maria Mercedes Santoro**, F Ceccherini-Silberstein, AG Marcelin, and F Garcia\*. Transmitted drug resistance to integrase based first-line HIV antiretroviral treatment in the MeditRes HIV collaboration. Virtual European Meeting on HIV & Hepatitis Treatment Strategies & Antiviral Drug Resistance, 28-30 October 2020 (Oral poster; abstract # 18).
195. Y Bouba\*, D Armenia, F Forbici, A Bertoli, V Borghi, R Gagliardini, A Vergori, S Cicalini, V Mazzotta, V Malagnino, M Lichtner, M Colafigli, M Andreoni, A Antinori, CF Perno, F Ceccherini-Silberstein, and **Maria Mercedes Santoro**. Evaluation of HIV-1 tropism in multidrug-resistant cART failing patients. Virtual European Meeting on HIV & Hepatitis Treatment Strategies & Antiviral Drug Resistance, 28-30 October 2020 (Oral poster; abstract # 24).
196. A Saracino\*, P Lorenzini, **Maria Mercedes Santoro**, A Tavelli, S Rusconi, N Bobbio, A Mondì, S Lo Caputo, A Antinori, E Girardi, A d'Arminio Monforte, and L Monno. Post-migration HIV infection in the foreign-born population enrolled in the ICONA cohort. 12° Congresso Nazionale ICAR (Italian Conference on AIDS and Antiviral Research). Webinar, 12-16 ottobre 2020 (Abstract OC4).
197. Y Bouba\*, D Armenia, F Forbici, A Bertoli, V Borghi, R Gagliardini, A Vergori, S Cicalini, V Mazzotta, V Malagnino, M Lichtner, M Colafigli, M Andreoni, CF Perno, F Ceccherini-Silberstein, and **Maria Mercedes Santoro**. Evaluation of HIV-1 tropism in multidrug-resistant cART failing patients. 12°

Congresso Nazionale ICAR (Italian Conference on AIDS and Antiviral Research). Webinar, 12-16 ottobre 2020 (Abstract OC22).

198. G Stella\*, L Volpicelli, D Di Carlo, I Vicenti, L Celani, F Maggiolo, AP Callegaro, W Gennari, D Francisci, F Lombardi, L Piermatteo, A Bezenchek, V Micheli, B Rossetti, and **Maria Mercedes Santoro**. Evaluation of the impact of resistance on virological efficacy of STR regimens and emergence of resistance at virological failure. 12° Congresso Nazionale ICAR (Italian Conference on AIDS and Antiviral Research). Webinar, 12-16 ottobre 2020 (Abstract OC48).

199. T Clemente\*, R Caccia, V Spagnuolo, L Galli, A Poli, A Galli, G Marchetti, M Zazzi, **Maria Mercedes Santoro**, P Cinque, and A Castagna, on the behalf of the PRESTIGIO Study Group. "Inflammatory burden in people living with four-class drug resistant HIV: data from the PRESTIGIO Registry. 12° Congresso Nazionale ICAR (Italian Conference on AIDS and Antiviral Research). Webinar, 12-16 ottobre 2020 (Abstract OC55).

200. **Santoro Maria Mercedes\***, N Gianotti, L Galli, R Scutari, C Alteri, A Poli, L Piermatteo, A Bigoloni, CF Perno, A Lazzarin, F Ceccherini-Silberstein, and A Castagna. Evaluation of total HIV-DNA and residual viremia in HIV-1 infected patients who continue a two-drug regimen with dolutegravir plus one reverse transcriptase inhibitor or switch to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide enrolled in the Be-OnE Study. 12° Congresso Nazionale ICAR (Italian Conference on AIDS and Antiviral Research). Webinar, 12-16 ottobre 2020 (Oral poster; Abstract OP1).

201. Armenia D\*, Fabeni, R Gagliardini, V Borghi, G Berno, A Vergori, S Cicalini, C Mussini, A Antinori, F Ceccherini-Silberstein, CF Perno, and **Maria Mercedes Santoro**. Virological response and resistance profile in highly treatment-experienced HIV-1 infected patients switching to dolutegravir plus boosted-darunavir in clinical practice. 12° Congresso Nazionale ICAR (Italian Conference on AIDS and Antiviral Research). Webinar, 12-16 ottobre 2020 (Oral poster; Abstract OP31).

202. **Maria Mercedes Santoro**, D Armenia\*, MC Bellocchi, L Carioti, L Galli, A Galli, R Scutari, E Salsi, C Mussini, G Sterrantino, L Calza, B Rossetti, M Zazzi, and A Castagna, on behalf of the PRESTIGIO Registry Study Group. HIV-1 RNA and DNA mutational load in HTE patients with MDR virus: a tool for deciding OBR? 12° Congresso Nazionale ICAR (Italian Conference on AIDS and Antiviral Research). Webinar, 16-20 ottobre 2020 (Oral poster; Abstract OP83).

203. R\* Scutari, MC Bellocchi, V Spagnuolo-, S Barbaliscia, L Galli, A Galli, A Poli, L Carioti, **Maria Mercedes Santoro**, CF Perno, C Alteri, F Ceccherini-Silberstein, and Antonella Castagna. Analytical treatment interruption and rearrangement of HIV-1 drug resistance mutations in peripheral reservoir". 47° Congresso Nazionale Società Italiana di Microbiologia Virtuale. 21-22 settembre 2020.

204. J Fokam\*, ML Mpouel-Bala, **Maria Mercedes Santoro**, D Takou, G Teto, B Dambaya, V Tala, G Beloumou, EN Semengue, C Chenwi, S Djupsa, FN Ateba, C Kamta, L Bala, AE Njom-Nlend, PN Koki, V Colizzi, A Ndjolo, and CF Perno. The presence of archived HIV drug resistance mutations is consistent with advanced clinical stage and CD4-nadir in vertically-infected adolescents failing treatment. 28th International Workshop on HIV Drug Resistance & Treatment Strategies. Johannesburg, South Africa 16-18 October 2019. Abstract 29.

205. Scutari R\*, MC Bellocchi, V Spagnuolo, L Galli, S Barbaliscia, A Galli, A Poli, L Carioti, **Maria Mercedes Santoro**, CF Perno, C Alteri, F Ceccherini Silberstein, and Antonella Castagna. Influence of analytical treatment interruption on rearrangement of peripheral archived HIV-1 resistance mutations. HIV Cure Symposium. Ghent, Belgium. 16-17 September 2019.

206. C Alteri\*, R Scutari, L Galli, MC Bellocchi, L Carioti, V Costabile, A Poli, A Galli, F Ceccherini Silberstein, CF Perno, **Maria Mercedes Santoro**, A Castagna, and V Spagnuolo. Analytical treatment interruption does not alter size but might cause genetic diversification of the HIV-1 peripheral reservoir. 11th ICAR (Italian Conference on AIDS and Antiviral Research). Milan 5-7 June 2019. Abstract ID OC21. ***Vincitore del Premio ICAR 2019 Scientific Committee Awards per la Basic Science***

207. D Armenia, B Yagai, A Bertoli, L Palandri, H Tchidjou Kuekou, F Forbici, R Gagliardini, M Lichtner, M Andreoni, A Antinori, F Ceccherini Silberstein, S Bernardi, CF Perno, and **Santoro Maria Mercedes\***. Dynamics of HIV- drug resistance over the years -017 in isolates from perinatally infected individuals followed in Italy". 11th ICAR (Italian Conference on AIDS and Antiviral Research). Milan 5-7 June 2019. Abstract OC54.

208. Armenia D\*, S Nozza, **Maria Mercedes Santoro**, MR Parisi, F Maggiolo, E Focà, C Cerva, S Rusconi, L Gazzola, F Ceccherini Silberstein, CF Perno and A Lazzarin on behalf of the INIMAGE Study Group. Evaluation of resistance profile and virological response in drug-naïve patients who start a first-line regimen containing an integrase inhibitor. 11th ICAR (Italian Conference on AIDS and Antiviral Research). Milan 5-7 June 2019. Abstract OC55.

209. F Lombardi\*, A Giacomelli, D Armenia, A Lai, A Dusina, A Bezenchek, L Timelli, F Saladini, F Vichi, P Corsi, G Colao, B Bruzzone, R Gagliardini, A Callegaro, A Castagna, and **Maria Mercedes Santoro**. Evaluation of multidrug resistance over the last two decades in ARTexperienced HIV-1 infected patients in the ARCA database. 11th ICAR (Italian Conference on AIDS and Antiviral Research). Milan 5-7 June 2019. Abstract OC60.

210. MR Parisi, A Poli, M Menozzi, M Fiscon, R Corsini, D Francisci, A Di Biagio, G Sterrantino, C Fornabaio, E Salsi, G Angarano, FM Fusco, A D'Arminio Monforte, GM Corbelli, **Maria Mercedes Santoro**, M Zazzi, and A Castagna on behalf of the PRESTIGIO Study Group. Burden of disease in people living with four classes resistant HIV-1: data from the PRESTIGIO Registry. 11th ICAR (Italian Conference on AIDS and Antiviral Research); Milan 5-7 June 2019. Abstract ID OC66.

211. Alkhatib M\*, Di Maio VC, De Murtas V, Aragri M, Scutari R, Sacco A, Polilli E, Masetti C, Teti E, Barbaliscia S, Bertoli A, Cento V, Calvaruso V, Morisco F, Pace Palitti V, Pasquazzi C, Cacciatore P, Francioso S, Sozio F, Pieri A, Babudieri S, Mussini C, Parruti G, Borghi V, Lenci I, Craxi A, Andreoni M, Angelico M, Maida I, Orro A, Milanese L, **Santoro Maria Mercedes**, Perno CF, Svicher V, Ceccherini-Silberstein F, and Salpini R, On behalf of HIRMA (Hepatocarcinoma Innovative Research MARKers) and Fondazione Vironet C (HCV Virology Italian Resistance Network). Specific NS5A polymorphisms correlate with hepatocellular carcinoma in cirrhotic patients infected with HCV genotype 1b. 11th ICAR (Italian Conference on AIDS and Antiviral Research). Milan 5-7 June 2019. Abstract OC76.

212. Canetti D\*, Galli L, Gianotti N, Brescia, Bologna, Gagliardini R, Sacco, Siena, Cenderello G, Ferrara M, **Santoro Maria**, Zazzi M, Castagna A on behalf of the PRESTIGIO Study Group. Simplification to high-genetic-barrier 2DR in PLWH harbouring 4-class drug-resistant HIV-1, enrolled in the PRESTIGIO Registry. 11th ICAR (Italian Conference on AIDS and Antiviral Research). Milan 5-7 June 2019. (Poster orale) Abstract PD66.

213. L Fabeni\*, B Yagai, G Berno, L Carioti, R Salpini, V Svicher, CF Perno, **Maria Mercedes Santoro**, and F Ceccherini-Silberstein. Some HIV-1 gp120 polymorphisms could be involved in resistance to Fostemsavir. 11th ICAR (Italian Conference on AIDS and Antiviral Research). Milan 5-7 June 2019. Abstract PD43 (Poster orale).

214. C Soulie, **Maria Mercedes Santoro**, A Storto, C Charpentier, D Armenia, F Forbici, A Bertoli, W Gennari, M Andreoni, C Mussini, A Antinori, CF Perno, V Calvez, F Ceccherini-Silberstein, D Descamps, and AG Marcelin\*. Epidemiological study of Doravirine associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy. 17th European Meeting on HIV & Hepatitis. Rome 22-24 May 2019. Abstract ID 9.

215. Alkhatib M\*, Di Maio VC, De Murtas V, Aragri M, Scutari R, Sacco A, Polilli E, Masetti C, Teti E, Barbaliscia S, Bertoli A, Cento V, Calvaruso V, Morisco F, Pace Palitti V, Pasquazzi C, Cacciatore P, Francioso S, Sozio F, Pieri A, Babudieri S, Mussini C, Parruti G, Borghi V, Lenci I, Craxi A, Andreoni M, Angelico M, Maida I, Orro A, Milanese L, **Santoro Maria Mercedes**, Perno CF, Svicher V, Ceccherini-Silberstein F, Salpini R, On behalf of HIRMA (Hepatocarcinoma Innovative Research MARKers) and Fondazione Vironet C (HCV Virology Italian Resistance Network). Specific NS5A polymorphisms

correlate with hepatocellular carcinoma in cirrhotic patients infected with HCV genotype 1b". 17th European Meeting on HIV & Hepatitis that will be held on 22-24 May 2019, Rome. Abstract ID14.

216. B Yagai\*, L Fabeni L, Berno G, Carioti L, R Salpini, V Svicher, CF Perno, **Maria Mercedes Santoro**, and F Ceccherini-Silberstein. Evaluation of HIV-1 gp120 polymorphisms potentially associated with resistance to Fostemsavir. 17th European Meeting on HIV & Hepatitis that will be held on 22-24 May 2019 in Rome. Presentazione oral poster. Abstract ID 53.

217. J Fokam\*, **Maria Mercedes Santoro**, D Takou, V TALA, C CHENWI, E SEMENGUE, G BELOUMOU, S DJUPSA, G TETO, SC Billong, JB Nfetam Elat, F Ceccherini-Silberstein, V Colizzi, CF Perno, and A Ndjolo, On behalf of the VIROFORUM Group. Thresholds of Pre-treatment HIV-1 Drug Resistance Indicate Regions for Priority Actions in the Antiretroviral Therapy Program of Cameroon. IAS 2019

218. D. Armenia\*, C. Gori, A. Bertoli, V. Borghi, A. Latini, R. Gagliardini, C. Pinnetti, S. Cicalini, A. Mondì, M. Lichtner, F. Forbici, F. Montella, C. Mussini, M. Andreoni, A. Antinori, F. Ceccherini-Silberstein, C.F. Perno, and **Maria Mercedes Santoro**. VALUTAZIONE DELLA PREVALENZA DELLA RESISTENZA AGLI INIBITORI DELL'INTEGRASI IN ITALIA DAL 2007 AL 2017. XVII Congresso Nazionale SIMIT, 2-5 dicembre 2018. Torino.

219. L Fabeni\*, B Yagai, L Carioti, R Salpini, V Svicher, CF Perno, **Maria Medercedes Santoro**, and F Ceccherini-Silberstein. EVALUATION OF HIV-1 GP120 MUTATIONAL PATHWAYS POTENTIALLY ASSOCIATED WITH RESISTANCE TO FOSTEMSAVIR. 2<sup>nd</sup> National Congress of the Italian Society of Virology – One Virology One Health- Rome 28-30 Novembre 2018. Abstract OC21

220. D. Armenia\*, C. Gori, F. Forbici, V. Borghi, W. Gennari, A. Bertoli, A. Giannetti, S. Cicalini, A. Mondì, M. Colafigli, M. Lichtner, M. Andreoni, C. Mussini, A. Antinori, F. Ceccherini-Silberstein, C.F. Perno, and **Maria Mercedes Santoro**. Longer duration of virological suppression and a fully active companion drug ensure a high rate of virological control in HIV-1 infected patients switching to a dual therapy containing integrase inhibitors. European HIV Clinical Forum 2018, 27 ottobre 2018. Glasgow. Abstract OC01.

221. D. Armenia, C. Gori, A. Bertoli, V. Borghi, M. Zaccarelli, A. Di Biagio, B. Bruzzone, L. Fabeni, W. Gennari, D. Pizzi, A. Giannetti, A. Vergori, I. Mastroirosa, A. Latini, M. Colafigli, C. Cerva, R. Marocco, M. Andreoni, C. Mussini, A. Antinori, F. Ceccherini-Silberstein, C.F. Perno, and **Maria Mercedes Santoro**\*. Factors associated with virological response and resistance profile in HIV-1 infected patients starting first-line integrase inhibitors based regimen in clinical settings. 16th European Meeting on HIV & Hepatitis. Rome 30 May – 1 June 2018. Abstract number 8.

222. D. Armenia\*, C. Gori, F. Forbici, V. Borghi, M. Zaccarelli, A. Bertoli, C. Alteri, W. Gennari, G. Berno, A. Giannetti, A. Vergori, I. Mastroirosa, V. Mazzotta, G. Maffongelli, M. Colafigli, I. Pozzetto, M. Lichtner, M. Andreoni, C. Mussini, A. Antinori, C.F. Perno, F. Ceccherini-Silberstein, and **Maria Mercedes Santoro**. Virological response and resistance profile in virologically suppressed HIV-1 infected patients switching to integrase inhibitors based treatment in clinical practice. 10° Italian Conference on AIDS and Antiviral Research, Roma, 22-24 maggio 2018. Abstract OC02.

223. M. Ferrara\*, M. Zazzi, L. Comi, E Focà, G. Sterrantino, A. Di Biagio, M. Zaccarelli, S. Rusconi, G. Cenderello, M Gargiulo, E. Schiaroli, F. Fusco, A.M. degli Antoni, M. Tavio, E. Garlassi, B. Rossetti, O. Bargiacchi, G. Maffongelli, **Maria Santoro**, C. della Casa, N. Gianotti, A. Poli, F. Rinaldi, L. Galli, A. Castagna on behalf of the PRESTIGIO Study Group. Use of NRTIs in salvage therapy of treatment-experienced subjects with HIV-1 NRTI, NNRTI PI and INSTI-drug resistance. 10° Italian Conference on AIDS and Antiviral Research, Roma, 22-24 maggio 2018. Abstract OC52.

224. R. Scutari\*, D. Di Carlo, I. Vicenti, C. Alteri, V. Zuccaro, A. Cascio, F. Incardona, V. Borghi, A. Bezenchek, M. Andreoni, A. Antinori, C.F. Perno, A. De Luca, M. Zazzi, and **Maria Mercedes Santoro**. Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors. ICAR 2018. Presentazione oral poster. Abstract 167.

225. C Alteri \*, L. Fabeni, R. Scutari, G. Berno, D. Di Carlo, C. Gori, A. Bertoli, V. Fedele, S. Carta, R. Bellagamba, A. Vergori, C. Mussini, M. Colafigli, F. Montella, A. Pennica, C. M. Mastroianni, E. Girardi, M. Andreoni, A. Antinori, F. Ceccherini-Silberstein, V. Svicher, C. F. Perno, and **Maria Mercedes Santoro**. HIV-1 CRF02\_AG recombinant form genetically diverges over the years 2004-2016 and changes its pathogenic potential. XXVI International workshop on HIV drug resistance and treatment strategies, 6-8 November 2017, Johannesburg, South Africa.

226. D Armenia\*, D Di Carlo, V Borghi, F Forbici, A Bertoli, C Gori, C Alteri, L Fabeni, W Gennari, F Continenza, C Pinnetti, M Zaccarelli, A Mondì, S Cicalini, G Maffongelli, F Montella, M Colafigli, R Marocco, CM Mastroianni, F Ceccherini-Silberstein, M Andreoni, C Mussini, A Antinori, CF Perno, and **Maria Mercedes Santoro**. HIV Multi-Drug Resistance is still a Clinical Relevant Issue Despite its Dramatic Drop over the Years. XXVI International HIV Drug Resistance and Treatment Strategies Workshop, 6-8 November 2017, Johannesburg, South Africa.

227. D. Armenia, D. Di Carlo, V. Borghi, F. Forbici, A. Bertoli, C. Gori, C. Alteri, L. Fabeni, W. Gennari, F. Continenza, C. Pinnetti, M. Zaccarelli, A. Mondì, S. Cicalini, G. Maffongelli, F. Montella, M. Colafigli, R. Marocco, C.M. Mastroianni, F. Ceccherini-Silberstein, M. Andreoni, C. Mussini, A. Antinori, C.F. Perno, and **Maria Mercedes Santoro**\*. HIV drug resistance remains a relevant clinical concern, despite its dramatic drop over the years. XVI European AIDS Conference. Milan, October 25-27 2017. Abstract PS3/2

228. V Calvez\*, C Charpentier, M Wirden, C Soulié, D Descamps, AG Marcelin, D Armenia, **Maria Santoro**, F Ceccherini-Silberstein, and CF Perno. Antiretroviral resistance selected at failure in HIV infected patients treated by triple and dual therapies. XVI European AIDS Conference. Milan, October 25-27 2017. Abstract PS1/4

229. D. Armenia\*, D. Di Carlo, V. Borghi, F. Forbici, A. Bertoli, C. Gori, C. Alteri, L. Fabeni, W. Gennari, F. Continenza, C. Pinnetti, M. Zaccarelli, A. Mondì, S. Cicalini, G. Maffongelli, F. Montella, M. Colafigli, R. Marocco, C.M. Mastroianni, F. Ceccherini-Silberstein, M. Andreoni, C. Mussini, A. Antinori, C.F. Perno, and **Maria Mercedes Santoro**. Is the management of HIV-1 drug-resistance still a clinical concern? A large Italian real life update in the modern antiretroviral era. IX Italian conference on AIDS and Antiviral Research (ICAR), 12-14 June, Siena, Italy. Oral poster. Abstract PD29.

230. C.Alteri\*, L. Fabeni, R. Scutari, G. Berno, D. Di Carlo, C. Gori, A. Bertoli, V. Fedele, S. Carta, A. Vergori, I. Mastroiosa, R. Bellagamba, M. Colafigli, C. Mussini, F. Montella, A. Pennica, C. M. Mastroianni, E. Girardi, M. Andreoni, A. Antinori, F. Ceccherini-Silberstein, V. Svicher, C. F. Perno, and **Maria Mercedes Santoro**. HIV-1 B subtype underwent a deep genetic evolution that impacted its pathogenic potential over the years 2003-2016. 9th ICAR- Italian Conference on AIDS and Antiviral Research, Siena 2017. Abstract 84.

231. C Alteri, R Scutari\*, A Bertoli, D Armenia, C Gori, G Fabbri, CM Mastroianni, C Cerva, A Cristaudo, M Andreoni, A Antinori, V Svicher, F Ceccherini-Silbersteina, CF Perno, and **Maria Mercedes Santoro**. HIV-1 tropism evolution is reduced in presence of Integrase Inhibitors based regimens. 9th ICAR- Italian Conference on AIDS and Antiviral Research, Siena 2017. Abstract 86.

232. A. Lai\*, M. Franzetti, G. Bozzi, F. Saladini, B. Bruzzone, S. Di Giambenedetto, A. Di Biagio, S. Lo Caputo, **Maria Mercedes Santoro**, F. Maggiolo, S. Parisi, S. Rusconi, N. Gianotti, and C. Balotta. New drug combinations and latest prescription guidelines are associated with a decrease in acquired resistance to antiretrovirals overtime. 9th ICAR- Italian Conference on AIDS and Antiviral Research, Siena 2017. Abstract PD25

233. D Armenia\*, C Gori, A Bertoli, F Forbici, V Fedele, D Pizzi, W Gennari, L. Monno, F Saladini, D. Francisci, M. Zaccarelli, A. Vergori, I. Mastroiosa, A Latini, C. Stingone, C.M. Mastroianni, F Montella, C Mussini, M Andreoni, F Ceccherini-Silberstein, M Zazzi, A Antinori, CF Perno, and **Maria Mercedes Santoro**. Variability of sumoylation sites in HIV-1 integrase correlates with viro-immunological parameters and integrase resistance. IX Italian conference on AIDS and Antiviral Research (ICAR), 12-14 June 2017, Siena, Italy. Abstract OC89.

234. L. Fabeni\*, C. Alteri, G. Berno, R. Scutari, D. Di Carlo, C. Gori, A. Bertoli, S. Carta, N. Orchi, S. Cicalini, C. Pinnetti, L. Mazzuti, O. Turriziani, A. Latini, V. Borghi, F. Montella, A. Pennica, C. M. Mastroianni, C. Mussini, M. Colafigli, E. Girardi, M. Andreoni, A. Antinori, F. Ceccherini-Silberstein, C. F. Perno, and **Maria Mercedes Santoro**. Dynamics of HIV-1 Transmission Clusters In Newly Diagnosed Individuals Between 2004-2016 In Italy. IX Italian conference on AIDS and Antiviral Research (ICAR), 12-14 June 2017, Siena, Italy. Abstract OC54

235. S Rusconi\*, **Maria Mercedes Santoro**, A Cozzi-Lepri, A Antinori, S Bonora, A Cingolani, N Gianotti, A Tavelli, F Ceccherini Silberstein, A d'Arminio Monforte, for the Icona Foundation Study Group. Are HIV+ Patients with Previous C-ART Failures Still at Risk of Losing Viral Control? ICAR 2017, 9° Italian conference on AIDS and Antiviral Research, Siena, Policlinico Santa Maria alle Scotte, Italy, June 12-14 2017 - Abstract OC 6

236. C. Alteri\*, L. Fabeni, R. Scutari, G. Berno, D. Di Carlo, C. Gori, A. Bertoli, V. Fedele, S. Carta, A. Vergori, I. Mastroianni, R. Bellagamba, C. Mussini, M. Colafigli, F. Montella, A. Pennica, C. M. Mastroianni, E. Girardi, M. Andreoni, A. Antinori, F. Ceccherini-Silberstein, V. Svicher, C.F. Perno, and **Maria Mercedes Santoro**. HIV-1 B subtype genetically diverges over the years 2003-2016 and changes its pathogenic potential. 15th European Meeting on HIV & Hepatitis Treatment Strategies & Antiviral Drug Resistance 7 – 9 June 2017, Rome, Italy. Abstract 01.

237. Alteri C, Scutari R\*, Bertoli A, Armenia D, Gori C, Fabbri G, Mastroianni C, Cerva C, Cristaudo A, Andreoni M, Antinori A, Svicher V, Ceccherini-Silberstein F, Perno C, and **Santoro Maria Mercedes**. Integrase Inhibitors based regimens limit HIV-1 tropism evolution. 15th European Meeting on HIV & Hepatitis Treatment Strategies & Antiviral Drug Resistance 7 – 9 June 2017, Rome, Italy. Abstract 02.

238. Marcelin A\*, **Santoro Maria**, Charpentier C, Storto A, Di Carlo D, Gennari W, Perno C, Calvez V, Descamps D, Ceccherini-Silberstein F. Epidemiological study of Doravirine associated resistance mutations in HIV-1-infected treatment-naïve patients from two large databases in France and Italy. 15th European Meeting on HIV & Hepatitis Treatment Strategies & Antiviral Drug Resistance 7 – 9 June 2017, Rome, Italy. Abstract 08.

239. D. Armenia, M. Zaccarelli, V. Borghi, W. Gennari, D. Di Carlo, A. Giannetti, F. Forbici, A. Bertoli, C. Gori, L. Fabeni, C. Pinnetti, R. Marocco, A. Latini, F. Ceccherini Silberstein, C.M. Mastroianni, C. Mussini, A. Antinori, C.F. Perno, and **Maria Mercedes Santoro**. Resistance detected in PBMC GRT predicts virological rebound in HIV-1 suppressed patients switching treatment. 15th European Meeting on HIV & Hepatitis Treatment Strategies & Antiviral Drug Resistance 7 – 9 June 2017, Rome, Italy. Abstract 52.

**240.** A Bertoli, D Armenia, **Maria Mercedes Santoro**, MC Bellocchi, L Carioti, C Alteri, M Mariani, F Ceccherini Silberstein, A Grimaldi, CF Perno, and Giovanna Picchi. An Italian case of transmitted integrase inhibitor resistance in a drug-naïve patient: a refined analysis by ultra-deep-454 pyrosequencing. European HIV clinical forum. Integrase inhibitors. Glasgow, United Kingdom, 22 October 2016. Abstract O\_04. ***Premio come migliore lavoro presentato al meeting.***

241. D. Armenia\*, M. Zaccarelli, V. Borghi, W. Gennari, A. Giannetti, F. Forbici, A. Bertoli, C. Gori, V. Fedele, C. Pinnetti, R. Marocco, M. Giuliani, A. Latini, F. Ceccherini Silberstein, C. Mastroianni, C. Mussini, CF. Perno, A. Antinori, and **Maria Mercedes Santoro**. Virologically suppressed patients switching therapy with PBMCs resistance and insufficient previous virological control have a higher risk of experiencing virological rebound. VIII Italian conference on AIDS and Antiviral Research (ICAR), Milano, 6-8 giugno 2016. Abstract OC57.

242. Fabeni L\*, Alteri C, Di Carlo D, Carioti L, Bertoli A, Gori C, Forbici F, Bellocchi MC, Continenza F, Cicalini S, Pinnetti C, Bellagamba R, Ammassari A, Borghi V, Giuliani M, De Carli G, Orchi N, Scognamiglio P, Pennica A, Mastroianni C, Montella F, Cristaudo A, Mussini C, Girardi E, Andreoni M, Antinori A, Ceccherini-Silberstein F, Perno CF, and **Santoro Maria Mercedes**. Dynamics and phylogenetic relationships of HIV-1 transmitted drug-resistance according to subtype in Italy over the

years 2000-2014. 7th Italian Conference on AIDS and Antiretroviral Research, Milan (Italy), June 6-8 2016. Abstract OC 59.

243. Di Carlo D\*, Armenia D, Calcagno A, Forbici F, Bertoli A, Berno G, Carta S, Continenza F, Fabeni L, D'Offizi G, Nicastrì E, Ammassari A, Libertone R, Zaccarelli M, Ghisetti V, Andreoni M, Ceccherini-Silberstein F, Bonora S, Di Perri G, Antinori A, Perno CF, and **Santoro Maria Mercedes**. Patients with pre-existent NRTI- and NNRTI-resistance have a higher risk to lose virological suppression under tenofovir/emtricitabine/rilpivirine single tablet regimen. 14th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance, Rome (Italy), May 25-27 2016. Reviews in Antiviral Therapy & Infectious Diseases - Volume 4: 2016. Abstract O 6.

**244. Santoro Maria Mercedes\***, Di Carlo D, Armenia D, Zaccarelli M, Pinnetti C, Colafigli M, Prati F, Boschi A, Degli Antoni A, Lagi F, Sighinolfi L, Gervasoni C, Andreoni M, Antinori A, Mussini C, Perno CF, Borghi V, and Sterrantino G. Viro-immunological response of naive HIV-1 infected patients starting a first-line regimen with viral load >500,000 copies/mL in clinical practice. 14th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance, Rome (Italy), May 25-27 2016. Reviews in Antiviral Therapy & Infectious Diseases - Volume 4: 2016. Abstract P 67. **Premio come miglior poster discussion HIV.**

245. **Santoro Maria Mercedes\***, Di Carlo D, Armenia D, Zaccarelli M, Pinnetti C, Colafigli M, Prati F, Boschi A, Degli Antoni A, Lagi F, Sighinolfi L, Gervasoni C, Andreoni M, Antinori A, Mussini C, Perno CF, Borghi V, Sterrantino G. Virological response and immunological recovery of HIV-1 infected patients starting a first line regimen with plasma HIV-1 RNA >500,000 copies/mL in clinical practice. 7th Italian Conference on AIDS and Antiretroviral Research, Milan (Italy), June 6-8 2016. Abstract OC 41.

**246.** J Fokam\*, MC Bellocchi, D Armenia, AJ Nanfack, L Carioti, F Continenza, D Takou, E Temgoua, C Tangimpundu, JN Torimiro, PN Koki, CN Fokunang, G Cappelli, A Ndjolo, V Colizzi, F Ceccherini-Silberstein, CF Perno<sup>1</sup>, and **Maria Mercedes Santoro**. Ultra-deep pyrosequencing of paediatric HIV-1 drug resistance and coreceptor suggests possible suitability of protease inhibitors and maraviroc at younger ages in Cameroon. 10th INTEREST Workshop, 3 - 6 May 2016, Yaoundé, Cameroon. **Vincitore dell'Award Joep Lange come miglior lavoro presentato al congresso.**

247. Armenia D\*, Di Carlo D, Gori C, Perez AB, Borghi V, Bertoli A, Alvarez M, Latini A, Sterrantino G, Lambert S, Callegaro AP, Milesi M, Ghisetti V, Fabeni L, Coppola N, Scognamiglio P, Bellagamba R, Ammassari A, Cicalini S, Cerva C, Maggiolo F, Di Perri G, Cristaudo A, Girardi E, Marcelin AG, Calvez V, Andreoni A, Mussini C, Garcia F, Antinori A, Ceccherini-Silberstein F, Perno CF, and **Santoro Maria Mercedes**. The Co-presence of Specific HIV-1 CRF02\_AG Polymorphisms Correlates with a Lower Response to PI-based first line HAART. International HIV Drug Resistance Workshop. Boston, Massachusetts USA, on February 20-21, 2016. Abstract 31.

248. D Armenia, M Zaccarelli, V Borghi, W Gennari, A Giannetti, F Forbici, C Pinnetti, F Ceccherini Silberstein, C Mussini, CF Perno, A Antinori, and **Maria Mercedes Santoro\***. Resistance in PBMCs Can Predict Virological Rebound after Therapy Switch in cART-Treated Patients with Undetectable HIV-RNA. International HIV Drug Resistance Workshop. Boston, Massachusetts USA, on February 20-21, 2016. Abstract 42.

249. J Fokam, MC Bellocchi, D Armenia, AJ Nanfack, L Carioti, F Continenza, D Takou, E Temgoua, C Tangimpundu, JN Torimiro, CN Fokunang, G Cappelli, A Ndjolo, V Colizzi, F Ceccherini-Silberstein, CF Perno, and **Maria Mercedes Santoro**. In Cameroonian Children under Five Years, CCR5-Variants Preval, Implying Vertical Transmission with CCR5-Tropic Viruses. International HIV Drug Resistance Workshop. Boston, Massachusetts USA, on February 20-21, 2016. Abstract 24.

250. D. Armenia\*, D. Di Carlo, C. Gori, V. Borghi, A. Latini, G. Sterrantino, A.P. Callegaro, M. Milesi, V. Ghisetti, A. Bertoli, L. Fabeni, N. Coppola, P. Scognamiglio, R. Bellagamba, A. Ammassari, S. Cicalini, C. Cerva, M. Zazzi, F. Maggiolo, G. Di Perri, A. Cristaudo, E. Girardi, C. Mussini, M. Andreoni, A. Antinori, F. Ceccherini-Silberstein, C.F. Perno, and **Maria Mercedes Santoro**. HIV-1 CRF02\_AG infected patients show a lower response to a PI based first line HAART for the presence of specific natural

polymorphisms. 15th European AIDS Conference from October 21-24, 2015. Barcelona, Spain. **Oral poster.**

**251.** Armenia D\*, Di Carlo D, Borghi V, Fabeni L, Gori C, Bertoli A, Alteri C, Forbici F, Zaccarelli M, Ammassari A, Nicastrì E, Bellagamba R, Cicalini S, D'Offizi G, Sarmati L, Latini A, Cristaudo A, Andreoni M, Mussini C, Antinori A, Perno CF, Ceccherini-Silberstein F, and **Santoro Maria Mercedes**. High Baseline Viremia Affects the Virological Response in HIV-1 Infected Patients Starting a First Raltegravir Containing Regimen. 1st HIV Forum: Integrase Inhibitors, Barcelona (Spain), 20th October 2015.

**252.** D. Di Carlo\*, D. Armenia, V. Svicher, C. Gori, A. Bertoli, F. Forbici, V. Borghi, C. Alteri, G. Bero, M. Zaccarelli, E. Nicastrì, M. Andreoni, C. Mussini, A. Antinori, F. Ceccherini-Silberstein, C.F. Perno, and **Maria Mercedes Santoro**. Viro-immunological efficacy and tropism evolution in treatment-experienced HIV-1 infected patients starting maraviroc in clinical practice. 13th European Workshop on HIV & Epatitis – Treatment Strategies & Antiviral Drug Resistance. Reviews in Antiviral Therapy & Infectious Diseases – Volume 5: 2015. Abstract O\_7.

**253.** Zaccarelli M, **Santoro Maria Mercedes**\*, Armenia D, Gori C, Forbici F, Giannetti A, Andreoni M, Mastroianni C, Mussini C, Perno CF, Antinori A. How Genotypic Resistance Test in PBMC (Proviral DNA) May Help to Identify Hidden Resistance in patients with Low Level or Undetectable HIV-RNA? 13<sup>th</sup> European Workshop on HIV & Epatitis – Treatment Strategies & Antiviral Drug Resistance. Reviews in Antiviral Therapy & Infectious Diseases – Volume 5: 2015. Abstract O\_14.

**254.** D. Armenia\*, C. Gori, D. Di Carlo, A. Bertoli, V. Borghi, L. Fabeni, S. Carta, P. Scognamiglio, R. Bellagamba, A. Ammassari, S. Cicalini, C. Cerva, A. Latini, A. Cristaudo, C. Mussini, E. Girardi, M. Andreoni, A. Antinori, F. Ceccherini-Silberstein, C.F. Perno, and **Maria Mercedes Santoro**. Patients infected with CRF02\_AG are more likely to experience virological rebound under first line PI/r based HAART. 13th European Workshop on HIV & Epatitis – Treatment Strategies & Antiviral Drug Resistance. Reviews in Antiviral Therapy & Infectious Diseases – Volume 5: 2015. Abstract O\_25.

**255.** **Maria Mercedes Santoro**\*, D. Armenia, M. Nasi, M.C. Bellocchi, L. Carioti, F. Continenza, M. Digaetano, A. Cossarizza, C.F. Perno, F. Ceccherini-Silberstein, and C. Mussini. Analysis of HIV-1 Coreceptor Tropism Evolution During Treatment Interruption. 7° Congresso Nazionale ICAR 2015, Italian Conference on AIDS and Retroviruses Riccione, 17-19 maggio 2015. Abstract OP10. (Oral poster).

**256.** D. Di Carlo\*, D. Armenia, C. Gori, A. Bertoli, F. Forbici, V. Borghi, V. Svicher, C. Alteri, G. Bero, M. Zaccarelli, E. Nicastrì, F. Ceccherini-Silberstein, M. Andreoni, C. Mussini, A. Antinori, C.F. Perno, and **Maria Mercedes Santoro**. Evaluation of viro-immunological efficacy in patients starting maraviroc in clinical practice. 7° Congresso Nazionale ICAR 2015, Italian Conference on AIDS and Retroviruses Riccione, 17-19 maggio 2015. Abstract OC11.

**257.** Malagnino V.\*, Maffongelli G., Cerva C., Viscione M., Leoni D., E Teti., Gini S, Gentilotti E., Alteri C., Bertoli A., **Santoro Maria**, Ricciardi A., Dori L., Perno C.F., Andreoni M., and Sarmati L. Clinical Infectious Diseases, "Tor Vergata" University of Rome, Italy Achievement of virological success as a risk factor for non-AIDS events in patients on HAART: A delay (> 6 months) of plasma viremia response to HAART correlates with a higher number of non-AIDS events in a population of HIV patients at first line of treatment. 7° Congresso Nazionale ICAR 2015, Italian Conference on AIDS and Retroviruses Riccione, 17-19 maggio 2015. Abstract OC40.

**258.** L. Fabeni\*, C. Alteri, N. Orchi, C. Gori, A. Bertoli, F. Forbici, F. Montella, A. Pennica, G. De Carli, M. Giuliani, F. Continenza, C. Pinnetti, E. Nicastrì, F. Ceccherini-Silberstein, C.M. Mastroianni, E. Girardi, M. Andreoni, A. Antinori, **Maria Mercedes Santoro**, and C.F. Perno. Identification of Recent Transmission Clusters of HIV-1 C and CRF17\_BF Strains with evidence of NNRTI-related mutations among Newly Diagnosed Men in Central Italy. 7° Congresso Nazionale ICAR 2015, Italian Conference on AIDS and Retroviruses Riccione, 17-19 maggio 2015. Abstract OC78.

**259.** M. Zaccarelli\*, **Maria Mercedes Santoro**, D. Armenia, C. Gori, F. Forbici, A. Giannetti, M. Andreoni, C. Mastroianni, C. Mussini, C.F. Perno, and A. Antinori. How Genotypic Resistance Test in PBMC (Proviral DNA) May Help to Identify Hidden Resistance in patients with Low Level or Undetectable HIV-



RNA?7° Congresso Nazionale ICAR 2015, Italian Conference on AIDS and Retroviruses Riccione, 17-19 maggio 2015. Abstract OC102.

260. VC Di Maio\*, D Armenia, MC Bellocchi, D Di Paolo, V Cento, M Tontodonati, V Micheli, L Carioti, F De Leonardis, M Aragri, E Polilli, A Manunta, C Magni, FP Antonucci, F De Luca, C Sarrecchia, A Bertoli, I Lenci, S Francioso, **Maria Mercedes Santoro**, J Vecchiet, A De Maria, A Picciotto, L Nosotti, F Morisco, S Bruno, M Puoti, S Babudieri, M Stella Mura, G Taliani, M Andreoni, G Rizzardini, G Parruti, M Angelico, CF Perno, and Francesca Ceccherini-Silberstein. CLINICAL RELEVANCE OF BASELINE/EARLY DETECTION AND PERSISTENCE OF RESISTANT ASSOCIATED VARIANTS IN HCV-1 PATIENTS TREATED WITH PROTEASE-INHIBITORS ASSESSED BY ULTRA-DEEP SEQUENCING. 6° Congresso Nazionale S.I.Vi.M.", Roma, 10-12 dicembre 2014. 6° Congresso Nazionale S.I.Vi.M.", Roma, 10-12 dicembre 2014.

261. D. Di Carlo\*, D. Armenia, G. Maffongelli, C. Alteri, F. Forbici, S. Carta, F. Continenza, V. Borghi, M. Giuliani, A. Latini, E. Nicastrì, M. Zaccarelli, C. Pinnetti, N. Petrosillo, G. D'Offizi, F. Ceccherini-Silberstein, C. Mussini, A. Antinori, M. Andreoni, C.F. Perno, and **Maria Mercedes Santoro**. Virological Response and Resistance Profile in HIV-1 Infected Patients Starting a First Darunavir Containing Regimen in Clinical Practice Darunavir. VI Italian conference on AIDS and Retroviruses, Roma, 25-27 maggio 2014. Abstract OC 72. **Vincitore del premio SIVIM come migliore presentazione orale.**

262. **Maria Mercedes Santoro\***, D. Armenia, C. Alteri, L. Fabeni, D. Di Pinto, D. Di Carlo, A. Bertoli, C. Gori, S. Carta, V. Fedele, F. Forbici, V. Svicher, G. Berno, D. Pizzi, E. Nicastrì, L. Sarmati, C. Pinnetti, A. Ammassari, G. D'Offizi, A. Latini, M. Andreoni, A. Antinori, F. Ceccherini-Silberstein, and C.F. Perno. HIV-1 Integrase Genotyping Is Reliable and Clinically Useful Also in Patients Failing at Low Levels Viremia. VI Italian conference on AIDS and Retroviruses, Roma, 25-27 maggio 2014. Abstract OC 67.

263. **Maria Mercedes Santoro\***, L. Fabeni, D. Armenia, D. Di Pinto, C. Alteri, D. Di Carlo, A. Bertoli, C. Gori, S. Carta, V. Fedele, F. Forbici, V. Svicher, G. Berno, E. Nicastrì, C. Pinnetti, A. Ammassari, N. Petrosillo, G. D'Offizi, A. Latini, M. Andreoni, A. Antinori, F. Ceccherini-Silberstein, C.F. Perno. Reliability of HIV-Integrase Genotyping in Patients with Low Viremia Levels. 12th European Meeting on HIV & Hepatitis, Barcelona, 36-28 March 2014, Spain. Abstract O\_09.

264. **Maria Mercedes Santoro\***, C Alteri, A Bertoli, C Gori, V Borghi, L Fabeni, N Orchi, C Pinnetti, C Tommasi, E Girardi, G D'Offizi, M Giuliani, A D'Arminio Monforte, M Andreoni, C Mussini, A Antinori, CF Perno, and F Ceccherini-Silberstein. Prevalence of mutations and determinants of genotypic resistance to rilpivirine in B and the most prevalent non-B HIV-1 subtypes in Italy. 11th European Meeting on HIV & Hepatitis, Rome 20-22 March 2013, Italy. Reviews in Antiviral Therapy & Infectious Diseases 2/2013, Abstract O\_17.

265. **Maria Mercedes Santoro**, L Fabeni\*, D Di Pinto, F Forbici, A Bertoli, C Gori, S Carta, V Fedele, C Alteri, A Ammassari, C Pinnetti, E Nicastrì, N Petrosillo, G D'Offizi, G Palamara, M Andreoni, F Ceccherini-Silberstein, and CF Perno. Performance of HIV- PR-RT genotyping on clinical samples with low viremia levels. 11th European Meeting on HIV & Hepatitis, Rome 20-22 March 2013, Italy. Reviews in Antiviral Therapy & Infectious Diseases 2/2013, Abstract O\_23.

266. D Armenia\*, **Maria Mercedes Santoro**, A Cozzi Lepri, A Calcagno, F Forbici, R Bellagamba, A Castagna, G Palamara, N Petrosillo, A Ammassari, F Castelli, S Di Giambenedetto, M Andreoni, A Antinori, G Di Perri, F Ceccherini-Silberstein, C Mussini, A Monforte, and CF Perno. Impact of pre-HAART viral load on virological rebound in HIV-1 infected patients starting their first line Regimen. 11th European Meeting on HIV & Hepatitis, Rome 20-22 March 2013, Italy. Reviews in Antiviral Therapy & Infectious Diseases 2/2013, Abstract O\_01.

267. **Maria Mercedes Santoro\***, V Cento, D Armenia, P Flandre, V Borghi, S Lo Caputo, L Fabeni, F Forbici, V Svicher, E Nicastrì, A Ammassari, A Di Biagio, S Fourati, B Masquelier, D Descamp, M Zaccarelli, M Andreoni, C Mussini, V Calvez, A Antinori, AG Marcelin, CF Perno, and F Ceccherini-Silberstein. Virological response and resistance profile in a retrospective cohort of HIV-1 infected

patients starting a first etravirine containing regimen. ICAR 2012. Napoli, 10-12 giugno 2012. Abstract OC18.

268. D Armenia\*, **Maria Mercedes Santoro**, C Soulie, L Fabeni, C Gori, F Forbici, V Svicher, A Bertoli, L Dori, M Giuliani, G Palamara, E Boumis, M Zaccarelli, R Bellagamba, M Andreoni, AG Marcelin, V Calvez, A Antinori, F Ceccherini-Silberstein and CF Perno. Genotypically-assessed CXCR4 tropism might be a predictive marker of poor immunological reconstitution in drug-naïve patients starting first line HAART. ICAR 2012. Napoli, 10-12 giugno 2012. Abstract OC48.

269. **Santoro Maria Mercedes**, D Armenia, A Calcagno, M Santoro, C Gori, L Fabeni, R Bellagamba, V Borghi, F Forbici, A Latini, G Palamara, R Libertone, V Tozzi, E Boumis, MP Trotta, A Ammassari, E Nicastrì, A Buonomini, V Svicher, F Ceccherini-Silberstein, M Andreoni, C Mussini, P Narciso, G Di Perri, A Antinori, and CF Perno\*. High pre-therapy viral load is associated with delayed and decreased control of HIV replication also at the time of modern HAART. 13<sup>th</sup> European AIDS Conference, 12-15 October 2011, Belgrade, Serbia. Abstract PS11/5.

270. C Alteri\*, **Santoro Maria Mercedes**, A Artese, L Fabeni, L Parrotta, C Gori, G Costa, V Cento, F Stazi, G Maffongelli, M Viscione, M Zaccarelli, P Narciso, M Andreoni, A Antinori, F Ceccherini-Silberstein, V Svicher, and CF Perno. The presence of PR compensatory mutations increases over the years and correlates with a shorter time to virological failure in PI treated patients. 9<sup>th</sup> European Workshop on HIV and Hepatitis Treatment Strategies and Antiviral Drug Resistance, 23-25 March 2011, Paphos, Cyprus. Reviews in Antiviral Therapies, Vol 2, pag 30, Abstract O\_06.

271. V Svicher\*, V Cento, G Rozera, I Abbate, **Santoro Maria Mercedes**, D Armenia, L Fabeni, G Palamara, A Latini, G Rizzardini, V Micheli, AR Buonomini, MP Trotta, A Antinori, M Andreoni, MR Capobianchi, F Ceccherini-Silberstein, CF Perno. The Genotypic False Positive Rate Determined by Population V3-Sequencing Predicts the Burden of X4 Minority Quasispecies. 9<sup>th</sup> European Workshop on HIV and Hepatitis Treatment Strategies and Antiviral Drug Resistance, 23-25 March 2011, Paphos, Cyprus. Reviews in Antiviral Therapies, Vol 2, pag 30, Abstract O\_19.

272. D Armenia\*, **Santoro Maria Mercedes**, M Santoro, L Fabeni, C Gori, F Forbici, V Cento, V Svicher, A Bertoli, L Dori, M Giuliani, G Palamara, E Boumis, M Zaccarelli, R Bellagamba, M Andreoni, A Antinori, F Ceccherini-Silberstein, and Carlo-Federico Perno. Relationship between HIV-1 genotypic tropism and CD4 cell-count gain in naïve patients starting first line-regimen. 9<sup>th</sup> European Workshop on HIV and Hepatitis Treatment Strategies and Antiviral Drug Resistance, 23-25 March 2011, Paphos, Cyprus. Reviews in Antiviral Therapies, Vol 2, pag 30, Abstract O\_27.

273. D Armenia\*, L Fabeni, I Malet, R D'Arrigo, S Reigadas, V Micheli, V Cento, MP Trotta, S Lo Caputo, **Santoro Maria Mercedes**, V Svicher, P Flandre, B Bruzzone, G Di Perri, A Capetti, P Narciso, B Masquelier, G Rizzardini, V Calvez, H Gomes da Silva, A Antinori, AG Marcelin, CF Perno, and F Ceccherini-Silberstein. Impact of baseline HIV-1 integrase polymorphisms with virological outcome in patients starting a Raltegravir-containing regimen. 8<sup>th</sup> European HIV Drug Resistance workshop, Sorrento, Italy, 15- 17 March 2010. Abstract 28, pag. 27.

274. F Ceccherini-Silberstein\*, D Armenia, L Fabeni, **Santoro Maria Mercedes**, R D'Arrigo, G Anies, F Forbici, V Micheli, MP Trotta, S Lo Caputo, B Masquelier, P Flandre, G Rizzardini, P Narciso, V Calvez, A Antinori, AG Marcelin, CF Perno. Impact of baseline HIV-1 integrase mutations with virological outcome in patients starting a raltegravir-containing regimen. 7<sup>th</sup> European HIV Drug Resistance Workshop, Stockholm, Sweden, 25-27 March 2009. Abstract 41.

275. **Santoro Maria Mercedes**\*, F Ceccherini-Silberstein, P Narciso, C Mussini, M Zaccarelli, V Borghi, E Boumis, V Tozzi, U Visco-Comandini, C Gori, F Forbici, R d'Arrigo, MC Bellocchi, A Bertoli, A Antinori, and CF Perno. Declining of HIV-1 drug resistance in treatment-failing patients in Italy over the years 2001-2007: a potential association with more effective antiretroviral regimens. 3° Congresso Nazionale SIVIM Roma 6 - 8 maggio 2008. Abstract book: 48.

276. **Santoro Maria Mercedes** \*. Analysis of chemioresistance of viruses with particular attention to HIV-resistance. 6th National Congress of Clinical Microbiology and Infettivology of the Bulgarian Association of Micorbiologists (BAM). Plovdiv, Bulgaria, 3 – 6 April 2008.

277. **Santoro Maria Mercedes** \*. F Ceccherini-Silberstein, P Narciso, C Mussini, M Zaccarelli, V Borghi, E Boumis, V Tozzi, U Visco-Comandini, C Gori, F Forbici, R d'Arrigo, MC Bellocchi, A Bertoli, A Antinori, and CF Perno. Declining of HIV-1 drug resistance in treatment failing patients: a potential association with more effective antiretroviral regimens. 6th European HIV Drug Resistance Workshop, Budapest, Hungary 26 -28 March, 2008. Abstract 2, pag 6.

278. F Ceccherini-Silberstein\*, V Svicher, F Forbici, T Sing, **Santoro Maria Mercedes**, C Gori, MP Trotta, A d'Arminio Monforte, A Antinori, CF Perno. Novel HIV protease mutations: insight to antiretroviral response and viral fitness. HIV Protease Inhibitors: A State-of-Art for Optimal Antiretroviral Combination. Taormina (CT) November 6 - 7, 2006.

279. V Svicher, T Sing, A Artese, **Santoro Maria Mercedes**, C Gori, A Bertoli, A d'Arminio Monforte, A Antinori, T Lengauer, CF Perno, F Ceccherini-Silberstein\*. Caratterizzazione di nuove mutazioni della trascrittasi inversa di HIV-1 coinvolte nella resistenza agli inibitori non nucleosidici. 34° Congresso Nazionale della Società Italiana di Microbiologia. Genova, 15 - 18 ottobre 2006.

280. F Ceccherini-Silberstein\*, V Svicher, T Sing, **Santoro Maria Mercedes**, A Bertoli, F Forbici, A Artese, A d'Arminio Monforte, A Antinori, and CF Perno. Additional mutations in HIV-1 reverse transcriptase involved in the tegulation of NNRTI resistance. 4th European HIV Drug Resistance Workshop, Monte Carlo, Cote d'Azur 29 -31 March, 2006. Abstract 95, pag 73.

281. F Ceccherini-Silberstein\*, V Svicher, T Sing, **Santoro Maria Mercedes**, N Beerenwinkel, F Gago, A Bertoli, F Forbici, MC Bellocchi, P Narciso, A D'Arminio Monforte, A Antinori and CF Perno. Involvement of novel HIV-1 reverse transcriptase mutations in the highly ordered regulation of NRTI resistance. XIX Congresso Nazionale AIDS e Sindromi correlate, Vibo Valentia, 21 - 23 ottobre 2005.

282. F Ceccherini-Silberstein\*, **Santoro Maria Mercedes**, C Gori, V Svicher, M Santoro, F Forbici, N Esposito, M Zaccarelli, R D'Arrigo, A Antinori, and CF Perno. Caratterizzazione della dinamica di scomparsa delle mutazioni associate a resistenza nella proteasi di HIV-1 Durante l'interruzione terapeutica. XIX Congresso Nazionale AIDS e Sindromi correlate, Vibo Valentia, 21 - 23 ottobre 2005.

283. F Ceccherini-Silberstein\*, F Gago, **Santoro Maria Mercedes**, C Gori, V Svicher, R D'Arrigo, M Ciccozzi, A Bertoli, J Balzarini, C Balotta, M Moroni, A Antinori, A d'Arminio-Monforte, CF Perno. High conservation of HIV-1 reverse transcriptase under drug pressure despite a continuous appearance of mutations. V programma Nazionale di ricerca sull'AIDS, Istituto Superiore di Sanità, Roma 2 - 6 maggio, 2005. Rapporti ISTISAN: 172.

284. CF Perno\*, F Ceccherini Silberstein, V Svicher, T Sing, **Santoro Maria**, C Gori, F Gago, R d'Arrigo, MC Bellocchi, S Giannella, A Bertoli, A d'Arminio Monforte, A Antinori. A highly ordered network of HIV-1 RT mutations regulates the continuous escape from antiviral drugs. V programma Nazionale di ricerca sull'AIDS, Istituto Superiore di Sanità, Roma 2 - 6 maggio, 2005. Rapporti ISTISAN: 98.

285. V Svicher\*, F Ceccherini-Silberstein, T Sing, **Santoro Maria**, N Beerenwinkel, F Rodriguez, F Forbici, A d'Arminio Monforte, A Antinori, and CF Perno. Additional mutations in HIV-1 reverse transcriptase are involved in the highly ordered regulation of NRTI resistance. 3rd European HIV Drug Resistance Workshop, Athens, Greece, 30 March - 1 April, 2005. Abstract 63, pag 63. **The oral presentation awarded the prize for the best oral presentation at the meeting.**

286. F Ceccherini-Silberstein\*, V Svicher, F Erba, **Santoro Maria**, C Gori, M C Bellocchi, F Forbici, S Giannella, A Cenci, M P Trotta, A d'Arminio Monforte, A Antinori, and C F Perno: Characterization of novel HIV-1 protease mutations potentially involved in resistance to protease Inhibitors. XVIII Convegno Nazionale AIDS e Sindromi Correlate, Milano, 28 - 30 Novembre 2004. Abstract O43, pag 155.

287. F Ceccherini-Silberstein\*, V Svicher, T Sing, **Santoro Maria Mercedes**, A Bertoli, F Forbici, A Artese, A d'Arminio Monforte, A Antinori, and CF Perno. Additional mutations in HIV-1 reverse transcriptase involved in regulation of NNRTI resistance. 4rd European HIV Drug Resistance Workshop, From Basic Science to Clinical Implications. Monte Carlo, Monaco, March 29 – 31, 2006. Abstract book: 95 pag 73.

288. V Svicher\*, **Santoro Maria**, F Forbici, C Gori, A Cenci, R D'Arrigo, MC Bellocchi, S Giannella, A Bertoli, A Antinori, CF Perno and F Ceccherini-Silberstein: Identificazione e caratterizzazione di mutazioni della proteasi e della trascrittasi inversa di HIV-1 non ancora associate a farmaco-resistenza. 31° Congresso Nazionale Società Italiana di Microbiologia, Roma, Italia, 19 - 22 Ottobre 2003.

#### Posters

289. A De Salazar, L Viñuela, A Fuentes, E Teyssou, C Charpentier, S Lambert-Niclot, L Fabeni, CF Perno, D Paraskevis, P Gomes, **Maria Mercedes Santoro**, F Ceccherini-Silberstein, AG Marcelin, and F Garcia. Transmitted drug resistance to integrase-based first-line treatment in Europe. CROI 2022. February 12-16, 2022 (abstract #516).

290. A Cozzi-Lepri, B. Rossetti, F. Incardona, G. Di Teodoro, D. Di Carlo, M. Prosperi, A. Shallvari, M. Böhm, C. Seguin-Devaux, M. Zazzi, and **Maria Mercedes Santoro**, on behalf of EuResist Network. Role of genotypic testing results for predicting virological failure in persons living with HIV with HIV-RNA  $\leq 50$  copies/mL who require an ART switch. 18<sup>th</sup> European AIDS Conference (EACS) October 27-30, 2021, London (abstract PE 1/11)

291. **E Bruzzesi, M Ranzenigo, D Di Carlo, V Costabile, F Lombardi, Y Bouba, F Maggiolo, AP Callegaro, A Zoncada, S Paolucci, V Micheli, S Renica, A Bezencheck, B Rossetti, and Maria Mercedes Santoro**. Characterization of PLWH with low-level viremia: results from the Italian ARCA cohort. 18<sup>th</sup> European AIDS Conference (EACS). October 27-30 2021, London, UK (abstract # PE2/30).

292. J Fokam, E Ngoufack Jagni Semengue, D Armenia, D Takou, B Dambaya, G Teto, C Ambe Chenwi, A Durand Nka, G Angong Beloumou, SC Djupsa Ndjeyep, MC Tommo Tchouaket, N Fainguem, SM Sosso, V Colizzi, CF Perno, A Ndjolo, F Ceccherini-Silberstein, and **Maria Mercedes Santoro**. Integrase genotyping is highly effective on diverse HIV-1 non-B clades circulating in Cameroon: toward a successful transition to Dolutegravir-based Regimens in Africa. Virtual European Meeting on HIV & Hepatitis 2021. 25-28 May 2021 (abstract #40).

293. **Maria Mercedes Santoro**, D Armenia, E Teyssou, J Ramón Santos, C Charpentier, S Lambert-Niclot, A Antinori, C Katlama, D Descamps, CF Perno, V Calvez, R Paredes, F Ceccherini-Silberstein, AG Marcelin, for LAMRES Study Group. Impact of M184V on the virological efficacy of switch to 3TC/DTG in real life. Virtual CROI 2021. March 6-10, 2021 (abstract #429).

294. G Stella, L Volpicelli, D Di Carlo, I Vicenti, L Celani, F Maggiolo, AP Callegaro, W Gennari, D Francisci, F Lombardi, L Piermatteo, A Bezenchek, V Micheli, B Rossetti, and **Maria Mercedes Santoro**. Virological efficacy and resistance evaluation in people living with HIV starting an STR regimen. Virtual European Meeting on HIV & Hepatitis Treatment Strategies & Antiviral Drug Resistance, 28-30 October 2020 (abstract # 41).

295. D Armenia, L Fabeni, R Gagliardini, V Borghi, G Berno, A Vergori, S Cicalini, C Mussini, A Antinori, F Ceccherini-Silberstein, CF Perno, and **Maria Mercedes Santoro**. Dual therapy including dolutegravir plus boosted-darunavir ensures high rate of virological control and rare resistance selection at failure in heavily treatment experienced PLWH. Virtual European Meeting on HIV & Hepatitis Treatment Strategies & Antiviral Drug Resistance, 28-30 October 2020 (abstract # 101).

296. F Saladini, F Giammarino, F Maggiolo, M Ferrara, G Cenderello, BM Celesia, F Martellotta, V Spagnuolo, GM Corbelli, N Gianotti, **Maria Mercedes Santoro**, S Rusconi, M Zazzi, and A Castagna, for the PRESTIGIO STUDY GROUP. Residual phenotypic susceptibility to second generation NNRTI in multidrug resistant HIV-1 from the PRESTIGIO Registry'. 12° Congresso Nazionale ICAR (Italian Conference on AIDS and Antiviral Research). Webinar, 12-16 ottobre 2020 (Abstract P106).

297. F Giammarino, F Saladini, M Tavio, AM Cattelan, B Menzaghi, E Garlassi, F Ortu, GM Corbelli, A Poli, **Maria Mercedes Santoro**, M Zazzi, and A Castagna, for the PRESTIGIO STUDY GROUP. In vitro

activity of Islatravir against HIV-1 mutants harboring multiple NRTI resistance mutations". 12° Congresso Nazionale ICAR (Italian Conference on AIDS and Antiviral Research). Webinar, 12-16 ottobre 2020 (Abstract P107).

298. C Alteri, R Scutari, V Costabile, S Carta, L Colagrossi, C Gori, A Bertoli, N Orchi, G De Carli, S Pittalis, LG Chianura, R Rossotti, V Malagnino, S Cicalini, R Gagliardini, A Latini, A Nava, D Fanti, M Lichtner, MC Moioli, F Ceccherini-Silberstein, E Girardi, **Maria Mercedes Santoro**, M Andreoni, M Puoti, A Antinori, and CF Perno. Characterization of HIV-1 transmission dynamics in North and Central Italy over the years 2012-2019. 12° Congresso Nazionale ICAR (Italian Conference on AIDS and Antiviral Research). Webinar, 12-16 ottobre 2020 (Abstract P107).

299. R Gagliardini, P Lorenzini, D Armenia, G Passavant, S Cicalini, Alessandra Vergori, F Forbici, A Bertoli, V Borghi, C Mussini, V Malagnino, F Ceccherini-Silberstein, M Andreoni, CF Perno, A Antinori, and **Maria Mercedes Santoro**. High efficacy after switching to integrase strand transfer inhibitors (INSTI) in PLWH with undetectable viremia and past virological failure and/or resistance. 23<sup>rd</sup> International AIDS Conference Virtual. 6-10 July 2020 (Abstract ID 3949; PEB0253).

300. T Clemente, R Caccia, V Spagnuolo, L Galli, A Poli, A Galli, G Marchetti, M Zazzi, **Maria Mercedes Santoro**, P Cinque, and A Castagna, on the behalf of the PRESTIGIO Study Group. Inflammatory burden in people living with four-class drug resistant HIV: data from the PRESTIGIO REGISTRY. 23<sup>rd</sup> International AIDS Conference Virtual. 6-10 July 2020 (Abstract ID PEB0250).

301. S Rusconi, F Saladini, S Barbaliscia, A Poli, L Galli, R Gagliardini, L Gazzola, D Francisci, F Vichi, E Focà, M Zazzi, **Maria Mercedes Santoro**, A Gabrieli, and A Castagna. PRO 140 in vitro activity in HTE subjects with a 4-class drug-resistant HIV-1 virus. 2020 Conference on Retroviruses and Opportunistic Infections (CROI); 8 - 11 March 2020, Boston, Massachusetts, USA. Abstract ID 524.

302. F Saladini, F Giammarino, F Maggiolo, M Ferrara, G Cenderello, BM Celesia, F Martellotta, V Spagnuolo, GM Corbelli, N Gianotti, **Maria Mercedes Santoro**, S Rusconi, M Zazzi, and A Castagna. Phenotypic doravirine susceptibility after NNRTI exposure in the prestigio registry. 2020 Virtual Conference on Retroviruses and Opportunistic Infections (CROI); 8 - 11 March 2020, Boston, Massachusetts, USA. Abstract ID 531.

303. **Maria Mercedes Santoro**, L Fabeni, P Lorenzini, S Rusconi, N Gianotti, A Costantini, L Sarmati, A Antinori, F Ceccherini Silberstein, A D'Arminio Monforte, A Saracino, and E Girardi. Evaluation of HIV transmission clusters among natives and foreigners living in Italy. 2020 Virtual Conference on Retroviruses and Opportunistic Infections (CROI); 8 - 11 March 2020, Boston, Massachusetts, USA. Abstract ID 920.

304. EG Kostaki, C Soulie, B Visseaux, A Storto, C Charpentier, M Wirden, R Landman, C Katlama, V Calvez, D Descamps, F García, **Maria Mercedes Santoro**, D Paraskevis, and AG Marcelin. Molecular analysis suggests post-migration HIV-1 acquisition among migrants in Paris. 2020 Virtual Conference on Retroviruses and Opportunistic Infections (CROI); 8 - 11 March 2020, Boston, Massachusetts, USA. Abstract ID 921.

305. C Guerrero Beltrán, EG Kostaki, L Carioti, M Alvarez, J Olalla, MC Vidal Ampurdanes, M Montero, S García-Bujalance, J-R Blanco, M Rivero, LJ Garcia-Fraile Fraile, **Maria Mercedes Santoro**, D. Paraskevis, and F. García. HIV TRACE vs phylogenetic analysis: unraveling transmission clusters in Spain. 2020 Virtual Conference on Retroviruses and Opportunistic Infections (CROI); 8 - 11 March 2020, Boston, Massachusetts, USA. Abstract ID 927.

306. C Stingone, R Scutari, E Teti, L Piermatteo, V Malagnino, M Brugneti, M Compagno, A Bertoli, V Svicher, **Maria Mercedes Santoro**, CF Perno, C Alteri, L Sarmati, M Andreoni, and F Ceccherini Silberstein. No evidence of clinical impact of STIs on seminal HIV burden during successful ART. 2020 Virtual Conference on Retroviruses and Opportunistic Infections (CROI); 8 - 11 March 2020, Boston, Massachusetts, USA. Abstract ID 1055.

307. J. Fokam, D. Takou, **Maria Mercedes Santoro**, N. Debimeh, W. Pabo, G. Teto, B. Dambaya, L. Mbuagbaw, V. Tala, R. Ndip, G. Beloumou, E.N. Semengue, C. Chenwi, S. Djupsa, F.N. Ateba, C. Kamta, L. Bala, A.E. Njom-Nlend, P.K. Ndombo, V. Colizzi, C.F. Perno, and A Ndjolo. High Rates of Virological Failure with Multi-Drug Resistance Among Vertically Infected Adolescents from Urban and Rural Settings of Cameroon. XXVIII International Workshop on HIV drug resistance and treatment strategies. 16 - 18 October 2019. Johannesburg, South Africa. Abstract 30.

308. B Yagai, C Cerva, L Piermatteo, A Giovinazzo, V Malagnino, M Ciotti, D Armenia, L Foroghi, A Bertoli, V Svicher, L Sarmati, **Maria Mercedes Santoro**, S Grelli, M Andreoni, and F Ceccherini-Silberstein. HEV infection in HIV-1 Italian patients is associated with a viral hepatitis history. XVIII congresso nazionale SIMIT, Palermo 24-27 Novembre 2019. Poster n° 270.
309. **Maria Mercedes Santoro**, N. Gianotti, L. Galli, R. Scutari, C. Alteri, A. Poli, L. Piermatteo, A. Bigoloni, C.F. Perno, A. Lazzarin, F. Ceccherini-Silberstein, and A. Castagna. Evaluation of total HIV-DNA changes in HIV-1 infected patients who continue a 2-drug regimen with dolutegravir plus one reverse transcriptase inhibitor or switch to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide enrolled in the Be-One Study. 17th European AIDS Conference. Basel, Switzerland, 6-9 November 2019. PE3/3.
310. D. Canetti, M. Franzin, A. Bigoloni, N. Gianotti, V. Spagnuolo, M. Cernuschi, L. Galli, S. Rusconi, **Maria Mercedes Santoro**, M. Zazzi, A. Lazzarin, and A. Castagna. Use of ibalizumab in a heavily treatment-experienced HIV-1-infected subject harbouring a multidrug-resistant virus. 17th European AIDS Conference. Basel, Switzerland, 6-9 November 2019. PE7/6.
311. D. Armenia, C. Gori, V. Micheli, A. Bertoli, G. Berno, S. Cicalini, C. Pinnetti, R. Gagliardini, A. Vergori, B. Bruzzone, A.P. Callegaro, M. Lichtner, F. Maggiolo, A. Di Biagio, A. Latini, G. Rizzardini, M. Andreoni, A. D'Arminio Monforte, C. Mussini, A. Antinori, F. Ceccherini-Silberstein, C.F. Perno, and **Maria Mercedes Santoro**, On Behalf of Italian INI-Surveillance Group. Impact of HIV-1 subtypes and integrase natural polymorphisms on virological response to first-line integrase inhibitors based regimens. 17th European AIDS Conference. Basel, Switzerland, 6-9 November 2019. PE13/8.
312. C. Alteri, R. Scutari, M.C. Bellocchi, V. Spagnuolo, L. Galli, S. Barbaliscia, A. Galli, A. Poli, L. Carioti, C.F. Perno, **Maria Mercedes Santoro**, F. Ceccherini-Silberstein, and A. Castagna. Analytical treatment interruption and its association with rearrangement of peripheral archived resistance mutations. 17th European AIDS Conference. Basel, Switzerland, 6-9 November 2019. PE13/11.
313. M.R. Parisi, A. Poli, M. Menozzi, M. Fiscon, E. Garlassi, D. Francisci, A. Di Biagio, G. Sterrantino, C. Fomabaio, A.M. Degli Antoni, G. Angarano, F.M. Fusco, A. D'Arminio Monforte, G.M. Corbelli, **Maria Santoro**, M. Zazzi, and A. Castagna. Burden of disease in PLWH harboring a 4-class drug resistant virus: data from PRESTIGIO Registry. 17th European AIDS Conference. Basel, Switzerland, 6-9 November 2019. PE20/11.
314. B. Yagai, C. Cerva, L. Piermatteo, A. Giovinazzo, V. Malagnino, M. Ciotti, D. Armenia, C. Stingone, F. Duranti, T. Guenci, L. Foroghi, P. Paba, A. Bertoli, E. Teti, V. Svicher, L. Sarmati, **Maria Mercedes Santoro**, S. Grelli, M. Andreoni, and F. Ceccherini-Silberstein. HEV seroprevalence in HIV-1 infected patients in a Roman Hospital is associated with other viral hepatitis coinfection history". 47th SIM 2019 (Società Italiana di Microbiologia) congress, Rome by 18-21 Sep 2019.
315. M. Alkhatib, V.C. Di Maio, V. De-Murtas, M. Aragri, R. Scutari, A. Sacco, ..... **Maria Mercedes Santoro**, C.F. Perno, V. Svicher, F. Ceccherini-Silberstein, R. Salpini, On behalf of HIRMA (Hepatocarcinoma Innovative Research MArkers) and Fondazione Vironet C (HCV Virology Italian Resistance Network). Specific polymorphisms of the NS5A prot-ein of hepatitis C virus genotype 1b are associated with hep-atocellular carcinoma in cirrhotic patients". 47th SIM 2019 (Società Italiana di Microbiologia) congress, Rome by 18-21 Sep 2019.
316. B Yagai, C Cerva, V Malagnino, M Ciotti, L Piermatteo, D Armenia, A Giovinazzo, C Stingone, T Guenci, L Foroghi, PP Paba, A Bertoli, E Teti, V Svicher, L Sarmati, **Maria Mercedes Santoro**, S Grelli, M Andreoni, and F Ceccherini-Silberstein. Low number of HEV cases in HIV-1 infected patients in a Roman Hospital: the seroprevalence was associated with other viral hepatitis coinfection history. 11th ICAR (Italian Conference on AIDS and Antiviral Research); 5-7 June 2019 in Milan. Abstract P41.
317. R Scutari, MC Bellocchi, V Spagnuolo, S Barbaliscia, L Galli, A Galli, A Poli, L Carioti, **Maria Mercedes Santoro**, CF Perno, C Alteri, F Ceccherini-Silberstein, and A Castagna. Impact of analytical treatment interruption on reassortment of HIV-1 drug resistance mutations in peripheral reservoir. 11th ICAR (Italian Conference on AIDS and Antiviral Research); 5-7 June 2019, Milan. Abstract P81.

318. D Armenia, B Yagai, A Bertoli, L Palandri, H Tchidjou Kuekou, F Forbici, R Gagliardini, M Lichtner, M Andreoni, A Antinori, F Ceccherini Silberstein, S Bernardi, CF Perno, and **Maria Mercedes Santoro**. Drug Resistance dynamics in isolates from HIV-1 Infected individuals with Mother-to-Child-Transmission in Italy from 1999 to 2017. 17th European Meeting on HIV & Hepatitis; 22-24 May 2019, Rome. Abstract ID60.
319. D Armenia, B Yagai, V Borghi, C Gori, W Gennari, G Berno, R Gagliardini, A Vergori, A Latini, C Mussini, A, Antinori, F Ceccherini-Silberstein, CF Perno, and **Maria Mercedes Santoro**. Evaluation of integrase inhibitor resistance in PBMC and plasma compartments in clinical isolates from HIV-1 infected patients with low/undetectable plasma viral load. 17th European Meeting on HIV & Hepatitis; 22-24 May 2019, Rome. Abstract ID65.
320. F Saladini, A Giannini, F Maggiolo, F Vichi, GM Corbelli, A Galli, A Bigoloni, **Maria Mercedes Santoro**, M Zazzi, and Antonella Castagna. GENOTYPIC AND PHENOTYPIC SUSCEPTIBILITY TO FOSTEMSAVIR IN MULTIDRUG-RESISTANT HIV-1". 2019 Conference on Retroviruses and Opportunistic Infections (CROI), 4-7 March 2019, Seattle, Washington. Abstract ID 1183.
321. **Maria Mercedes Santoro**, C Fornabaio, M Malena, L Galli, A Poli, S Marcotullio, M Menozzi, M Zazzi, KL White, A Castagna. SUSCEPTIBILITY TO BICTEGRAVIR IN HIGHLY ARV-EXPERIENCED PATIENTS AFTER INSTI FAILURE". 2019 Conference on Retroviruses and Opportunistic Infections (CROI), 4-7 March 2019, Seattle, Washington. Abstract ID 1628.
- 322.** D Armenia, C Gori, A Bertoli, V Borghi, A Latini, R Gagliardini, M Lichtner, F Forbici, F Montella, C Mussini, M Andreoni, A Antinori, F Ceccherini Silberstein, CF Perno, and **Maria Mercedes Santoro**. INI-RESISTANCE DYNAMICS FROM 2007 TO 2017 IN ITALIAN CLINICAL ISOLATES. 2019 Conference on Retroviruses and Opportunistic Infections (CROI), 4-7 March 2019, Seattle, Washington. Abstract ID 2302. ***Vincitore dell' ICAR – CROI Awards 2019 for the Italian Scientific Research.***
323. J Fokam, **Maria Mercedes Santoro**, D Takou, C Chenwi, G Teto, CN Fokunang, J Kamgno, V Colizzi, F Ceccherini-Silberstein, A Ndjolo, CF Perno. Evaluation of Novel Protease and Reverse-Transcriptase Mutations Selected in Non-B Subtype HIV-1 Infected Patients Failing Antiretroviral Therapy in Cameroon. XXVII International Workshop on HIV Drug Resistance and Treatment Strategies. 22 to 23 October 2018. Johannesburg, South Africa.
324. J Fokam, D Takou, **Maria Mercedes Santoro**, C Chenwi, IK Domkam, G Teto, ES Ngoufack, GA Beloumou, EH Assomo, SCN Djupsa, B Dambaya, AJ Nanfack, S Moudourou, SM Sosso, SC Billong, CN Fokunang, J Kamgno, V Colizzi, F Ceccherini-Silberstein, CF Perno, and A Ndjolo. Declining Trends of HIV-1 Drug Resistance Among Patients Failing Antiretroviral Treatment Following the "Test&Treat" Implementation in Cameroon. XXVII International Workshop on HIV Drug Resistance and Treatment Strategies. 22 to 23 October 2018. Johannesburg, South Africa.
325. Salpini R., Varini F., Di Maio C., De Murtas V., Polilli E., Masetti C., Alkhatib M., Aragri M., Barbaliscia S., Battisti A., Bertoli A., Cento V., Calvaruso V., Morisco F., Pace Palitti V., Pasquazzi C., Cacciatore P., Francioso S., Sozio F., Pieri A., Babudieri S., Mussini C., Parruti G., Borghi V., Lenci I., Craxi A., Andreoni M., Angelico M., Maida I., **Santoro Maria Mercedes**, Svicher V., Perno C.F., Ceccherini-Silberstein F. on behalf of HIRMA (Hepatocarcinoma Innovative Research MArkers). Specific Genetic Determinants in NS5A and Core Regions Correlate with Genotype 1b HCV-Induced Hepatocellular Carcinoma: Implications for Viral Markers of Disease Progression". The AASLD Liver Meeting® 2018, 9-13 Novembre 2018. San Francisco. Abstract 1027.
326. Lai A, Bergna A, Franzetti M, Saladini F, Bruzzone B, Di Giambenedetto S, Di Biagio A, Lo Caputo S, **Santoro Maria**, Maggiolo F, Parisi S, Rusconi S, Gianotti N, and Balotta C. A marked decrease in acquired resistance to antiretrovirals is associated with new drug combinations and latest prescription guidelines. 16th European Meeting on HIV & Hepatitis. Rome 30 May – 1 June 2018. Abstract number 24.

327. D. Armenia, C. Gori, F. Forbici, V. Borghi, M. Zaccarelli, A. Bertoli, C. Alteri, W. Gennari, G. Bero, A. Giannetti, A. Vergori, I. Mastroso, V. Mazzotta, G. Maffongelli, M. Colafigli, I. Pozzetto, M. Lichtner, M. Andreoni, C. Mussini, A. Antinori, C.F. Perno, F. Ceccherini-Silberstein, and **Maria Mercedes Santoro**. Evaluation of virological response and resistance profile in virologically suppressed HIV-1 infected patients switching to integrase inhibitors based treatment in clinical settings. 16th European Meeting on HIV & Hepatitis. Rome 30 May – 1 June 2018. Abstract number 42.
328. L. Fabeni, C. Alteri, G. Bero, R. Scutari, A. Bertoli, C. Gori, N. Orchi, G. De Carli, A. Vergori, I. Mastroso, L. Mazzuti, O. Turriziani, M. Colafigli, V. Borghi, F. Montella, A. Pennica, M. Lichtner, A. Latini, E. Girardi, M. Andreoni, C. Mussini, A. Antinori, F. Ceccherini-Silberstein, C. F. Perno, and **Maria Mercedes Santoro**. Newly diagnosed individuals infected with HIV-1 non-B subtypes are frequently involved in transmission clusters in Italy. Poster discussion. 16th European Meeting on HIV & Hepatitis 2018, Roma, 30 Maggio-1 Giugno 2018 ABS 43
329. D. Armenia, C. Gori, A. Bertoli, V. Borghi, M. Zaccarelli, A. Di Biagio, B. Bruzzone, L. Fabeni, W. Gennari, D. Pizzi, A. Giannetti, A. Vergori, I. Mastroso, A. Latini, M. Colafigli, C. Cerva, R. Marocco, M. Andreoni, C. Mussini, A. Antinori, F. Ceccherini-Silberstein, C.F. Perno, and **Maria Mercedes Santoro**. Evaluation of factors associated with virological response and resistance profile in HIV-1 infected patients starting first-line integrase inhibitors based regimen. 10° Italian Conference on AIDS and Antiviral Research, Roma, 22-24 maggio 2018. Abstract P12.
330. R. Scutari, D. Di Carlo, I. Vicenti, C. Alteri, V. Zuccaro, A. Cascio, F. Incardona, V. Borghi, A. Bezenchek, M. Andreoni, A. Antinori, C.F. Perno, A. De Luca, M. Zazzi, and **Maria Mercedes Santoro**. HIV-1 integrase drug-resistance emergence and evolution in patients treated with integrase inhibitors. 16th European Meeting on HIV & Hepatitis. Rome 30 May – 1 June 2018. Abstract 48.
331. R. Scutari, A. Bertoli, D. Armenia, C. Gori, G. Fabbri, CM Mastroianni, C. Cerva, A. Cristaudo, M. Andreoni, A. Antinori, V. Svicher, F. Ceccherini-Silberstein, C.F. Perno, **Maria Mercedes Santoro**, and C. Alteri. HIV-1 tropism evolution is reduced in presence of Integrase Inhibitors based regimens. Congresso Nazionale SIV-ISV, Milano 2017. Poster N:101.
332. D. Redi, C. Spertilli Raffaelli, D. Di Carlo, A. D'Avino, M.C. Postorino, A. Bezenchek, R. Scutari, A. Emiliozzi, M. Digaetano, S. Barbaliscia, I. Fanti, S. Di Giambenedetto, V. Borghi, M. Zazzi, and **Maria Mercedes Santoro**. Virological Response and Resistance Profile in HIV-1 Infected Patients Starting a First-Line Regimen Containing a Protease Inhibitor or an Integrase Inhibitor in Clinical Settings. EACS 2017 – Milan 25-27 October 2017. Abstract PE9/30
333. L. Galli, A. Castagna, A. Vergori, G. Baldin, N. Galizzi, A. Poli, E. Girardi, **Maria Mercedes Santoro**, A. Saracino, A. Cingolani, C. Mussini, A. Lazzarin, A. Antinori, and A. d'Arminio Monforte. High pre-ART viral load and risk of death in HIV-1 infected subjects: an Italian inter-cohort study. EACS 2017 – Milan 25-27 October 2017. Abstract PE21/17.
334. J. Fokam, D. Takou, G. Teto, OP. Kome, SE. Nforbih, **Maria Mercedes Santoro**, ES. Ngoufack, B. Dambaya, M. Eyongetah, D. Palmer, AJ. Nanfack, ET. Fokunang, CN. Fokunang, V. Colizzi, C.F. Perno, and A. Ndjolo. PRETREATMENT DRUG RESISTANCE AND HIV-1 GENETIC DIVERSITY IN RURAL AND URBAN SETTINGS OF NORTHWEST CAMEROON. ICASA 2017.
335. D. Di Carlo, M. Zaccarelli, V. Borghi, W. Gennari, A. Giannetti, F. Forbici, A. Bertoli, C. Gori, L. Fabeni, C. Pinnetti, R. Marocco, A. Latini, F. Ceccherini Silberstein, C.M. Mastroianni, C. Mussini, A. Antinori, C.F. Perno, **Maria Mercedes Santoro** and D. Armenia. RESISTANCE RETRIEVED IN PROVIRAL DNA PREDICTS VIROLOGICAL RESPONSE IN HIV-1 INFECTED PATIENTS SWITCHING THERAPY UNDER UNDETECTABLE VIREMIA. Congresso Nazionale SIV-ISV. ONE VIROLOGY ONE HEALTH. Il mondo dei virus umani, animali e ambientali. Milano 25-28 Giugno 2017.
336. Armenia D, Di Carlo D, Borghi V, Forbici F, Bertoli A, Gori C, Alteri C, Fabeni L, Gennari W, Continenza F, Pinnetti C, Zaccarelli M, Mondì A, Cicalini S, Maffongelli G, Montella F, Colafigli M, Marocco R, Mastroianni CM, Ceccherini-Silberstein F, Andreoni M, Mussini C, Antinori A, Perno CF, and **Santoro Maria Mercedes**. Is the management of HIV-1 drug-resistance still a clinical concern? An update in the modern antiretroviral era. 15th European Meeting on HIV & Hepatitis Treatment Strategies & Antiviral Drug Resistance 7 – 9 June 2017, Rome, Italy. Abstract 69.



337. D. Armenia, M. Zaccarelli, V. Borghi, W. Gennari, D. Di Carlo, A. Giannetti, F. Forbici, A. Bertoli, C. Gori, L. Fabeni, C. Pinnetti, R. Marocco, A. Latini, F. Ceccherini Silberstein, C. Mastroianni, C. Mussini, A. Antinori, CF. Perno, and **Maria Mercedes Santoro**. Resistance detected at baseline PBMC GRT predicts virological rebound in suppressed patients switching treatment. IX Italian conference on AIDS and Antiviral Research (ICAR), 12-14 June 2017, Siena, Italy. Poster P136.
338. D. Redi, C. Spertilli Raffaelli, A. D'Avino, M.C. Postorino, A. Bezenchek, R. Scutari, A. Emiliozzi, M. Di Gaetano, S. Barbaliscia, I. Fanti, D. Di Carlo, S. Di Giambenedetto, V. Borghi, M. Zazzi, and **Maria Mercedes Santoro**. Virological Response and Resistance Profile in HIV-1 Infected Patients Starting a First-Line Regimen Containing a Protease Inhibitor or an Integrase Inhibitor in Clinical Practice. IX Italian conference on AIDS and Antiviral Research (ICAR), 12-14 June 2017, Siena, Italy. Poster P50.
339. L. Palandri, A. Bertoli, **Maria Mercedes Santoro**, L. Fabeni, H. Tchdjou, G. Polti, P. Palma, S. Bernardi. Evaluation of the variability of hiv-1 from mother to child: a retrospective analysis from a paediatric cohort. 35th European society for paediatric infectious diseases, Madrid, Spain, May 23.27 2017. Abstract N 1225.
340. S Rusconi, **Maria Mercedes Santoro**, A Cozzi-Lepri, A Antinori, S Bonora, A Cingolani, N Gianotti, A Tavelli, F Ceccherini Silberstein, A d'Arminio Monforte, for the Icona Foundation Study Group. Are HIV+ Patients with Previous C-ART Failures Still at Risk of Losing Viral Control? 21th International Workshop on HIV Observational Databases. Lisbon, Portugal, 30 March – 01 April 2017. Poster 120.
341. J Fokam, **Maria Mercedes Santoro**, C Musolo, I Chimbi, G Chikwenga, R Deula, R Massari, A Lungu, and CF Perno. IMPACT OF A HOLISTIC INTERVENTION ON PMTCT UPTAKE WITHIN SUB-SAHARAN AFRICA: EVIDENCE FROM 'SAVE THE FAMILIES FOR AFRICA' IN MALAWI. February 12, 2 (Suppl 2) A49; DOI: 10.1136/bmjgh-2016-000260.131
342. L. Fabeni, C. Alteri, D. Di Carlo, L. Carioti, A. Bertoli, C. Gori, F. Forbici, M.C. Bellocchi, F. Continenza, S. Cicalini, C. Pinnetti, R. Bellagamba, A. Ammassari, V. Borghi, M. Giuliani, G. De Carli, N. Orchi, P. Scognamiglio, A. Pennica, C. Mastroianni, F. Montella, A. Cristaudo, C. Mussini, E. Girardi, M. Andreoni, A. Antinori, F. Ceccherini-Silberstein, C.F. Perno and **Maria Mercedes Santoro**. Different trends in HIV-1 drug resistance transmission according to subtype in Italy over the years 2000-2014, poster. 44° Congresso Nazionale della Società Italiana di Microbiologia, SIM 2016, Pisa, 25-28/09/2016.
343. D. Di Carlo, D. Armenia, A. Calcagno, F. Forbici, A. Bertoli, G. Bero, S. Carta, F. Continenza, L. Fabeni, G. D'Offizi, E. Nicastrì, A. Ammassari, R. Libertone, M. Zaccarelli, V. Ghisetti, M. Andreoni, F. Ceccherini-Silberstein, S. Bonora, G. Di Perri, A. Antinori, CF. Perno, and **Maria Mercedes Santoro**. Pre-existent NRTI and NNRTI resistance and pre-therapy viremia >500,000 cps/ML are associated with a higher risk to lose virological suppression in HIV-1 infected patients switching to a tenofovir/emtricitabine/rilpivirine single-tablet regimen. 7th Italian Conference on AIDS and Antiretroviral Research, Milan (Italy), June 6-8 2016. Abstract OC 41.
344. D Armenia, M Zaccarelli, V Borghi, W Gennari, A Giannetti, F Forbici, C Pinnetti, F Ceccherini Silberstein, C Mussini, CF Perno, A Antinori, and **Maria Mercedes Santoro**. Resistance in PBMCs Can Predict Virological Rebound after Therapy Switch in cART-Treated Patients with Undetectable HIV-RNA. XIV European HIV & Hepatitis workshop, 25-27 Maggio 2016, Roma. Abstract 67.
345. J. Fokam, D. Takou, **Maria Mercedes Santoro**, M.N. Mbazo'o, L. Fabeni, F. Ceccherini-Silberstein, G.P. Ngaba, V. Colizzi, C.F. Perno, and A. Ndjolo. Comparable Outcomes in Pretreatment HIV-1 Drug Resistance between Urban and Rural Settings in the Littoral Region of Cameroon. 10th INTEREST Workshop, 3 - 6 May 2016, Yaoundé, Cameroon. Abstract number P\_38.
346. L Fabeni, C Alteri, D Di Carlo, L Carioti, A Bertoli, C Gori, F Forbici, MC Bellocchi, F Continenza, S Cicalini, C Pinnetti, R Bellagamba, G D'Offizi, V Borghi, M Giuliani, G De Carli, N Orchi, FM Fusco, P Scognamiglio, A Pennica, C Mastroianni, F Montella, A Cristaudo, C Mussini, E Girardi, M Andreoni, A Antinori, F Ceccherini-Silberstein, CF Perno and **Maria Mercedes Santoro**. Dynamics of Transmitted HIV-1 Drug Resistance according to Subtype in Italy over the Years 2000-2014. International HIV Drug Resistance Workshop. Boston, Massachusetts USA, on February 20-21, 2016. Abstract 74.

347. L Fabeni, C Alteri, D Di Carlo, C Gori, M Andreoni, C Mussini, E Girardi, A Antinori, CF Perno, and **Maria Mercedes Santoro**. Dynamics of transmitted HIV-1 drug resistance among naive patients, Italy 2000-2014. XIV Congresso Nazionale SIMIT, 8-11 novembre 2015. Catania, Italia. Abstract 136.
348. D. Di Carlo, D. Armenia, A. Calcagno, F. Forbici, A. Bertoli, G. Berno, G. D'Offizi, E. Nicastrì, A. Ammassari, R. Libertone, M. Zaccarelli, V. Ghisetti, M. Andreoni, F. Ceccherini-Silberstein, S Bonora, G Di Perri, A. Antinori, CF. Perno, and **Maria Mercedes Santoro**\*. Cumulative Genotypic Resistance to NRTIs and NNRTIs is Associated with a Higher Risk to Loose Virological Suppression in HIV-positive Patients Switching to Tenofovir/Emtricitabine/Rilpivirine Single-tablet Regimen. 15th European AIDS Conference from October 21-24, 2015. Barcelona, Spain. Abstract number PE9/6.
349. Zaccarelli M, **Santoro Maria Mercedes**, Armenia D, Gori C, Giannetti A, Andreoni M, Mastroianni C, Mussini C, Perno CF, and Antinori A. Characterization of HIV Resistance in Peripheral Blood Mononuclear Cells (PBMC-DNA) in Patients with Suppressed or Low Level Viremia. 15th European AIDS Conference from October 21-24, 2015. Barcelona, Spain. Abstract number PE9/14.
350. **Maria Mercedes Santoro**, D. Armenia, M. Nasi, M.C. Bellocchi, L. Carioti, F. Continenza, D. Di Carlo, M. Digaetano, A. Cossarizza, C.F. Perno, F. Ceccherini-Silberstein, and C. Mussini. Analysis of coreceptor tropism evolution in HIV-1 infected patients interrupting suppressive antiretroviral therapy. 13th European Workshop on HIV & Epatitis – Treatment Strategies & Antiviral Drug Resistance. Reviews in Antiviral Therapy & Infectious Diseases – Volume 5: 2015. Abstract 28.
351. L. Fabeni, C. Alteri, N. Orchi, C. Gori, A. Bertoli, F. Forbici, F. Montella, A. Pennica, G. De Carli, M. Giuliani, F. Continenza, C. Pinnetti, E. Nicastrì, F. Ceccherini-Silberstein, C.M. Mastroianni, E. Girardi, M. Andreoni, A. Antinori, **Maria Mercedes Santoro**, and C.F. Perno. Recent transmission clusters of HIV-1 C and CRF17\_BF strains with evidence of NNRTI-related mutations among newly diagnosed men in central Italy. 13th European Workshop on HIV & Epatitis – Treatment Strategies & Antiviral Drug Resistance. Reviews in Antiviral Therapy & Infectious Diseases – Volume 5: 2015. Abstract 73.
352. D Armenia, **Maria Mercedes Santoro**, C Gori, E Nicastrì, A Cristaudo, M Andreoni, A Antinori, Z Debysler, CF Perno, and Francesca Ceccherini-Silberstein. Integrase S119P Mutation Correlates With Disease Progression in HIV-1 Naïve Patients. Conference of retroviruses and opportunistic infections (CROI), February 23-26, 2015. Seattle, Washington, USA. Abstract 611. **Vincitore del premio ICAR-CROI come giovane ricercatore.**
353. D Armenia, **Maria Mercedes Santoro**, L Fabeni, D Di Carlo, C Gori, A Bertoli, A Latini, E Nicastrì, R Bellagamba, R Libertone, A Cristaudo, M Andreoni, Z Debysler, A Antinori, CF Perno, and F Ceccherini-Silberstein. Impact of Polymorphisms at HIV-1 Integrase Position 119 on Viro-Immunological Parameters in HIV-1 Infected Naïve Patients. XXIV International HIV Drug Resistance Workshop, February 21-22, 2015. Seattle, Washington, USA. Global Antiviral Journal. Abstract 1.
354. J Fokam, D Takou, **Maria Mercedes Santoro**, F Ceccherini-Silberstein, AJ Nanfack, R Salpini, G Teto, C Gori, JN Torimiro, CN Fokunang, G Cappelli, V Colizzi, CF Perno, and A Ndjolo. Usefulness of HIV-1 Resistance Testing in Switching Patients from First- to Second-Line Antiretroviral Regimens in Resource-Limited Settings. XXIV International HIV Drug Resistance Workshop, February 21-22, 2015. Seattle, Washington, USA. Global Antiviral Journal. Abstract 17.
355. **Maria Mercedes Santoro**, D Di Carlo, D Armenia, MC Bellocchi, L Fabeni, R. Salpini, C Pinnetti, M Zaccarelli, R Libertone, A Cristaudo, C Mussini, M Andreoni, F Ceccherini-Silberstein, A Antinori, CF Perno, and V Svicher. Specific PR/RT Genetic Determinants Correlate with Low- Level Viremia During First-Line HAART. XXIV International HIV Drug Resistance Workshop, February 21-22, 2015. Seattle, Washington, USA. Global Antiviral Journal. Abstract 28.
356. M Zaccarelli, **Maria Mercedes Santoro**, D Armenia, C Gori, A Giannetti, M Andreoni, C Mastroianni, C Mussini, CF Perno, and A Antinori. Genotypic Resistance Test in PBMC DNA can Identify Patients with Hidden Resistance. XXIV International HIV Drug Resistance Workshop, February 21-22, 2015. Seattle, Washington, USA. Global Antiviral Journal. Abstract 54.
357. D. Armenia, C. Gori, D. Di Carlo, A. Bertoli, V. Borghi, L. Fabeni, S. Carta, P. Scognamiglio, R. Bellagamba, A. Ammassari, S. Cicalini, C. Cerva, A. Latini, A. Cristaudo, C. Mussini, E. Girardi, M. Andreoni, A. Antinori, F. Ceccherini-Silberstein, C.F. Perno, and **Maria Mercedes Santoro**. Impact of

HIV-1 subtype on virological response to first line PI/r regimens. 43° Congresso Nazionale della Società Italiana di Microbiologia, 27 - 30 Settembre 2015, Napoli.

**358.** G. Berno, L. Fabeni, D. Armenia, D. Di Carlo, C. Gori, A. Bertoli, V. Svicher, V. Fedele, E. Boumis, C. Pinnetti, R. Bellagamba, R. Libertone, V. Malagnino, F.M. Fusco, D. Pizzi, F. Montella, A. Pennica, A. Cristaudo, M. Lichtner, E. Girardi, F. Ceccherini-Silberstein, M. Andreoni, A. Antinori, C.F. Perno, and **Maria Mercedes Santoro**. Evaluation of HIV-1 Coreceptor Tropism in naïve patients in central Italy over years 2009-2013 according to subtype. 7° Congresso Nazionale ICAR 2015, Italian Conference on AIDS and Retroviruses Riccione, 17-19 maggio 2015. Abstract P120.

**359.** S. Tagliazucchi, W. Gennari, M. Pecorari, **Maria Mercedes Santoro**, D. Armenia, C.F. Perno, C. Lazzaretti, C. Mussini, and V. Borghi. Evaluation HIV-1 subtypes and transmitted drug resistance prevalence using an HIV local Surveillance system in Emilia Romagna. 7° Congresso Nazionale ICAR 2015, Italian Conference on AIDS and Retroviruses Riccione, 17-19 maggio 2015. Abstract P115.

360. D. Armenia, L. Carioti, V.C. Di Maio, M.C. Bellocchi, D. Di Paolo, F. Guerrieri, L. Calvo, V. Cento, M. Tontodonati, V. Micheli, F. De Leonardis, M. Aragri, E. Polilli, A. Manunta, C. Magni, F.P. Antonucci, F. De Luca, C. Sarrechia, A. Bertoli, I. Lenci, S. Francioso, **Maria Mercedes Santoro**, J. Vecchiet, S. Marengo, A. Picciotto, L. Nosotti, F. Morisco, S. Bruno, M. Puoti, S. Babudieri, M.S. Mura, M. Andreoni, G. Rizzardini, G. Parruti, M. Levrero, M. Angelico, C.F. Perno, F. Ceccherini-Silberstein. Clinical relevance of next generation sequencing on baseline detection of minority resistance associated variants in HCV-1 patients treated with protease inhibitors. 48<sup>th</sup> Annual Meeting of the Italian Association for the Study of the Liver - AISF. Rome, February 19<sup>th</sup>-20<sup>th</sup>, 2015. Abstract n 166.

361. R. Alfieri, **Maria Mercedes Santoro**, M. Gnocchi, M. Moscatelli, O. Carpina, C. Vischi, C. Pisano, V. De Murtas, E. Polilli, F.P. Antonucci, I. Maida, P. Tarquini, G. Garrucci, F. Bandiera, D. Di Giammartino, D. Laccabue, A. Olivani, V. Borghi, T. Quirino, I. Lenci, G. Tisone, M. Angelico, C. Mussini, G. Rizzardini, M. Temponi, G. Parruti, M.S. Mura, F. Ceccherini-Silberstein, C.F. Perno, and L. Milanese. A Web Portal for Clinical and Genotype Data Management for the Study of Hepatocellular Carcinoma. Workshop "Innovation in HIV and Viral Hepatitis - Beyond viral undetectability: new frontiers and strategies", Milan, January 26-27 2015.

362. D. Armenia, D. Di Carlo, L. Fabeni, C. Gori, A. Bertoli, M.C. Bellocchi, R. Salpini, C. Pinnetti, M. Zaccarelli, R. Libertone, A. Cristaudo, C. Mussini, M. Andreoni, F. Ceccherini-Silberstein, A. Antinori, C.F. Perno, **Maria Mercedes Santoro**, and V. Svicher. Factor associated with persistent low-level viremia during first-line HAART in clinical practice. 6° Congresso Nazionale S.I.Vi.M., Roma, 10-12 dicembre 2014.

363. L. Fabeni, G. Berno, V. Svicher, F. Ceccherini-Silberstein, C. Gori, A. Bertoli, C. Mussini, M. Lichtner, M. Zaccarelli, A. Ammassari, C. Pinnetti, S. Cicalini, C. Mastroianni, M. Andreoni, A. Antinori, C.F. Perno, and **Maria Mercedes Santoro**. Comparison of HIV-1 genotypically predicted tropism between circulating plasma RNA and proviral DNA in drug-experienced patients. 6° Congresso Nazionale S.I.Vi.M., Roma, 10-12 dicembre 2014.

364. Fabeni, C. Alteri, **Maria Mercedes Santoro**, C. Gori, D. Di Pinto, L. Carioti, F. Forbici, A. Bertoli, M. C. Bellocchi, V. Fedele, S. Carta, G. Berno, A. Ricciardi, M. Zaccarelli, A. Ammassari, E. Nicastrì, A. Latini, G. Liuzzi, M. Lichtner, E. Teti, F. Di Sora, R. Bellagamba, G. De Carli, N. Orchi, P. Scognamiglio, A. Pennica, M. Giuliani, F. Montella, V. Svicher, C. Mastroianni, E. Girardi, F. M. Fusco, M. Andreoni, A. Antinori, F. Ceccherini-Silberstein, and C. F. Perno. Drug resistance transmission clusters in HIV-1 infected patients diagnosed in central Italy between 1997-2014. VI Italian conference on AIDS and Retroviruses, Roma, 25-27 maggio 2014. Abstract PD28. **Oral poster.**

365. D. Armenia, D. Di Carlo, C. Gori, F. Forbici, A. Bertoli, V. Borghi, M. Giuliani, V. Fedele, G. Berno, G. Liuzzi, R. Bellagamba, L. Sarmati, C. Mussini, M. Andreoni, A. Antinori, F. Ceccherini-Silberstein, C.F. Perno, and **Maria Mercedes Santoro**. Impact of the HIV-1 subtype associated polymorphism L89M on virological response in patients starting their first boosted protease-inhibitor containing regimen. VI Italian conference on AIDS and Retroviruses, Roma, 25-27 maggio 2014. Abstract PD27. **Oral poster.**

366. D Takou, J Fokam, A Nanfack, R Salpini, **Maria Mercedes Santoro**, L Fabeni, C Gori, G Cappelli, J Torimiro, CF Perno, et Vittorio Colizzi. Résistance du VIH-1 aux Antirétroviraux en Fonction de l'Utilisation du Tenofovir ou de la Zidovudine en Première Ligne Thérapeutique: Cas du Cameroun. French AIDS Conference in Montpellier, 27-30 April 2014.
367. D. Armenia, D Di Carlo, G Maffongelli, C Alteri, F Foribici, V Borghi, M Giuliani, E Nicastrì, M Zaccarelli, C Pinnetti, N Petrosillo, G D'Offizi, F Ceccherini-Silberstein, C Mussini, A Antinori, M Andreoni, CF Perno, and **Maria Mercedes Santoro**. Evaluation of virological efficacy and resistance profile in patients starting darunavir in clinical practice. 12th European Meeting on HIV & Hepatitis, Barcellona, 26-28 March 2014, Spain. Abstract P\_25.
- 368. Maria Mercedes Santoro**, D Armenia, C Alteri, L Fabeni, D Di Pinto, F Foribici, A Bertoli, C Gori, A Antinori, and Carlo Federico Perno. Feasibility and clinical utility of HIV-1 genotype testing in the setting of low level viremia. Conference on Retroviruses and Opportunistic Infections 2014, Boston 3-6 March 2014, Massachusetts, USA. *Topics in antiviral medicine* 2014. Abstract P#610. **Vincitore del premio ICAR-CROI come giovane ricercatore.**
369. The Etravirine Cohort Study Group (V Calvez, AG Marcelin, P Flandre, A Cozzi-Lepri, J Grarup, J Lundgren, R Kaiser, F Incardona, A Sonnerborg, H Günthard, B Ledergerber, R Paredes, B Clotet, F Ceccherini-Silberstein, **Maria Mercedes Santoro**, CF Perno, M Nelson, Ruth Bateson; Chelsea and Westminster Hospital, London, J Vingerhoets, S Nijs, L Tambuyzer, L Lavreys, and M Opsomer). The Virologic Response in HIV-1 Infected Patients Treated With Etravirine Combined With Boosted PIs Other Than DRV/r: an Observational Study Using Pooled European Cohort Data. EACS, 16-19 October 2013, Bruxelles, Belgium.
370. M Gnocchi, R Alfieri, A Orro, **Maria Mercedes Santoro**, E Mosca, D Armenia, F Ceccherini-Silberstein, Carlo Federico Perno, Luciano Milanese. A web portal for clinical and genotype data management for the study of hepatocellular carcinoma. 10<sup>th</sup> Annual Meeting of the Bioinformatics Italian Society. 21-23 May 2013. Udine Italy.
371. **Santoro Maria Mercedes**, V Cento, V Borghi, L Fabeni, D Armenia, C Gori, A Bertoli, M Garau, M Andreoni, E Nicastrì, A Ammassari, L Loiacono, R Libertone, R Termini, M Zaccarelli, A Antinori, C Mussini, CF Perno, and Francesca Ceccherini-Silberstein. Viro-immunological response and resistance profile in HIV-1 infected patients starting a first etravirine containing regimen in clinical practice. 10th European Meeting on HIV & Hepatitis Treatment Strategies & Antiviral Drug Resistance, March 28-30 2012, Barcelona, Spain, *Reviews in Antiviral Therapy & Infectious Diseases* 2/2012 # P\_30 pp 51-52
372. Armenia D, **Santoro Maria Mercedes**, Soulie C, Fabeni L, Gori C, Foribici F, Svicher V, Bertoli A, Dori L, Giuliani M, Palamara G, Boumis E, Iaconi F, Zaccarelli M, Bellagamba R, Andreoni M, Calvez A-G, Marcelin V, Antinori A, Ceccherini Silberstein F, Perno CF, Impact of genotypic-tropism on immunological reconstitution in drug-naïve Patients starting first line regimen, 10th European Meeting on HIV & Hepatitis Treatment Strategies & Antiviral Drug Resistance, March 28-30 2012, Barcelona, Spain, *Reviews in Antiviral Therapy & Infectious Diseases* 2/2012 # P\_31 pp 52-53
373. **Santoro Maria Mercedes**, D Armenia, C Mirabelli, V Borghi, M Andreoni, P Narciso, G Palamara, M Zaccarelli, U Visco Comandini, E Boumis, V Tozzi, A Antinori, C Mussini, CF Perno, and F Ceccherini-Silberstein. Characterization of virological-response and immunological recovery in patients starting darunavir in clinical practice. 13<sup>th</sup> European AIDS Conference, 12-15 October 2011, Belgrade, Serbia. Abstract PS7.9/11.
374. **Santoro Maria Mercedes**, F Ceccherini-Silberstein, F Foribici, L Bansi, D Dunn, E Feamhill, E Boumis, P Narciso, A Antinori, G Palamara, A Callegaro, D Francisci, A Zoncada, F Maggiolo, M Zazzi, C Sabin3, CF Perno, C Mussini. Different drug-resistance development in HIV- infected patients failing a first-line antiretroviral therapy containing NNRTIs. 6<sup>th</sup> IAS conference on HIV pathogenesis, treatment and prevention. Rome, Italy, 17-20 July 2011. Abstract CDB343. Poster elettronico.

375. R Salpini, C Alteri, C Gori, F Stazi, A Bertoli, G Maffongelli, M Zaccarelli, D Armenia, P Narciso, A Antinori, M Giuliani, G Palamara, M Andreoni, V Svicher, F Ceccherini-Silberstein, **Santoro Maria Mercedes**, and CF Perno. Characterization of HIV- infection among immigrants to Italy: implications for HIV/AIDS surveillance. 6<sup>th</sup> IAS conference on HIV pathogenesis, treatment and prevention. Rome, Italy, 17-20 July 2011. Abstract MOPE374.
376. **Santoro Maria Mercedes**, V. Svicher, A Cozzi-Lepri, L Fabeni, B Bruzzone, C Mussini, A De Luca, M Andreoni, I Fanti, A Antinori, M Zazzi, CF Perno, A D'Arminio Monforte, and F Ceccherini-Silberstein 1 for Icona Foundation. Impact of natural polymorphisms of HIV-1 reverse transcriptase at position 135 on virologic response to a first line NNRTI-containing HAART. 15th International Workshop on HIV Observational Databases, Prague, Czech Republic, 24-26 March 2011. Abstract 83.
377. **Santoro Maria Mercedes**, NM Collaço Vêras, RR Gray, AJ Tatem, A Lo Presti, F Olearo, G Cappelli, V Colizzi, D Takou, J Torimiro, G Russo, AP Callegaro, R Salpini, R D'Arrigo, CF Perno, MM Goodenow, M Ciccozzi, M Salemi. Estimation of the origin, demographic history, and gene flow of HIV-1 CRF02\_AG in Cameroon by phylodynamics and phylogeography. 9° Congresso Nazionale SIMIT, Roma, 24-27 novembre 2010. Poster 302.
378. J Fokam, R Salpini, **Santoro Maria Mercedes**, V Cento, R D'Arrigo, C Gori, CF Perno, G Cappelli, J Torimiro, C Nkenfou, A Nanfack, D Takou, V Colizzi. Performance evaluation of an in-house genotyping assay on samples from HIV-1 infected Cameroonian subjects. XVIII International AIDS Conference, to be held in Vienna 18-23 July 2010. Poster Exhibition N° TUPE 0129.
379. M Zaccarelli M, F Ceccherini-Silberstein F, P Lorenzini, **Santoro Maria Mercedes**, G Palamara, C Mussini, A Cozzi-Lepri, A d'Arminio Monforte, CF Perno, and A Antinori. Using the Latest Rega Interpretation System (Version 8.0.1) to Understand the Impact of Primary HIV Resistance on First Line Treatment Options. 8th European HIV Drug Resistance workshop, Sorrento, Italy, 15- 17 March 2010. Abstract 76, pag. 70.
380. **Santoro Maria Mercedes**, C Alteri, L Ronga, P Flandre, F Mercurio, R D'arrigo, C Gori, G Palamara, A Bertoli, F Forbici, R Salpini, F Stazi, E Boumis, V Tozzi, U Visco-Comandini, M Zaccarelli, M Van Houtte, T Pattery, P Narciso, A Antinori, F Ceccherini-Silberstein, and CF Perno Evaluation of drug resistance among HIV-1 B, C and F subtypes drug-treated patients followed in Central Italy. 8th European HIV Drug Resistance workshop, Sorrento, Italy, 15- 17 March 2010. Abstract 87, pag 80.
381. V Svicher, C Alteri, I Abbate, A Bruselles, B Bartolini, F Forbici, G Rozera, **Santoro Maria Mercedes**, MR Capobianchi, and F Ceccherini Silberstein. Sentinel mutations in standard population sequencing can predict the presence of RT major mutations detected only by 454-pyrosequencing. 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, California, February 16 - 19, 2010. <http://www.retroconference.org/2010/Abstract>. Abstract 565, session 107 (2010).
382. **Santoro Maria Mercedes**, C Alteri, L Ronga, R D'arrigo, C Gori, G Palamara, A Bertoli, R Salpini, F Stazi, E Boumis, V Tozzi, U Visco-Comandini, M Zaccarelli, P Narciso, A Antinori, F Ceccherini-Silberstein, CF Perno. Evaluation of HIV-1 non-B subtypes in Italian treated patients from central Italy over the years 2001-2008. 7th European HIV Drug Resistance workshop, Stockholm, Sweden, 25- 27 March 2009. Abstract 130.
383. A De Luca, S Di Giambenedetto, F Marando, R Maserati, N Gianotti, P Narciso, A Antinori, G Di Perri, F Baldanti, V Micheli, M Zazzi, CF Perno, and **Santoro Maria Mercedes** for the TMC114-C226 and the ARCA study groups. Validation of available rules and update of a new genotypic score for HIV-1 protease substitutions predicting the virological response to darunavir/ritonavir. 7th European HIV Drug Resistance workshop, Stockholm, Sweden, 25- 27 March 2009. Abstract 61.
384. J Scherer, JM Schapiro, F Maggiolo, C Perno, CA Boucher, JD Baxter, H Gellermann, C Tilke, **Santoro Maria**, DB Hall. Improved tipranavir weighted score predicts virologic response in diverse treatment-experienced patient populations. 7th European HIV Drug Resistance workshop, Stockholm, Sweden, 25- 27 March 2009. Abstract 94.

385. J Scherer, F Maggiolo, CF Perno, H Gellermann, A Di Biagio, S LoCaputo, AM Cattelan, C Mussini, **Santoro Maria Mercedes**, and DB Hall. Improved tipranavir weighted score validated in italian treatment-experienced patient cohort. 7th European HIV Drug Resistance workshop, Stockholm, Sweden, 25- 27 March 2009. Abstract 98.
386. S Lo Caputo, **Santoro Maria Mercedes**, F Ceccherini-Silberstein, V Svicher, P Pierotti, F Vichi, R D'Arrigo, C Gori, CF Perno, and F Mazzotta. Antiretroviral treatment Efficacy after Mutations Reversion during T20 Mono-Therapy, an Alternative Strategy in Multi-Failed HIV-1 infected Patients. Ninth International Congress on Drug Therapy in HIV Infection, Glasgow, UK, 09-13 November 2008.
387. M Giuliani, M Ciccozzi, S Montieri, A Latini, G Palamara, CF Perno, **Santoro Maria**, and G Rezza. Non-B HIV-1 subtypes among man who have sex with man in Rome, Italy. 24th Conference on Sexually Transmitted Infections and HIV/AIDS IUSTI Europe, Milan September 4-6, 2008.
388. C Alteri, C Gori, R D'Arrigo, **Santoro Maria Mercedes**, MC Bellocchi, F Ceccherini-Silberstein, N Orchi, E Girardi, V Svicher, CF Perno. Complex patterns of drug resistance mutations in newly-diagnosed HIV-infected patients: implications with the transmission of resistant strains. 3° Congresso Nazionale SIVIM Roma 6 - 8 maggio 2008. Abstract book: 58.
389. C Alteri, V Svicher, C Gori, R D'Arrigo, **Santoro Maria Mercedes**, MC Bellocchi, F Ceccherini-Silberstein, N Orchi, E Girardi, and CF Perno. Complex patterns of drug resistance mutations in newly-diagnosed HIV-infected patients: implications with the transmission of resistant strains. 6th European HIV Drug Resistance Workshop, Budapest, Hungary 26 -28 March, 2008. Abstract 13, pag 16.
390. F Ceccherini-Silberstein, V Svicher, **Santoro Maria Mercedes**, MCF Prosperi, F Forbici, A Bertoli, A De Luca, C Mussini, G Palamara, P Narciso, A Antinori, C Balotta, A d'Arminio Monforte, CF Perno, and ICoNA Study Group, INMI-Collaborative Group for Clinical Use of HIV Genotype Resistance Test. Impact of HIV-1 Reverse Transcriptase Polymorphism R83K on Virological Response in Drug-Naïve Patients starting Thymidine Analogue Containing HAART. XI European AIDS Conference/EACS, Madrid, Spain, 24 – 27 October, 2007.
391. **Santoro Maria Mercedes**, P Lorenzini, F Ceccherini-Silberstein, A Bertoli, F Forbici, P Narciso, N Petrosillo, F Antonucci, V Tozzi, R Bellagamba, M Andreoni, A Antinori, and CF Perno. Determination of a genotypic resistance score for tenofovir in HIV-1 infected NRTI-experienced patients. XI European AIDS Conference/EACS, Madrid, Spain, 24 – 27 October, 2007.
392. V Svicher, T Sing, A Artese, **Santoro Maria Mercedes**, C Gori, S Alcaro, A Bertoli, A d'Arminio Monforte, A Antinori, T Lengauer, F Ceccherini-Silberstein, and CF Perno (2007). Involvement of Two Additional HIV-1 Reverse Transcriptase Mutations in the Regulation of NNRTI Resistance. 5th European HIV Drug Resistance Workshop Cascais, Portugal 28 - 30 March, 2007. Abstract 117, pag. 92.
393. F Ceccherini-Silberstein, V Svicher, M Zaccarelli, **Santoro Maria Mercedes**, M Trignetti, E Boumis, P De Longis, P Narciso, A Antinori, and CF Perno. Dynamics of NRTI resistance mutations during treatment interruption after failure of NRTI-containing regimens. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, February 25 - 28, 2007. <http://www.retroconference.org/2007/Abstract>. Abstract 587, session 104 (2007).
394. V Svicher, T Sing, A Artese, **Santoro Maria Mercedes**, C Gori, S Alcaro, A Bertoli, A d'Arminio Monforte, A Antinori, T Lengauer, F Ceccherini-Silberstein, and CF Perno. Characterization of the role of two additional HIV-1 reverse transcriptase mutations in the regulation of NNRTI resistance. 7th Annual Symposium on Antiviral Drug Resistance, Chantilly, Virginia, November 12 - 15, 2006. Poster 39.
395. C de Mendoza, AG Marcelin, F Ceccherini-Silberstein, P Flandre, V Svicher, M Garcia Leon, **Santoro Maria Mercedes**, V Soriano, CF Perno, V Calvez. Description and application of the EuroGene Network for HIV resistance. 4th European HIV Drug Resistance Workshop, Monte Carlo, Cote d'Azur 29 - 31 March, 2006. Abstract 80, pag. 59.

396. A Bertoli, **Santoro Maria Mercedes**, P Lorenzini, A Lazzarin, A Antinori, R Esposito, G Carosi, G Di Perri, G Filice, C F Perno. Viro-immunological response to Atazanavir in a large Cohort of multiply failing patients: the CARE Study. 4th European HIV Drug Resistance Workshop, Monte Carlo, Cote d'Azur 29 -31 March, 2006. Abstract 59, pag. 46.
397. F Ceccherini-Silberstein, C de Mendoza, AG Marcelin, V Svicher, M García-León, **Santoro Maria Mercedes**, A Antinori, V Soriano, V Calvez, and CF Perno on behalf of the EuroGene HIV Network. Characterization of E34Q, K43T and C95F HIV-1 protease mutations and their association with PI failure. 4th European HIV Drug Resistance Workshop, Monte Carlo, Cote d'Azur 29 -31 March, 2006. Abstract 43, pag 34.
398. F Ceccherini-Silberstein, V Svicher, T Sing, **Santoro Maria Mercedes**, N Beerenwinkel, A Bertoli, F Forbici, MC Bellocchi, P Narciso, F Gago, A d'Arminio Manforte, A Antinori, CF Perno. Caratterizzazione di nuove mutazioni della trascrittasi inversa di HIV-1 coinvolte nei meccanismi di farmaco resistenza. 33° Congresso Nazionale Società Italiana Di Microbiologia, Napoli, 16 - 19 Ottobre 2005.
399. **Santoro Maria Mercedes**, C Gori, V Svicher, M Santoro, N Esposito, M Zaccarelli, S Giannella, R D'Arrigo, A Antinori, CF Perno, F Ceccherini-Silberstein. Studio della dinamica di mutazioni nella proteasi di HIV-1 associate a resistenza durante l'interruzione terapeutica. 33° Congresso Nazionale Società Italiana Di Microbiologia, Napoli, 16 - 19 Ottobre 2005.
400. **Santoro Maria Mercedes**, C Gori, V Svicher, M Santoro, F Forbici, N Esposito, M Zaccarelli, A Cenci, A Antinori, CF Perno, F Ceccherini-Silberstein. Characterization on the dynamics of disappearance of protease resistance mutations during treatment interruption. BioSapiens-viRgil Workshop on Bioinformatics for Viral Infections, Caesar Bonn, Germany, September 21 - 23, 2005.
401. F Ceccherini-Silberstein, V Svicher, T Sing, **Santoro Maria**, F Gago, A Bertoli, N Beerenwinkel, F Forbici, MC Bellocchi., C Gori, R D'Arrigo, A Cenci, A D'Arminio Manforte, A Antinori, CF, Involvement of novel HIV-1 reverse transcriptase mutations in the regulation of NRTI resistance. 2° Congresso Nazionale SIVIM Roma 16 - 18 maggio 2005. Abstract book: 118.
402. V Svicher, F Ceccherini-Silberstein, T Sing, **Santoro Maria**, C Gori, N Beerenwinkel, F Gago, R D'Arrigo, MC Bellocchi, S Giannella, A Bertoli, A d'Arminio Monforte, A Antinori, CF Perno. A highly ordered network of HIV-1 RT mutations regulates the continuous escape from antiviral drugs. HIV Dynamics and Evolution at Cleveland, Ohio on April 23 – 26, 2005.
403. C Gori, F Ceccherini-Silberstein, **Santoro Maria**, V Svicher, M Santoro, F Forbici, M Zaccarelli, A Bertoli, A Antinori, and CF Perno. Dynamics of Major and Minor Protease Resistance Mutations during Treatment Interruption. 3rd European HIV Drug Resistance Workshop, Athens, Greece, 30 March - 1 April, 2005. Abstract 80, pag. 75.
404. **Santoro Maria**, F Ceccherini-Silberstein, C Gori, V Svicher, M Santoro, N Esposito, A Cenci, MP Trotta, A Antinori, and CF Perno. Similar Dynamics of Disappearance between recently associated and major protease Inhibitor-resistance mutations during treatment interruptions. 3rd European HIV Drug Resistance Workshop, Athens, Greece 30 March - 1 April, 2005. Abstract 79, pag. 75.
405. F Ceccherini-Silberstein, C Gori, **Santoro Maria**, V Svicher, F Forbici, R D'Arrigo, MC Bellocchi, N Esposito, A Bertoli, A Cenci, A Antinori and CF Perno. Dynamics of protease Inhibitors resistance mutations during treatment interruptions. XII Conference on Retroviruses and Opportunistic Infections, Boston, 22 - 25 February, 2005. <http://www.retroconference.org/2005/Abstract>, Abstract 681, Session 117 (2005).
406. F Ceccherini-Silberstein, F Gago, **Santoro Maria**, V Svicher, C Gori, F Rodríguez-Barrios, R D'Arrigo, A Bertoli, MC Bellocchi, S Giannella, A d'Arminio Monforte, J Balzarini, A Antinori, and CF Perno: High Sequence conservation of HIV-1 Reverse transcriptase under drug Pressure despite a

continuous appearance of mutations. XVIII Convegno Nazionale AIDS e Sindromi Correlate, Milano, 28 - 30 Novembre 2004, Abstract P 109, pag 195.

407. F Ceccherini-Silberstein, **Santoro Maria**, V Svicher, C Gori, F Gago, F Rodriguez, M Ciccozzi, M Ruiz Alvarez, R d'Arrigo, A Bertoli, S Giannella, A Cenci, MP Trotta, A d'Arminio Monforte, A Antinori, and CF Perno: High Conservation of the HIV-1 reverse transcriptase under drug pressure. XI Conference on Retroviruses and Opportunistic Infections, San Francisco, 8 - 11 February, 2004. <http://www.retroconference.org/2004/Abstract>, abstract 643, Session 90 (2004).

408. **Santoro Maria**, V Svicher, C Gori, F Forbici, A Cenci, R D'Arrigo, MC Bellocchi, S Giannella, A Bertoli, A Antinori, CF Perno and F Ceccherini-Silberstein: Caratterizzazione temporale della frequenza delle mutazioni conferenti farmaco-resistenza presenti nelle proteasi e nella trascrittasi inversa di HIV-1. 31° Congresso Nazionale Società Italiana di Microbiologia, Roma, Italia, 19 - 22 Ottobre 2003.

Atti congressuali

409. CF Perno, F Scopelliti, **Santoro Maria Mercedes**. Resistenza alle nuove classi: una chance e un rischio. Atti del congresso. "Antiinfective Therapies: go beyond. Nuovi antiretrovirali Impatto su rinnovati obiettivi e strategie terapeutiche". Milano 6-7 giugno 2008. HIV nuove prospettive, 2008; 1:13-17. Editore Adriano Lazzarin.

410. R Cammarota, D Armenia, C Alteri, M Trignetti, **Santoro Maria**, and CF Perno. La resistenza ai farmaci antiretrovirali: aspetti virologici. Quaderni di Malattie infettive e Tropicali. Anno 2, numero 3 2008. Editore Gaetano Filice.

DATI PERSONALI

Autorizzo il trattamento dei miei dati personali ai sensi del GDPR e del Decreto Legislativo 30 giugno 2003, n. 196 "Codice in materia di protezione dei dati personali" ai fini di attività di Ricerca e Selezione del Personale e contatti lavorativi.

La sottoscritta è a conoscenza che, ai sensi dell'art. 26 della legge 15/68, le dichiarazioni mendaci, la falsità negli atti e l'uso di atti falsi sono puniti ai sensi del codice penale e delle leggi speciali. Ai sensi del D.P.R. 445/2000 attesto la veridicità di quanto riportato nel presente curriculum vitae

Roma 09/03/2022



Maria Santoro